

**Connecticut Quality Council  
Annual Review of the Core Measure Set  
Measure Specifications**

#	Measure Name	Page Number
1	PCMH – CAHPS Measure	2
2	Plan All-cause Readmission	7
3	Breast Cancer Screening	17
4	Cervical Cancer Screening	23
5	Chlamydia Screening in Women	28
6	Colorectal Cancer Screening	32
7	Immunizations for Adolescents (Combo 2)	40
8	Developmental Screening in the First Three Years of Life	45
9	Well-child Visits in the First 30 Months of Life	51
10	Child and Adolescent Well-care Visits	55
11	Prenatal Care & Postpartum Care	58
12	Screening for Clinical Depression and Follow-up Plan	65
13	Behavioral Health Screening (pediatric, Medicaid only, custom measure)	75
14	Asthma Medication Ratio	76
15	Comprehensive Diabetes Care: HbA1c Poor Control	83
16	Comprehensive Diabetes Care: Eye Exam	83
17	Kidney Health Evaluation for Patients with Kidney Disease	101
18	Controlling High Blood Pressure	107
19	Follow-up Care for Children Prescribed ADHD Medication	115
20	Metabolic Monitoring for Children and Adolescents on Antipsychotics (pediatric, Medicaid only, custom measure)	122
21	Follow-up After Hospitalization for Mental Illness (7-Day)	126
22	Follow-up After Emergency Department Visit for Mental Illness (7-Day)	131
23	Substance Use Assessment in Primary Care	136
24	Concurrent Use of Opioids and Benzodiazepines	138
25	Use of Pharmacotherapy for Opioid Use Disorder	142

Questions	Placement and Other Instructions
<p><b>PCMH1.</b> Did this provider's office give you information about what to do if you needed care during evenings, weekends, or holidays?</p> <p><sup>1</sup> <input type="checkbox"/> Yes</p> <p><sup>2</sup> <input type="checkbox"/> No</p>	<p>After core question 8</p>
<p><b>PCMH2.</b> Specialists are doctors like surgeons, heart doctors, allergy doctors, skin doctors, and other doctors who specialize in one area of health care. In the last 6 months, did you see a specialist for a particular health problem?</p> <p><sup>1</sup> <input type="checkbox"/> Yes</p> <p><sup>2</sup> <input type="checkbox"/> No → <b>If No, go to PCMH4</b></p>	<p>After core question 18</p>
<p><b>PCMH3.</b> In the last 6 months, how often did the provider named in Question 1 seem informed and up-to-date about the care you got from specialists?</p> <p><sup>1</sup> <input type="checkbox"/> Never</p> <p><sup>2</sup> <input type="checkbox"/> Sometimes</p> <p><sup>3</sup> <input type="checkbox"/> Usually</p> <p><sup>4</sup> <input type="checkbox"/> Always</p>	<p>After PCMH2</p> <p>Note: Use with PCMH2</p>
<p><b>PCMH4.</b> Please answer these questions about the provider named in Question 1 of this survey.</p> <p>In the last 6 months, did someone from this provider's office talk with you about specific goals for your health?</p> <p><sup>1</sup> <input type="checkbox"/> Yes</p> <p><sup>2</sup> <input type="checkbox"/> No</p>	<p>After PCMH3</p>
<p><b>PCMH5.</b> In the last 6 months, did someone from this provider's office ask you if there are things that make it hard for you to take care of your health?</p> <p><sup>1</sup> <input type="checkbox"/> Yes</p> <p><sup>2</sup> <input type="checkbox"/> No</p>	<p>After PCMH4</p>
<p><b>PCMH6.</b> In the last 6 months, did you and someone from this provider's office talk about things in your life that worry you or cause you stress?</p> <p><sup>1</sup> <input type="checkbox"/> Yes</p> <p><sup>2</sup> <input type="checkbox"/> No</p>	<p>After PCMH5</p>

## Questions

Question #	Question	Adult/Child
PCMH1	<u>Patient got information about what to do if care is needed on evenings, weekends, or holidays</u>	Adult
PCMH2	<u>Patient saw a specialist for a particular health problem</u>	Adult
PCMH3	<u>Provider seemed informed and up-to-date about care from specialists</u>	Adult
PCMH4	<u>Someone from provider's office talked with patient about specific health goals</u>	Adult
PCMH5	<u>Someone from provider's office asked if there were things that made it hard for patient to take care of health</u>	Adult
PCMH6	<u>Someone from provider's office talked about worrying/stressful aspects of patient's life</u>	Adult
PCMH1	<u>Respondent got information about what to do if child needed care on evenings, weekends, or holidays</u>	Child
PCMH2	<u>Child saw a specialist for a particular health problem</u>	Child
PCMH3	<u>Provider seemed informed and up-to-date about care from specialists</u>	Child
PCMH4	<u>Respondent and provider talked about age-appropriate behaviors</u>	Child
PCMH5	<u>Respondent and provider talked about child's physical development</u>	Child
PCMH6	<u>Respondent and provider talked about child's moods and emotions</u>	Child
PCMH7	<u>Respondent and provider talked about injury prevention</u>	Child
PCMH8	<u>Respondent and provider talked about child's eating habits</u>	Child
PCMH9	<u>Respondent and provider talked about child's eating habits</u>	Child
PCMH10	<u>Respondent and provider talked about how child gets along with others</u>	Child

# Composites

## Adult Version

### Talking With You About Taking Care of Your Own Health

PCMH4. Someone from provider's office talked with patient about specific health goals

PCMH5. Someone from provider's office asked if there were things that made it hard for patient to take care of health

## Child Version

### Provider's Attention to Your Child's Growth and Development

PCMH4. Respondent and provider talked about age-appropriate behaviors

PCMH5. Respondent and provider talked about child's physical development

PCMH6. Respondent and provider talked about child's moods and emotions

PCMH10. Respondent and provider talked about how child gets along with others

### Provider's Advice on Keeping Your Child Safe and Healthy

PCMH7. Respondent and provider talked about injury prevention

PCMH8. Respondent and provider talked about child's eating habits

PCMH9. Respondent and provider talked about child's physical activity

## Appendix A. Items in the PCMH Item Set

The table below lists the individual questions in the PCMH Item Set, the measures that can be calculated, and the PCMH topics that the items address.

To download a version of the Clinician & Group Survey that combines the 12-Month Survey with the complete set of formatted PCMH items, go to <https://cahps.ahrq.gov/surveys-guidance/cg/instructions/index.html>. Both the Adult and Child versions are available.

Additional information on using other supplemental items with the PCMH Item Set, including placement instructions, is available in *CAHPS Clinician & Group Surveys: Supplemental Items for the Adult Surveys* and *CAHPS Clinician & Group Surveys: Supplemental Items for the Child Surveys*.

Number in the Adult PCMH Item Set	Number in the Child PCMH Item Set	Short Item Title	PCMH Item Set Measure	PCMH Topic Addressed
PCMH1	PCMH1	Number of days wait for urgent care appointment	Individual item	Access
PCMH2	PCMH2	Patient got information about what to do if care is needed on evenings, weekends, or holidays	Individual item	Access
PCMH3	PCMH3	Patient needed care during evenings, weekends, or holidays	(Screening item)	Access
PCMH4	PCMH4	Patient able to get needed care on evenings, weekends, or holidays	Individual item	Access
PCMH5	PCMH5	Patient got reminders from provider's office between visits	Individual item	Access
PCMH6		Patient started or stopped a medicine	(Screening item)	
PCMH7		Provider talked to patient about reasons patient might want to take a medicine	Talking with you about medication decisions (composite)	Shared decisionmaking
PCMH8		Provider talked to patient about reasons patient might not want to take a medicine		Shared decisionmaking
PCMH9		Provider asked what patient thought was best		Shared decisionmaking
PCMH10	PCMH6	Patient saw a specialist for a particular health problem	(Screening item)	
PCMH11	PCMH7	Provider seemed informed and up-to-date about care from specialists	Individual item	Coordination

Number in the Adult PCMH Item Set	Number in the Child PCMH Item Set	Short Item Title	PCMH Item Set Measure	PCMH Topic Addressed
PCMH12	PCMH8	Anyone in provider's office talked with patient about specific health goals	Talking with you about taking care of your own health (composite)	Self-management support
PCMH13	PCMH9	Anyone in provider's office asked if there were things that made it hard for patient to take care of health		Self-management support
PCMH14	PCMH10	Patient took prescription medicine	(Screening item)	
PCMH15	PCMH11	Anyone in provider's office talked with patient about all prescriptions	Individual item	Coordination
PCMH16		Anyone in provider's office asked if patient had felt sad, empty, or depressed	Attention to your mental and emotional health (composite)	Comprehensive-ness
PCMH17		Anyone in provider's office talked about worrying/stressful aspects of patient's life		Comprehensive-ness
PCMH18		Anyone in provider's office talked with patient about personal problem, family problem, alcohol use, drug use, or a mental or emotional illness		Comprehensive-ness

## Plan All-Cause Readmissions (PCR)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Revised the measure description.
- Added a *Note* to the definition of “plan population” to clarify that it should be used as a denominator for the outlier rate.
- Removed “Risk Adjustment Tables” from the Definitions.
- Replaced references to “Table HCC-Surg” with references to the “Surgery Procedure Value Set” in the *Risk Adjustment Determination* section.
- Replaced references to “Table PCR-DischCC” with “Table CC\_Mapping” in the *Risk Adjustment Determination* section.
- Updated the *Note* in the *Risk Adjustment Weighting* section for IHS that are discharged or transferred to skilled nursing care.
- Removed references to specific risk weight tables in the *Risk Adjustment Weighting* section.
- Clarified rounding rules in step 8 of the *Risk Adjustment Weighting* section.
- Revised the data element tables to separate the Medicaid and commercial product lines from the Medicare product line.

### Description

For members 18 years of age and older, the number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.

**Note:** For commercial and Medicaid, report only members 18–64 years of age.

### Definitions

<b>HIS</b>	Index hospital stay. An acute inpatient or observation stay with a discharge on or between January 1 and December 1 of the measurement year, as identified in the denominator.
<b>Index Admission Date</b>	The IHS admission date.
<b>Index Discharge Date</b>	The IHS discharge date. The index discharge date must occur on or between January 1 and December 1 of the measurement year.
<b>Index Readmission Stay</b>	An acute inpatient or observation stay for any diagnosis with an admission date within 30 days of a previous Index Discharge Date.
<b>Index Readmission Date</b>	The admission date associated with the Index Readmission Stay.
<b>Planned hospital stay</b>	A hospital stay is considered planned if it meets criteria as described in step 3 (required exclusions) of the numerator.

<b>Plan population</b>	<p>Members who meet all of the following criteria:</p> <ul style="list-style-type: none"><li>• 18 and older as of January 1 of the measurement year.</li><li>• Continuously enrolled for at least 395 days, with no more than one gap in enrollment of up to 45 days during the 395-day period, between January 1 of the year prior to the measurement year and December 1 of the measurement year.</li></ul> <p>Assign members to the product and product line at the start of this defined continuous enrollment period.</p> <p><b>Note:</b> The plan population is only used as a denominator for the Outlier Rate.</p>
<b>Outlier</b>	<p>Medicaid and Medicare members in the eligible population with four or more index hospital stays between January 1 and December 1 of the measurement year.</p> <p>Commercial members in the eligible population with three or more index hospital stays between January 1 and December 1 of the measurement year.</p> <p>Assign members who transition between product lines during the measurement year to the product they were enrolled in on January 1 of the measurement year. If the member is an outlier and has a gap on January 1 of the measurement year, the member is assigned to the product line based on their last enrollment segment prior to January 1.</p>
<b>Nonoutlier</b>	<p>Members in the plan population who are not considered outliers.</p>
<b>Classification period</b>	<p>365 days prior to and including an Index Discharge Date.</p>

## Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

Refer to General Guideline 10: Reporting for small denominator limits.

<b>Product line stratification</b>	<p>Commercial, Medicare, Medicaid (report each product line separately).</p> <p>For only Medicare IHS, report the following SES stratifications and total:</p> <ul style="list-style-type: none"><li>• Non-LIS/DE, Nondisability.</li><li>• LIS/DE.</li><li>• Disability.</li><li>• LIS/DE and Disability.</li><li>• Other.</li><li>• Unknown.</li><li>• Total Medicare.</li></ul>
------------------------------------	--

**Note:** The stratifications are mutually exclusive and the sum of all six stratifications is the Total population.



<b>Ages</b>	<p>For commercial, ages 18–64 as of the Index Discharge Date.</p> <p>For Medicare, ages 18 and older as of the Index Discharge Date.</p> <p>For Medicaid, ages 18–64 as of the Index Discharge Date.</p>
<b>Continuous enrollment</b>	365 days prior to the Index Discharge Date through 30 days after the Index Discharge Date.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the 365 days prior to the Index Discharge Date and no gap during the 30 days following the Index Discharge Date.
<b>Anchor date</b>	Index Discharge Date.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	<p>An acute inpatient or observation stay discharge on or between January 1 and December 1 of the measurement year.</p> <p>The denominator for this measure is based on discharges, not members. Include all acute inpatient or observation stay discharges for nonoutlier members who had one or more discharges on or between January 1 and December 1 of the measurement year.</p> <p>Follow the steps below to identify acute inpatient and observation stays.</p>

### Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Step 1</b>	<p>Identify all acute inpatient and observation stay discharges on or between January 1 and December 1 of the measurement year. To identify acute inpatient and observation stay discharges:</p> <ol style="list-style-type: none"> <li>1. Identify all acute and nonacute inpatient stays (<u>Inpatient Stay Value Set</u>) and observation stays (<u>Observation Stay Value Set</u>).</li> <li>2. Exclude nonacute inpatient stays (<u>Nonacute Inpatient Stay Value Set</u>).</li> <li>3. Identify the discharge date for the stay.</li> </ol> <p>Inpatient and observation stays where the discharge date from the first setting and the admission date to the second setting are two or more calendar days apart must be considered distinct stays.</p> <p>The measure includes acute discharges from any type of facility (including behavioral healthcare facilities).</p>
<b>Step 2</b>	<p><b>Direct transfers:</b> For discharges with one or more direct transfers, use the last discharge.</p> <p>Using the discharges identified in step 1, identify direct transfers between acute inpatient and observation or between observation and acute inpatient using the definition found in the <i>Guidelines for Risk Adjusted Utilization Measures</i>.</p> <p>Exclude the hospital stay if the direct transfer's discharge date occurs after December 1 of the measurement year.</p>

**Step 3** Exclude hospital stays where the Index Admission Date is the same as the Index Discharge Date.

**Step 4** Exclude hospital stays for the following reasons:

- The member died during the stay.
- Female members with a principal diagnosis of pregnancy (Pregnancy Value Set) on the discharge claim.
- A principal diagnosis of a condition originating in the perinatal period (Perinatal Conditions Value Set) on the discharge claim.

**Note:** For hospital stays where there was a direct transfer (identified in step 2), use the original stay and any direct transfer stays to identify exclusions in this step.

**Step 5** Calculate continuous enrollment.

**Step 6** Remove hospital stays for outlier members and report these members as outliers in Table PCR-1/2/3.

**Note:** Count discharges with one or more direct transfers (identified in step 2) as one discharge when identifying outlier members.

**Step 7** Assign each remaining acute inpatient or observation stay to an age and stratification category using the reporting instructions below.

---

### Risk Adjustment Determination

For each IHS among nonoutlier members, use the following steps to identify risk adjustment categories based on presence of observation stay status at discharge, surgeries, discharge condition, comorbidity, age and gender.

<b>Observation Stay</b>	Determine if the IHS at discharge was an observation stay ( <u>Observation Stay Value Set</u> ). For direct transfers, determine the hospitalization status using the last discharge.
<b>Surgeries</b>	Determine if the member underwent surgery during the stay ( <u>Surgery Procedure Value Set</u> ). Consider an IHS to include a surgery if at least one procedure code is present from any provider between the admission and discharge dates.
<b>Discharge Condition</b>	Assign a discharge Clinical Condition (CC) category code or codes to the IHS based on its primary discharge diagnosis, using Table CC_Mapping. For direct transfers, use the primary discharge diagnosis from the last discharge.  Exclude diagnoses that cannot be mapped to Table CC_Mapping.
<b>Comorbidities</b>	Refer to the <i>Risk Adjustment Comorbidity Category Determination</i> in the <i>Guidelines for Risk Adjusted Utilization Measures</i> .

---

### Risk Adjustment Weighting

For each IHS among nonoutliers, use the following steps to identify risk adjustment weights based on observation stays status at discharge, surgeries, discharge condition, comorbidity, age and gender. Weights are specific to product line (Medicare Under 65, Medicare 65+, commercial, Medicaid). Refer to the reporting indicator column in the risk adjustment tables to ensure that weights are linked appropriately.

**Note:** For Medicare product lines, IHS that are discharged or transferred to skilled nursing care should be assigned two sets of risk adjustment weights; the skilled nursing care risk weights for reporting in Table PCR-E-3 and the standard set of risk weights for reporting in Table PCR-C-3 and Table PCR-D-3. For reporting IHS that are discharged or transferred to skilled nursing care, do not assign the skilled nursing care risk weights for the stays when reporting in Table PCR-C-3 and Table PCR-D-3 and do not assign the standard set or risk weights for the stays when reporting in Table PCR-E-3.

- Step 1** For each IHS discharge that is an observation stay, link the observation stay IHS weight.
- Step 2** For each IHS with a surgery, link the surgery weight.
- Step 3** For each IHS with a discharge CC Category, link the primary discharge weights.
- Step 4** For each IHS with a comorbidity HCC Category, link the comorbidity weights.
- Step 5** Link the age and gender weights for each IHS.
- Step 6** Sum all weights associated with the IHS (i.e., observation stay, presence of surgery, primary discharge diagnosis, comorbidities, age and gender) and use the formula below to calculate the Estimated Readmission Risk for each IHS:

$$\text{Estimated Readmission Risk} = \frac{e^{(\sum \text{WeightsForIHS})}}{1 + e^{(\sum \text{WeightsForIHS})}}$$

**OR**

$$\text{Estimated Readmission Risk} = [\exp (\text{sum of weights for IHS})] / [1 + \exp (\text{sum of weights for IHS})]$$

**Note:** “Exp” refers to the exponential or antilog function.

- Step 7** Calculate the Count of Expected Readmissions for each age and stratification category. The Count of Expected Readmissions is the sum of the Estimated Readmission Risk calculated in step 6 for each IHS in each age and stratification category.

$$\text{Count of Expected Readmissions} = \sum (\text{Estimated Readmission Risk})$$

- Step 8** Use the formula below and the Estimated Readmission Risk calculated in step 6 to calculate the variance for each IHS.

$$\text{Variance} = \text{Estimated Readmission Risk} \times (1 - \text{Estimated Readmission Risk})$$

**Example:** If the Estimated Readmission Risk is 0.1518450741 for an IHS, then the variance for this IHS is 0.1518450741 x 0.8481549259 = 0.1287881476.

**Note:** When calculating variance at the IHS level, do not round. Organizations must sum the variances for each stratification and age when populating the Variance cells in the reporting tables. When reporting, round the variance to 4 decimal places using the .5 rule.

**Numerator** At least one acute readmission for any diagnosis within 30 days of the Index Discharge Date.

- Step 1** Identify all acute inpatient and observation stays with an admission date on or between January 3 and December 31 of the measurement year. To identify acute inpatient and observation admissions:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set) and observation stays (Observation Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the admission date for the stay.

**Step 2** *Direct transfers:* For discharges with one or more direct transfers, use the last discharge.

Using the discharges identified in step 1, identify direct transfers between acute inpatient and observation or between observation and acute inpatient using the definition found in the *Guidelines for Risk Adjusted Utilization Measures*.

**Step 3** Exclude acute hospitalizations with any of the following criteria on the discharge claim:

- Female members with a principal diagnosis of pregnancy (Pregnancy Value Set).
- A principal diagnosis for a condition originating in the perinatal period (Perinatal Conditions Value Set).
- Planned admissions using any of the following:
  - A principal diagnosis of maintenance chemotherapy (Chemotherapy Encounter Value Set).
  - A principal diagnosis of rehabilitation (Rehabilitation Value Set).
  - An organ transplant (Kidney Transplant Value Set, Bone Marrow Transplant Value Set, Organ Transplant Other Than Kidney Value Set, Introduction of Autologous Pancreatic Cells Value Set).
  - A potentially planned procedure (Potentially Planned Procedures Value Set) without a principal acute diagnosis (Acute Condition Value Set).

**Note:** For hospital stays where there was a direct transfer (identified in step 2), use the original stay and any direct transfer stays to identify exclusions in this step.

**Step 4** For each IHS identified in the denominator, determine if any of the acute inpatient and observation stays identified in the numerator have an admission date within 30 days after the Index Discharge Date.

**Note:** Count each acute hospitalization only once toward the numerator for the last denominator event.

If a single numerator event meets criteria for multiple denominator events, only count the last denominator event. For example, consider the following events:

- Acute inpatient stay 1: May 1–10.
- Acute inpatient stay 2: May 15–25 (principal diagnosis of maintenance chemotherapy).
- Acute inpatient stay 3: May 30–June 5.

All three acute inpatient stays are included as denominator events. Stay 2 is excluded from the numerator because it is a planned hospitalization. Stay 3 is within 30 days of Stay 1 and Stay 2. Count Stay 3 as a numerator event only toward the last denominator event (Stay 2, May 15–25).

---

**Reporting: Number of Members in Plan Population**

---

- Step 1** Determine the member's age as of January 1 of the measurement year.
- Step 2** Report the count of members in the plan population for each age group and the overall total. Enter these values in reporting Tables PCR-1/2 and PCR-A-3.

---

**Reporting: Number of Outliers**

---

- Step 1** Determine the member's age as of January 1 of the measurement year.
- Step 2** Report the count of outlier members for each age group and the overall total. Enter these values in reporting Tables PCR-1/2 and PCR-A-3.

---

**Calculated: Outlier Rate**

---

The number of outlier members divided by the number of members in the plan population, displayed as a permillage (multiplied by 1,000), for each age group and the overall totals calculated by IDSS.

---

**Reporting: Denominator**

---

Count the number of IHS among nonoutlier members for each age group and enter these values into the reporting table under Count of Index Stays.

---

**Reporting: SES Stratification (Medicare only)**

---

- Step 1** Determine the member's SES stratifications as of the end of the continuous enrollment period for each Medicare discharge:
- *Non-LIS/DE, Nondisability*: Member is eligible for Medicare due to age only (does not receive LIS, is not DE for Medicaid, does not have disability status).
  - *LIS/DE*: Member is eligible for Medicare due to age and receives LIS (includes members eligible for Medicare due to DE), does not have disability status.
  - *Disability*: Member is eligible for Medicare due to disability status only.
  - *LIS/DE and Disability*: Member is eligible for Medicare, receives LIS and has disability status.
  - *Other*: Member has ESRD-only status or is assigned "9—none of the above."
  - *Unknown*: Member's SES is unknown.
  - *Total Medicare*: Total of all categories.
- Step 2** Report Medicare discharges based on the SES stratification assigned for each Medicare index stay in Table PCR-D-3.

---

**Reporting: Skilled Nursing Care Stratification (Medicare only)**

---

- Step 1** For Medicare nonoutlier members, determine if the IHS was discharged or transferred to skilled nursing care (Skilled Nursing Stay Value Set).

An index stay is discharged or transferred to skilled nursing care when the discharge date from the acute inpatient or observation stay precedes the admission date for skilled nursing care by one calendar day or less. For example:

- An index stay discharge on June 1, followed by an admission to a skilled nursing setting on June 1, is an IHS discharged or transferred to skilled nursing care.
- An index stay discharge on June 1, followed by an admission to a skilled nursing setting on June 2, is an IHS discharged or transferred to skilled nursing care.
- An index stay discharge on June 1, followed by an admission to a skilled nursing setting on June 3, is not an IHS discharged or transferred to skilled nursing care.

**Step 2** Report Medicare discharges for each IHS discharged or transferred to skilled nursing care to an age group in Table PCR-E-3.

---

**Reporting: Numerator**

---

Count the number of observed IHS among nonoutlier members with a readmission within 30 days of discharge for each age group and enter these values into the reporting tables under Count of Observed 30-Day Readmissions.

---

**Calculated: Observed Readmission Rate**

---

The Count of Observed 30-Day Readmissions divided by the Count of Index Stays calculated by IDSS.

---

**Reporting: Count of Expected 30-Day Readmissions**

---

**Step 1** Calculate the Count of Expected Readmissions among nonoutlier members for each age group and overall total.

**Step 2** Round to four decimal places using the .5 rule and enter the Count of Expected Readmissions into the reporting tables.

---

**Calculated: Expected Readmission Rate**

---

The Count of Expected 30-Day Readmissions divided by the Count of Index Stays calculated by IDSS.

---

**Reporting: Variance**

---

**Step 1** Calculate the total (sum) variance for each SES stratification (Medicare only), skilled nursing stratification (Medicare only) and age group.

**Step 2** Round to four decimal places using the .5 rule and enter the variance into the reporting tables.

---

**Calculated: O/E Ratio**

---

The Count of Observed 30-Day Readmissions divided by the Count of Expected 30-Day Readmissions calculated by IDSS.

---

**Note**

---

- *Supplemental data may not be used for this measure.*

**Table PCR-1/2: Plan Population and Outlier Rate (Medicaid, Commercial, 18-64)**

Age	Members in Plan Population	Outlier Members	Outlier Rate
18-44			
45-54			
55-64			
<b>18-64 Total</b>			

**Table PCR-A-3: Plan Population and Outlier Rate (Medicare, 18+)**

Age	Members in Plan Population	Outlier Members	Outlier Rate
18-44			
45-54			
55-64			
65-74			
75-84			
85+			
<b>18-64 Total</b>			
<b>65+ Total</b>			

**Table PCR-B-1/2: Plan All-Cause Readmissions Rates Among Nonoutlier Members by Age (Medicaid, Commercial, 18-64)**

Age	Count of Index Stays	Count of Observed 30-Day Readmissions	Observed Readmission Rate	Count of Expected 30-Day Readmissions	Expected Readmission Rate	Variance	O/E Ratio
18-44							
45-54							
55-64							
<b>18-64 Total</b>							

**Table PCR-C-3: Plan All-Cause Readmissions Rates Among Nonoutlier Members by Age (Medicare, 18+)**

Age	Count of Index Stays	Count of Observed 30-Day Readmissions	Observed Readmission Rate	Count of Expected 30-Day Readmissions	Expected Readmission Rate	Variance	O/E Ratio
18-44							
45-54							
55-64							
65-74							
75-84							
85+							
<b>18-64 Total</b>							
<b>65+ Total</b>							

**Table PCR-D-3: Plan All-Cause Readmissions Rates Among Nonoutlier Members by SES Stratification (Medicare, 18+)**

SES Stratification	Age	Count of Index Stays	Count of Observed 30-Day Readmissions	Observed Readmission Rate	Count of Expected 30-Day Readmissions	Expected Readmission Rate	Variance	O/E Ratio
Non-LIS/ DE, Non-disability	18-64							
	65+							
LIS/DE	18-64							
	65+							
Disability	18-64							
	65+							
LIS/DE and Disability	18-64							
	65+							
Other	18-64							
	65+							
Unknown	18-64							
	65+							

**Table PCR-E-3: Plan All-Cause Readmissions Rates Among Nonoutlier Members Discharged or Transferred to Skilled Nursing Care by Age (Medicare, 18+)**

Age	Count of Index Stays	Count of Observed 30-Day Readmissions	Observed Readmission Rate	Count of Expected 30-Day Readmissions	Expected Readmission Rate	Variance	O/E Ratio
18-44							
45-54							
55-64							
65-74							
75-84							
85+							
<b>18-64 Total</b>							
<b>65+ Total</b>							



## ***Breast Cancer Screening (BCS)***

### **SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021**

- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added the “Number of required exclusions” data element to the Data Elements for Reporting table.
- Added guidance adjusting required exclusions criteria in the *Rules for Allowable Adjustments* section.

### **Description**

The percentage of women 50–74 years of age who had a mammogram to screen for breast cancer.

### **Eligible Population**

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Stratification** For only Medicare, report the following SES stratifications and total:

- Non-LIS/DE, Nondisability.
- LIS/DE.
- Disability.
- LIS/DE and Disability.
- Other.
- Unknown.
- Total Medicare.

**Note:** The stratifications are mutually exclusive, and the sum of all six stratifications is the Total population.

**Ages** Women 52–74 years as of December 31 of the measurement year.

**Continuous enrollment** October 1 two years prior to the measurement year through December 31 of the measurement year.

**Allowable gap** No more than one gap in enrollment of up to 45 days for each full calendar year of continuous enrollment (the measurement year and the year prior to the measurement year). To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled) during each year of continuous enrollment.

No gaps in enrollment are allowed from October 1 two years prior to the measurement year through December 31 two years prior to the measurement year.

**Anchor date** December 31 of the measurement year.

**Benefit** Medical.

**Event/diagnosis** None.

**Required exclusion** Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

**Exclusions** Exclude members who meet any of the following criteria:

**Note:** *Supplemental and medical record data may not be used for these exclusions.*

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty **and** advanced illness. Members must meet **BOTH** of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
      3. Identify the discharge date for the stay.
    - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).

- At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- A dispensed dementia medication (Dementia Medications List).

#### **Dementia Medications**

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"> <li>• Donepezil</li> <li>• Galantamine</li> <li>• Rivastigmine</li> </ul>
Miscellaneous central nervous system agents	<ul style="list-style-type: none"> <li>• Memantine</li> </ul>
Dementia combinations	<ul style="list-style-type: none"> <li>• Donepezil-memantine</li> </ul>

#### **Administrative Specification**

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	One or more mammograms ( <u>Mammography Value Set</u> ) any time on or between October 1 two years prior to the measurement year and December 31 of the measurement year.

#### **Exclusion (optional)**

Bilateral mastectomy any time during the member's history through December 31 of the measurement year. Any of the following meet criteria for bilateral mastectomy:

- Bilateral mastectomy (Bilateral Mastectomy Value Set).
- Unilateral mastectomy (Unilateral Mastectomy Value Set) with a bilateral modifier (Bilateral Modifier Value Set).
- Unilateral mastectomy found in clinical data (Clinical Unilateral Mastectomy Value Set) with a bilateral modifier (Clinical Bilateral Modifier Value Set).  
***Note:** The "clinical" mastectomy value sets identify mastectomy; the word "clinical" refers to the data source, not to the type of mastectomy.*
- History of bilateral mastectomy (History of Bilateral Mastectomy Value Set).
- Any combination of codes from the table below that indicate a mastectomy on **both** the left **and** right side on the same or different dates of service.

Left Mastectomy (any of the following)	Right Mastectomy (any of the following)
<ul style="list-style-type: none"> <li>Unilateral mastectomy (<u>Unilateral Mastectomy Value Set</u>) <b>with</b> a left-side modifier (<u>Left Modifier Value Set</u>) (same procedure)</li> </ul>	<ul style="list-style-type: none"> <li>Unilateral mastectomy (<u>Unilateral Mastectomy Value Set</u>) <b>with</b> a right-side modifier (<u>Right Modifier Value Set</u>) (same procedure)</li> </ul>
<ul style="list-style-type: none"> <li>Unilateral mastectomy found in clinical data (<u>Clinical Unilateral Mastectomy Value Set</u>) <b>with</b> a left-side modifier (<u>Clinical Left Modifier Value Set</u>) (same procedure)</li> </ul>	<ul style="list-style-type: none"> <li>Unilateral mastectomy found in clinical data (<u>Clinical Unilateral Mastectomy Value Set</u>) <b>with</b> a right-side modifier (<u>Clinical Right Modifier Value Set</u>) (same procedure)</li> </ul>
<ul style="list-style-type: none"> <li>Absence of the left breast (<u>Absence of Left Breast Value Set</u>)</li> </ul>	<ul style="list-style-type: none"> <li>Absence of the right breast (<u>Absence of Right Breast Value Set</u>)</li> </ul>
<ul style="list-style-type: none"> <li>Left unilateral mastectomy (<u>Unilateral Mastectomy Left Value Set</u>)</li> </ul>	<ul style="list-style-type: none"> <li>Right unilateral mastectomy (<u>Unilateral Mastectomy Right Value Set</u>)</li> </ul>

### Note

- This measure assesses the use of imaging to detect early breast cancer in women. Because the measure denominator does not remove women at higher risk of breast cancer, all types and methods of mammograms (screening, diagnostic, film, digital or digital breast tomosynthesis) qualify for numerator compliance. Do not count MRIs, ultrasounds or biopsies towards the numerator: although these procedures may be indicated for evaluating women at higher risk for breast cancer or for diagnostic purposes, they are performed as an adjunct to mammography and do not alone count toward the numerator.*

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table BCS-1/2: Data Elements for Breast Cancer Screening**

	Administrative
Measurement year	✓
Eligible population	✓
Number of optional exclusions	✓
Number of required exclusions	✓
Numerator events by administrative data	✓
Numerator events by supplemental data	✓
Reported rate	✓

**Table BCS-3: Data Elements for Breast Cancer Screening**

	Administrative
Measurement year	✓
Eligible population	<i>Each of the 6 stratifications and total</i>
Number of optional exclusions	<i>Each of the 6 stratifications and total</i>
Number of required exclusions	<i>Each of the 6 stratifications and total</i>
Numerator events by administrative data	<i>Each of the 6 stratifications and total</i>
Numerator events by supplemental data	<i>Each of the 6 stratifications and total</i>
Reported rate	<i>Each of the 6 stratifications and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Breast Cancer Screening

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age range may be expanded to 40-74 years of age.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefit	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	NA	There is no event/diagnosis for this measure.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Value sets may not be changed.
Required Exclusions	Yes	The palliative care exclusion is not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Exclusions: I-SNP, LTI, Frailty or Advanced Illness	Yes	These exclusions are not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Mammogram	No	Value sets and logic may not be changed.

## Cervical Cancer Screening (CCS)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Added palliative care as a required exclusion.
- Updated the Hybrid Specification to indicate that sample size reduction is allowed.
- Clarified that documentation of “vaginal hysterectomy” meets criteria for documentation of hysterectomy with no residual cervix (optional exclusion).
- Added the “Number of required exclusions” data element to the Data Elements for Reporting table.
- Added guidance adjusting required exclusions criteria in the *Rules for Allowable Adjustments* section.

### Description

The percentage of women 21–64 years of age who were screened for cervical cancer using either of the following criteria:

- Women 21–64 years of age who had cervical cytology performed within the last 3 years.
- Women 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Women 30–64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last 5 years.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. If an organization reports this measure using the Hybrid method, and a member is found to be in hospice or using hospice services during medical record review, the member is removed from the sample and replaced by a member from the oversample. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	Women 24–64 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	<p><i>Commercial:</i> The measurement year and the two years prior to the measurement year.</p> <p><i>Medicaid:</i> The measurement year.</p>
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.
<b>Required exclusion</b>	Members receiving palliative care ( <u>Palliative Care Assessment Value Set</u> ; <u>Palliative Care Encounter Value Set</u> ; <u>Palliative Care Intervention Value Set</u> ) during the measurement year.

## Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	<p>The number of women who were screened for cervical cancer. Either of the following meets criteria:</p> <ul style="list-style-type: none"> <li>• Women 24–64 years of age as of December 31 of the measurement year who had cervical cytology (<u>Cervical Cytology Lab Test Value Set</u>; <u>Cervical Cytology Result or Finding Value Set</u>) during the measurement year or the two years prior to the measurement year.</li> <li>• Women 30–64 years of age as of December 31 of the measurement year who had cervical high-risk human papillomavirus (hrHPV) testing (<u>High Risk HPV Lab Test Value Set</u>, <u>High Risk HPV Test Result or Finding Value Set</u>) during the measurement year or the four years prior to the measurement year <b>and</b> who were 30 years or older on the date of the test.</li> </ul> <p><b>Note:</b> Evidence of hrHPV testing within the last 5 years also captures patients who had cotesting; therefore additional methods to identify cotesting are not necessary.</p>

## Exclusion (optional)

Hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix (Absence of Cervix Diagnosis Value Set; Hysterectomy With No Residual Cervix Value Set) any time during the member's history through December 31 of the measurement year.

## Hybrid Specification

<b>Denominator</b>	A systematic sample drawn from the eligible population. Organizations may reduce the sample size using the current year's administrative rate or the prior year's audited rate. Refer to the <i>Guidelines for Calculations and Sampling</i> for information on reducing the sample size.
<b>Numerator</b>	The number of women who were appropriately screened for cervical cancer as documented through either administrative data or medical record review.
<b>Administrative</b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from the administrative data.
<b>Medical record</b>	<p>Appropriate screenings are defined by any of the following:</p> <ul style="list-style-type: none"> <li>• Women 24–64 years of age as of December 31 of the measurement year who had cervical cytology during the measurement year or the two years prior to the measurement year. <ul style="list-style-type: none"> <li>– Documentation in the medical record must include both of the following: <ul style="list-style-type: none"> <li>▪ A note indicating the date when the cervical cytology was performed.</li> <li>▪ The result or finding.</li> </ul> </li> <li>– Count any cervical cancer screening method that includes collection and microscopic analysis of cervical cells. Do not count lab results that explicitly state the sample was inadequate or that “no cervical cells were present”; this is not considered appropriate screening.</li> </ul> </li> </ul>



- Do not count biopsies because they are diagnostic and therapeutic only and are not valid for primary cervical cancer screening.

**Note:** Lab results that indicate the sample contained “no endocervical cells” may be used if a valid result was reported for the test.

- Women 30–64 years of age as of December 31 of the measurement year who had cervical high-risk human papillomavirus (hrHPV) testing during the measurement year or the four years prior to the measurement year **and** who were 30 years or older as of the date of testing.
  - Documentation in the medical record must include both of the following:
    - A note indicating the date when the hrHPV test was performed. Generic documentation of “HPV test” can be counted as evidence of hrHPV test.
    - The results or findings.
  - Do not count biopsies because they are diagnostic and therapeutic only and are not valid for primary cervical cancer screening.

**Note:** Evidence of hrHPV testing within the last 5 years also captures patients who had cotesting.

### Exclusion (optional)

---

Refer to *Administrative Specification* for exclusion criteria. Evidence of a hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix any time during the member’s history through December 31 of the measurement year. The following examples meet criteria for documentation of hysterectomy with no residual cervix:

- Documentation of “complete,” “total” or “radical” hysterectomy (abdominal, vaginal or unspecified).
- Documentation of “vaginal hysterectomy.”
- Documentation of “vaginal pap smear” in conjunction with documentation of “hysterectomy.”
- Documentation of “hysterectomy” in combination with documentation that the patient no longer needs pap testing/cervical cancer screening.
  - Documentation of hysterectomy alone does not meet the criteria, because it is not sufficient evidence that the cervix was removed.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CCS-1/2: Data Elements for Cervical Cancer Screening**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of required exclusions	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year's administrative rate (before exclusions)		✓
Minimum required sample size (MRSS)		✓
Oversampling rate		✓
Number of oversample records		✓
Number of medical records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	✓	✓
Numerator events by medical records		✓
Numerator events by supplemental data	✓	✓
Reported rate	✓	✓

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Cervical Cancer Screening

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefit	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	NA	There is no event/diagnosis for this measure.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Required Exclusions	Yes	The palliative care exclusion is not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i>
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Value sets may not be changed.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Cervical cancer screening	No	Value sets and logic may not be changed.

## Chlamydia Screening in Women (CHL)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- No changes to this measure.

#### Description

The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

#### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	<p>Women 16–24 years as of December 31 of the measurement year. Report two age stratifications and a total rate:</p> <ul style="list-style-type: none"> <li>• 16–20 years.</li> <li>• 21–24 years.</li> <li>• Total.</li> </ul> <p>The total is the sum of the age stratifications.</p>
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	<p><i>Sexually active.</i> Two methods identify sexually active women: pharmacy data and claim/encounter data. The organization must use both methods to identify the eligible population; however, a member only needs to be identified in one method to be eligible for the measure.</p> <p><i>Claim/encounter data.</i> Members who had a claim or encounter indicating sexual activity during the measurement year. A code from any of the following meets criteria:</p> <ul style="list-style-type: none"> <li>• <u>Pregnancy Value Set.</u></li> <li>• <u>Sexual Activity Value Set.</u></li> <li>• <u>Pregnancy Tests Value Set.</u></li> </ul>

*Pharmacy data.* Members who were dispensed prescription contraceptives during the measurement year ([Contraceptive Medications List](#)).

#### Contraceptive Medications

Description	Prescription
Contraceptives	<ul style="list-style-type: none"> <li>• Desogestrel-ethinyl estradiol</li> <li>• Dienogest-estradiol (multiphasic)</li> <li>• Drospirenone-ethinyl estradiol</li> <li>• Drospirenone-ethinyl estradiol-levomefolate (biphasic)</li> <li>• Ethinyl estradiol-ethynodiol</li> <li>• Ethinyl estradiol-etonogestrel</li> <li>• Ethinyl estradiol-levonorgestrel</li> <li>• Ethinyl estradiol-norelgestromin</li> <li>• Ethinyl estradiol-norethindrone</li> <li>• Ethinyl estradiol-norgestimate</li> <li>• Ethinyl estradiol-norgestrel</li> <li>• Etonogestrel</li> <li>• Levonorgestrel</li> <li>• Medroxyprogesterone</li> <li>• Mestranol-norethindrone</li> <li>• Norethindrone</li> </ul>
Diaphragm	<ul style="list-style-type: none"> <li>• Diaphragm</li> </ul>
Spermicide	<ul style="list-style-type: none"> <li>• Nonoxynol 9</li> </ul>

#### Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	At least one chlamydia test ( <a href="#">Chlamydia Tests Value Set</a> ) during the measurement year.

#### Exclusion (optional)

Exclude members who qualified for the denominator based on a pregnancy test ([Pregnancy Tests Value Set](#)) alone **and** who meet either of the following:

- A pregnancy test ([Pregnancy Test Exclusion Value Set](#)) during the measurement year and a prescription for isotretinoin ([Retinoid Medications List](#)) on the date of the pregnancy test or the six days after the pregnancy test.
- A pregnancy test ([Pregnancy Test Exclusion Value Set](#)) during the measurement year and an x-ray ([Diagnostic Radiology Value Set](#)) on the date of the pregnancy test or the six days after the pregnancy test.

#### Retinoid Medications

Description	Prescription
Retinoid	<ul style="list-style-type: none"> <li>• Isotretinoin</li> </ul>

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CHL-1/2: Data Elements for Chlamydia Screening in Women**

	Administrative
Measurement year	✓
Eligible population	<i>For each age stratification and total</i>
Number of optional exclusions	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>For each age stratification and total</i>
Numerator events by supplemental data	<i>For each age stratification and total</i>
Reported rate	<i>For each age stratification and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Chlamydia Screening in Women

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	The age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are acceptable.
Benefit	Yes	Organizations are not required to use a benefit; adjustments are acceptable.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	Yes, with limits	Only events that contain (or map to) codes in medication lists and value sets may be used to identify sexual activity. Medication lists, value sets and logic may not be changed. Claims/encounter data or pharmacy data may be used to identify sexual activity.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Medication lists, and value sets may not be changed.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Chlamydia test	No	Value sets and logic may not be changed.

## Colorectal Cancer Screening (COL)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added the “Number of required exclusions” data element to the Data Elements for Reporting table.
- Added guidance adjusting required exclusions criteria in the *Rules for Allowable Adjustments* section.

### Description

The percentage of members 50–75 years of age who had appropriate screening for colorectal cancer.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. If an organization reports this measure using the Hybrid method, and a member is found to be in hospice or using hospice services during medical record review, the member is removed from the sample and replaced by a member from the oversample. Refer to General Guideline 17: Members in Hospice.

**Product lines** Commercial, Medicare (report each product line separately).

**Stratification** For only Medicare, report the following SES stratifications and total:

- Non-LIS/DE, Nondisability.
- LIS/DE.
- Disability.
- LIS/DE and Disability.
- Other.
- Unknown.
- Total Medicare.

**Note:** The stratifications are mutually exclusive, and the sum of all six stratifications is the Total population.

**Ages** 51–75 years as of December 31 of the measurement year.

**Continuous enrollment** The measurement year and the year prior to the measurement year.

**Allowable gap** No more than one gap in continuous enrollment of up to 45 days during each year of continuous enrollment.

**Anchor date** December 31 of the measurement year.

**Benefit** Medical.

**Event/  
diagnosis** None.



**Required  
exclusion**

Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

**Exclusions**

Exclude members who meet any of the following criteria:

**Note:** *Supplemental and medical record data may not be used for these exclusions.*

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty **and** advanced illness. Members must meet **BOTH** of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
      3. Identify the discharge date for the stay.
    - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
    - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
      2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).

3. Identify the discharge date for the stay.
- A dispensed dementia medication (Dementia Medications List).

#### **Dementia Medications**

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"> <li>• Donepezil</li> <li>• Galantamine</li> <li>• Rivastigmine</li> </ul>
Miscellaneous central nervous system agents	<ul style="list-style-type: none"> <li>• Memantine</li> </ul>
Dementia combinations	<ul style="list-style-type: none"> <li>• Donepezil-memantine</li> </ul>

#### **Administrative Specification**

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	<p>One or more screenings for colorectal cancer. Any of the following meet criteria:</p> <ul style="list-style-type: none"> <li>• Fecal occult blood test (<u>FOBT Lab Test Value Set</u>; <u>FOBT Test Result or Finding Value Set</u>) during the measurement year. For administrative data, assume the required number of samples were returned, regardless of FOBT type.</li> <li>• Flexible sigmoidoscopy (<u>Flexible Sigmoidoscopy Value Set</u>; <u>History of Flexible Sigmoidoscopy Value Set</u>) during the measurement year or the four years prior to the measurement year.</li> <li>• Colonoscopy (<u>Colonoscopy Value Set</u>; <u>History of Colonoscopy Value Set</u>) during the measurement year or the nine years prior to the measurement year.</li> <li>• CT colonography (<u>CT Colonography Value Set</u>) during the measurement year or the four years prior to the measurement year.</li> <li>• FIT-DNA test (<u>FIT DNA Lab Test Value Set</u>; <u>FIT DNA Test Result or Finding Value Set</u>) during the measurement year or the two years prior to the measurement year.</li> </ul>

#### **Exclusion (optional)**

Either of the following any time during the member's history through December 31 of the measurement year:

- Colorectal cancer (Colorectal Cancer Value Set).
- Total colectomy (Total Colectomy Value Set; History of Total Colectomy Value Set).

#### **Hybrid Specification**

<b>Denominator</b>	A systematic sample drawn from the eligible population for each product line. Organizations may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate. Refer to the <i>Guidelines for Calculations and Sampling</i> for information on reducing the sample size.
--------------------	--

For Medicare reporting, the denominator (MRSS) for the Total category is the entire systematic sample. Do not pull samples for each stratification. The individual stratifications for the denominators and all numerators must sum to the totals.

**Numerator**

One or more screenings for colorectal cancer. Appropriate screenings are defined by one of the following:

- FOBT during the measurement year.
- Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year.
- Colonoscopy during the measurement year or the nine years prior to the measurement year.
- CT colonography during the measurement year or the four years prior to the measurement year.
- FIT-DNA during the measurement year or the two years prior to the measurement year.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from the administrative data.

**Medical record** Documentation in the medical record must include a note indicating the date when the colorectal cancer screening was performed. A result is not required if the documentation is clearly part of the member's "medical history"; if this is not clear, the result or finding must also be present (this ensures that the screening was performed and not merely ordered).

A pathology report that indicates the type of screening (e.g., colonoscopy, flexible sigmoidoscopy) and the date when the screening was performed meets criteria.

For pathology reports that do not indicate the type of screening and for incomplete procedures:

- Evidence that the scope advanced beyond the splenic flexure meets criteria for a completed colonoscopy.
- Evidence that the scope advanced into the sigmoid colon meets criteria for a completed flexible sigmoidoscopy.

There are two types of FOBT tests: guaiac (gFOBT) and immunochemical (FIT). Depending on the type of FOBT test, a certain number of samples are required for numerator compliance. Follow the instructions below to determine member compliance.

- If the medical record does not indicate the type of test and there is no indication of how many samples were returned, assume the required number was returned. The member meets the screening criteria for inclusion in the numerator.
- If the medical record does not indicate the type of test and the number of returned samples is specified, the member meets the screening criteria only if the number of samples specified is greater than or equal to three samples. If there are fewer than three samples, the member does not meet the screening criteria for inclusion.

- FIT tests may require fewer than three samples. If the medical record indicates that an FIT was done, the member meets the screening criteria, regardless of how many samples were returned.
- If the medical record indicates that a gFOBT was done, follow the scenarios below.
  - *If the medical record does not indicate the number of returned samples, assume the required number was returned. The member meets the screening criteria for inclusion in the numerator.*
  - *If the medical record indicates that three or more samples were returned, the member meets the screening criteria for inclusion in the numerator.*
  - *If the medical record indicates that fewer than three samples were returned, the member does not meet the screening criteria.*

*Do not count* digital rectal exams (DRE), FOBT tests performed in an office setting or performed on a sample collected via DRE.

### **Exclusion (*optional*)**

---

Refer to *Administrative Specification* for exclusion criteria. Exclusionary evidence in the medical record must include a note indicating colorectal cancer or total colectomy any time during the member's history through December 31 of the measurement year.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table COL-2: Data Elements for Colorectal Cancer Screening**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of required exclusions	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year's administrative rate (before exclusions)		✓
Minimum required sample size (MRSS)		✓
Oversampling rate		✓
Number of oversample records		✓
Number of medical records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	✓	✓
Numerator events by medical records		✓
Numerator events by supplemental data	✓	✓
Reported rate	✓	✓

**Table COL-3: Data Elements for Colorectal Cancer Screening**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	<i>Each of the 6 stratifications and total</i>	<i>Each of the 6 stratifications and total</i>
Number of required exclusions	<i>Each of the 6 stratifications and total</i>	<i>Each of the 6 stratifications and total</i>
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year's administrative rate (before exclusions)		✓
Minimum required sample size (MRSS)		✓
Oversampling rate		✓
Number of oversampling records		✓
Number of medical records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		<i>Each of the 6 stratifications and total</i>
Numerator events by administrative data	<i>Each of the 6 stratifications and total</i>	<i>Each of the 6 stratifications and total</i>
Numerator events by medical records		<i>Each of the 6 stratifications and total</i>
Numerator events by supplemental data	<i>Each of the 6 stratifications and total</i>	<i>Each of the 6 stratifications and total</i>
Reported rate	<i>Each of the 6 stratifications and total</i>	<i>Each of the 6 stratifications and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Colorectal Cancer Screening

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	The age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefit	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	NA	There is no event/diagnosis for this measure.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Required Exclusions	Yes	The palliative care exclusion is not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i>
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Value sets may not be changed.
Exclusions: I-SNP, LTI, Frailty or Advanced Illness	Yes	These exclusions are not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Colorectal Cancer Screening	No	The value sets and the logic may not be changed.

## ***Immunizations for Adolescents (IMA)***

---

### **SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021**

---

- No changes to this measure.

#### **Description**

The percentage of adolescents 13 years of age who had one dose of meningococcal vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates.

#### **Eligible Population**

**Note:** Members in hospice are excluded from the eligible population. If an organization reports this measure using the Hybrid method, and a member is found to be in hospice or using hospice services during medical record review, the member is removed from the sample and replaced by a member from the oversample. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Age</b>	Adolescents who turn 13 years of age during the measurement year.
<b>Continuous enrollment</b>	12 months prior to the member's 13th birthday.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the 12 months prior to the 13th birthday. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not continuously enrolled).
<b>Anchor date</b>	Enrolled on the member's 13th birthday.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

#### **Administrative Specification**

<b>Denominator</b>	The eligible population.
<b>Numerators</b>	For meningococcal, Tdap and HPV count <i>only</i> evidence of the antigen or combination vaccine.
<b><i>Meningococcal serogroups A, C, W, Y</i></b>	At least one meningococcal serogroups A, C, W, Y vaccine ( <a href="#">Meningococcal Immunization Value Set</a> ; <a href="#">Meningococcal Vaccine Procedure Value Set</a> ), with a date of service on or between the member's 11th and 13th birthdays.



**Tdap** At least one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine (Tdap Immunization Value Set; Tdap Vaccine Procedure Value Set), with a date of service on or between the member's 10th and 13th birthdays.

**HPV** • At least two HPV vaccines (HPV Immunization Value Set; HPV Vaccine Procedure Value Set), with dates of service at least 146 days apart on or between the member's 9th and 13th birthdays. For example, if the service date for the first vaccine was March 1, then the service date for the second vaccine must be after July 25.

**OR**

• At least three HPV vaccines (HPV Immunization Value Set; HPV Vaccine Procedure Value Set), with different dates of service on or between the member's 9th and 13th birthdays.

**Combination 1** Adolescents who are numerator compliant for both the meningococcal and Tdap indicators.  
(*Meningococcal, Tdap*)

**Combination 2** Adolescents who are numerator compliant for all three indicators (meningococcal, Tdap, HPV).  
(*Meningococcal, Tdap, HPV*)

**Exclusion (optional)**

---

Exclude adolescents who had a contraindication for a specific vaccine from the denominator for all antigen rates and the combination rates. The denominator for all rates must be the same. Contraindicated adolescents may be excluded only if administrative data do not indicate that the contraindicated immunization was rendered.

Any of the following meet optional exclusion criteria:

**Any particular vaccine** • Anaphylactic reaction to the vaccine or its components (Anaphylactic Reaction Due To Vaccination Value Set) any time on or before the member's 13th birthday.  
• Anaphylactic reaction to the vaccine or its components (Anaphylactic Reaction Due To Serum Value Set), with a date of service prior to October 1, 2011.

**Tdap** • Encephalopathy (Encephalopathy Due To Vaccination Value Set) with a vaccine adverse-effect code (Vaccine Causing Adverse Effect Value Set) anytime on or before the member's 13th birthday.

**Hybrid Specification**

**Denominator** A systematic sample drawn from the eligible population for each product line. Organizations may reduce the sample size using current year's administrative rate or prior year's audited, product line-specific rate for the lowest rate across all antigens and combinations. For information on reducing the sample size, refer to the *Guidelines for Calculations and Sampling*.

<b>Numerators</b>	For meningococcal, Tdap and HPV, count <i>only</i> the evidence of the antigen or combination vaccine.
<b>Administrative</b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from the administrative data.
<b>Medical record</b>	For immunization information obtained from the medical record, count members where there is evidence that the antigen was rendered from either of the following: <ul style="list-style-type: none"> <li>• A note indicating the name of the specific antigen and the date of the immunization.</li> <li>• A certificate of immunization prepared by an authorized health care provider or agency, including the specific dates and types of immunizations administered.</li> </ul>

For the two-dose HPV vaccination series, there must be at least 146 days between the first and second dose of the HPV vaccine.

For meningococcal, *do not count* meningococcal recombinant (serogroup B) (MenB) vaccines. Immunizations documented under a generic header of “meningococcal” and generic documentation that “meningococcal vaccine,” “meningococcal conjugate vaccine” or “meningococcal polysaccharide vaccine” were administered meet criteria.

Immunizations documented using a generic header of “Tdap/Td” can be counted as evidence of Tdap. The burden on organizations to substantiate the Tdap antigen is excessive compared to a risk associated with data integrity.

## Exclusion (optional)

---

Refer to *Administrative Specification* for exclusion criteria. The exclusion must have occurred on or before the member’s 13th birthday.

## Note

---

- To align with Advisory Committee on Immunization Practices (ACIP) recommendations, only the quadrivalent meningococcal vaccine (serogroups A, C, W and Y) is included in the measure.
- To align with ACIP recommendations, the minimum interval for the two-dose HPV vaccination schedule is 150 days (5 months), with a 4-day grace period (146 days).

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table IMA-1/2: Data Elements for Immunizations for Adolescents**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (administrative or hybrid)	✓	✓
Eligible population	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		<i>Each of the 5 rates</i>
Current year's administrative rate (before exclusions)		<i>Each of the 5 rates</i>
Minimum required sample size (MRSS)		✓
Oversampling rate		✓
Number of oversample records		✓
Number of medical records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical record data records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Numerator events by medical records		<i>Each of the 5 rates</i>
Numerator events by supplemental data	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Reported rate	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Immunizations for Adolescents

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select, "age 13 as of June 30"). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefit	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	NA	There is no event/diagnosis for this measure.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Value sets may not be changed.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
<ul style="list-style-type: none"> <li>• Meningococcal</li> <li>• Tdap</li> <li>• HPV</li> </ul>	No	Value sets and logic may not be changed. Vaccine dose requirements may not be changed.
<ul style="list-style-type: none"> <li>• Combination Rates</li> </ul>	Yes, with limits	Organizations are not required to calculate combination rates; alternate combinations of specified immunizations are allowed.

## MEASURE DEV-CH: DEVELOPMENTAL SCREENING IN THE FIRST THREE YEARS OF LIFE

Oregon Health and Sciences University

## A. DESCRIPTION

Percentage of children screened for risk of developmental, behavioral, and social delays using a standardized screening tool in the 12 months preceding or on their first, second, or third birthday.

Data Collection Method: Administrative or Hybrid

## Guidance for Reporting:

- This measure includes three age-specific indicators assessing whether children are screened before or on their first, second or third birthdays. Four rates, one for each age group and a combined rate, are to be calculated and reported. The code 96110 has been shown to have questionable validity in states that do not have policies clarifying the standardized tools meeting the criterion stated in the specification (see Section C).
- The measure steward recommends that such policies be in place if a state uses the administrative data component of the specifications. It is recommended (although not required) that states assess the accuracy of their claims/encounter data compared to medical charts. For example, a state could do a chart review on a sample of records where the CPT code was used to determine whether the developmental screening occurred and whether the tools used met the criteria for a standardized developmental screening. Another example, is that states may encourage use of a Z code or other modifiers to distinguish amongst tools ([https://www.aap.org/en-us/documents/coding\\_preventive\\_care.pdf](https://www.aap.org/en-us/documents/coding_preventive_care.pdf)).
- To facilitate CMS's understanding of the data reported for this measure, states should use the "Additional Notes/Comments on Measure" section to document whether a medical chart review was conducted to validate the use of the 96110 CPT code for this measure.
- States may calculate this measure using either the administrative specification (which depends on the 96110 CPT code) or the hybrid specification (which does not rely solely on this code).
- Only those tools cited in the specifications for this measure meet the criteria for the numerator. During the development of this measure, it was determined that the ASQ:SE and M-CHAT screening tools were too specific because they screen for a domain-specific condition (social emotional development or autism, respectively), rather than a full, general assessment of developmental delays. States should use the "Deviations from Measure Specifications" field to document any deviations from the specifications for this measure.

The following coding system is used in this measure: CPT. Refer to the Acknowledgments section at the beginning of the manual for copyright information.

## B. ELIGIBLE POPULATION

Age	Children age 1, 2, or 3 between January 1 and December 31 of the measurement year.
Continuous enrollment	Children who are enrolled continuously for 12 months prior to the child's 1st, 2nd, or 3rd birthday.
Allowable gap	No more than one gap in enrollment of up to 45 days during the 12 months prior to the child's first, second, or third birthday. To determine continuous enrollment for a beneficiary for whom enrollment is verified monthly, the beneficiary may not have more than a 1-month gap in coverage (i.e., a beneficiary whose coverage lapses for 2 months or 60 days is not considered continuously enrolled).
Anchor date	Enrolled on the child's first, second, or third birthday.
Benefit	Medical.
Event/diagnosis	None.

## C. ADMINISTRATIVE SPECIFICATION

**Denominator**

## Denominator 1

The children in the eligible population who turned 1 during the measurement year.

## Denominator 2

The children in the eligible population who turned 2 during the measurement year.

## Denominator 3

The children in the eligible population who turned 3 during the measurement year.

## Denominator 4

All children in the eligible population who turned 1, 2, or 3 during the measurement year, i.e., the sum of denominators 1, 2, and 3.

**Numerators**

The numerators identify children who were screened for risk of developmental, behavioral, and social delays using a standardized tool. National recommendations call for children to be screened three times in the first three years of life. This measure is based on three, age-specific indicators.

## Numerator 1

Children in Denominator 1 who had a claim with CPT code 96110 before or on their first birthday.

## Numerator 2

Children in Denominator 2 who had a claim with CPT code 96110 after their first and before or on their second birthdays.

**Numerator 3**

Children in Denominator 3 who had a claim with CPT code 96110 after their second and before or on their third birthdays.

**Numerator 4**

Children in the entire eligible population who had claim with CPT code 96110 in the 12 months preceding or on their 1st, 2nd, or 3rd birthday (the sum of numerators 1, 2 and 3).

**Claims data**

CPT code 96110 (Developmental testing, with interpretation and report)

**Important note about appropriate use of claims data**

This measure is anchored to standardized tools that meet four criteria specified below in the paragraph beginning with “Tools must meet the following criteria.” States that have policies clarifying that standardized tools meeting this criterion must be used to bill for 96110 should be able to report using claims data.

**Claims NOT included in this measure**

It is important to note that modified 96110 claims (for example, where modifiers are added to claims indicating standardized screening for a specific domain of development such as social emotional screening via the ASQ-SE, autism screening) should not be included as this measure is anchored to recommendations focused on global developmental screening using tools that focus on identifying risk for developmental, behavioral, and social delays.

**Exclusions**

None.

**D. MEDICAL RECORD SPECIFICATION****Denominator**

A systematic sample of 411 drawn from the eligible population stratified by age.

**Denominator 1**

137 children from the sample who turned 1 during the measurement year.

**Denominator 2**

137 children from the sample who turned 2 during the measurement year.

**Denominator 3**

137 children from the sample who turned 3 during the measurement year.

**Denominator 4**

The entire sample of 411 children.

**Numerators****Numerator 1**

Children in Denominator 1 who had screening for risk of developmental, behavioral, and social delays using a standardized screening tool that was documented before or on their first birthday.

#### Numerator 2

Children in Denominator 2 who had screening for risk of developmental, behavioral, and social delays using a standardized screening tool that was documented after their first and before or on their second birthday.

#### Numerator 3

Children in Denominator 3 who had screening for risk of developmental, behavioral, and social delays using a standardized screening tool that was documented after their second and before or on their third birthday.

#### Numerator 4

Children in Denominator 4 who had screening for risk of developmental, behavioral, and social delays using a standardized screening tool that was documented in the 12 months preceding or on their first, second or third birthday (the sum of numerators 1, 2 and 3).

Documentation in the medical record must include all of the following:

- A note indicating the date on which the test was performed, and
- The standardized tool used (see below), and
- Evidence of a screening result or screening score

Tools must meet the following criteria:

1. Developmental domains: The following domains must be included in the standardized developmental screening tool: motor (fine and gross), language, cognitive, and social-emotional.
2. Established Reliability: Reliability scores of approximately 0.70 or above.
3. Established Findings Regarding the Validity: Validity scores for the tool must be approximately 0.70 or above. Measures of validity must be conducted on a significant number of children and using an appropriate standardized developmental or social-emotional assessment instrument(s).
4. Established Sensitivity/Specificity: Sensitivity and specificity scores of approximately 0.70 or above.

The following tools included in the Bright Futures Recommendations for Preventive Care which reference the updated January 2020 American Academy of Pediatrics Statement: Promoting Optimal Development: Identifying Infants and Young Children with Developmental Disorders Through Developmental Surveillance and Screening and meet the above criteria:

- Ages and Stages Questionnaire - 3rd Edition (ASQ-3)
- Parents' Evaluation of Developmental Status (PEDS) - Birth to age 8
- Parent's Evaluation of Developmental Status - Developmental Milestones (PEDS-DM)
- Survey of Well-Being in Young Children (SWYC)

Note: The 2020 AAP statement provides descriptive information about the screening tool properties that may be useful for states to consider in designing their policies.



Tools that meet the criteria, were included in the 2006 statement, and not listed in 2020 Statement as they often are not used by primary care providers in the context of routine well-child care include the following:

- Battelle Developmental Inventory Screening Tool (BDI-ST) - Birth to 95 months
- Bayley Infant Neuro-developmental Screen (BINS) - 3 months to age 2
- Brigance Screens-II - Birth to 90 months
- Child Development Inventory (CDI) - 18 months to age 6
- Infant Development Inventory - Birth to 18 months

Tools NOT included in this measure: It is important to note that standardized tools specifically focused on one domain of development (e.g., child's socio-emotional development [ASQ-SE] or autism [M-CHAT]) are not included in the list above as this measure is anchored to recommendations related to global developmental screening using tools that identify risk for developmental, behavioral, and social delays.

Tools listed above: The tools listed above are not specific recommendations for tools but are examples of tools cited in Bright Futures that have met the above criteria. Bright Futures cites the 2020 American Academy of Pediatrics Statement: Promoting Optimal Development: Identifying Infants and Young Children With Developmental Disorders Through Developmental Surveillance and Screening..

### **Exclusions**

None.

## **E. CALCULATION ALGORITHM**

### **Step 1**

Determine the denominators.

From the total denominator, sort into three age cohorts: children who turned age one, two or three between January 1 and December 31 of the measurement year.

### **Step 2**

Determine the numerators.

For each age cohort, and for the total, identify children who had a screening for developmental, behavioral, and social delays performed before or on their birthday as found through claims data or documented in the medical chart.

Administrative Data: Children for whom a claim of 96110 was submitted for services in the 12 months preceding or on their birthday.

Medical Record Review: Children who had documentation in the medical record of developmental screening using a standardized, validated tool in the 12 months preceding or on their birthday. Documentation must include a note indicating the standardized tool that was used, the date of screening, and evidence that the tool was completed and scored.

### **Step 3**

Calculate the age-specific indicators (ages 1 to 3) by dividing the age-specific numerator by the age-specific denominator and multiplying by 100 to get a percentage.

#### Step 4

Create the overall measure of screening based on the age-specific numerators and denominators.

Total Numerator: Numerator 1 + Numerator 2 + Numerator 3

Total Denominator: Denominator 1 + Denominator 2 + Denominator 3

#### Sampling Methodology

If administrative data are used, the entire eligible population is used for the denominator. If using the hybrid method (administrative plus medical record data sources), a systematic sample can be drawn of 411, with 137 in each age group.

### F. OPTIONAL AGE-SPECIFIC OVERSAMPLING FOR THE DENOMINATOR

A sample of 411 will provide sufficient statistical power for states reporting a statewide developmental screening rate for children ages 1 to 3. With the smaller age-specific samples, the confidence intervals around the age-specific rates will be larger. Some states may wish to augment the sample in order to monitor screening rates for a particular age group; compare screening rates for a particular age group with that in other states; or look within an age group at subgroups, defined by race/ethnicity, geographic region, or language. For these applications, the age-specific sample of 137 may be insufficient, and the state may need a larger sample to obtain statistically meaningful results. The size of the sample required depends on the use of the data, so consultation with a statistician is recommended. The following instructions guide the development of an oversample.

The eligible population, from which the original sample was drawn, should be stratified by age, and the age-specific sample drawn from within each stratum. To oversample for any age group, the state should return to the original listing of eligible children in that age group, and continue adding children to the sample until the larger sample is complete. However, to maintain consistency of reporting and avoid having to weight the age groups to calculate the total, the state should only include the first 137 children sampled in the age-specific and total rates reported to CMS.

## Well-Child Visits in the First 30 Months of Life (W30)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Revised the measure name to *Well-Child Visits in the First 30 Months of Life*.
- Retired the 0, 1, 2, 3, 4 and 5 well-child visit rates.
- Added Rate 2 for children who turned 30 months old during the measurement year and had two or more well-child visits in the last 15 months.
- Removed the Hybrid Data Collection Method.
- Removed the telehealth exclusion.
- Revised the Data Elements for Reporting table.
- Revised the Ages criteria in the *Rules for Allowable Adjustments* section to only allow ranges within the specified age range of the measure.

### Description

The percentage of members who had the following number of well-child visits with a PCP during the last 15 months. The following rates are reported:

1. *Well-Child Visits in the First 15 Months*. Children who turned 15 months old during the measurement year: Six or more well-child visits.
2. *Well-Child Visits for Age 15 Months–30 Months*. Children who turned 30 months old during the measurement year: Two or more well-child visits.

### Note

- *This measure has the same structure as measures in the Effectiveness of Care domain. The organization must follow the Guidelines for Effectiveness of Care Measures when calculating this measure.*

### Eligible Population: Rate 1—Well-Child Visits in the First 15 Months

**Note:** *Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.*

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	Children who turn 15 months old during the measurement year. Calculate the 15-month birthday as the child's first birthday plus 90 days.
<b>Continuous enrollment</b>	31 days–15 months of age. Calculate 31 days of age by adding 31 days to the date of birth.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the continuous enrollment period. To determine continuous enrollment for a Medicaid member for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	The date when the child turns 15 months old.

<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

### Administrative Specification: *Rate 1—Well-Child Visits in the First 15 Months*

<b>Denominator</b>	The Rate 1 eligible population.
<b>Numerator</b>	Six or more well-child visits ( <u>Well-Care Value Set</u> ) on different dates of service on or before the 15-month birthday.  The well-child visit must occur with a PCP, but the PCP does not have to be the practitioner assigned to the child.

### Eligible Population: *Rate 2—Well-Child Visits for Age 15 Months–30 Months*

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	Children who turn 30 months old during the measurement year. Calculate the 30-month birthday as the second birthday plus 180 days.
<b>Continuous enrollment</b>	15 months plus 1 day–30 months of age. Calculate the 15-month birthday plus 1 day as the first birthday plus 91 days.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the continuous enrollment period. To determine continuous enrollment for a Medicaid member for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	The date when the child turns 30 months old.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

### Administrative Specification: *Rate 2—Well-Child Visits for Age 15 Months–30 Months*

<b>Denominator</b>	The Rate 2 eligible population.
<b>Numerator</b>	Two or more well-child visits ( <u>Well-Care Value Set</u> ) on different dates of service between the child's 15-month birthday plus 1 day and the 30-month birthday.  The well-child visit must occur with a PCP, but the PCP does not have to be the practitioner assigned to the child.

### Note

- Refer to Appendix 3 for the definition of PCP.
- This measure is based on the American Academy of Pediatrics Bright Futures: Guidelines for Health Supervision of Infants, Children and Adolescents (published by the National Center for Education in Maternal and Child Health). Visit the Bright Futures website for more information about well-child visits (<https://brightfutures.aap.org/materials-and-tools/guidelines-and-pocket-guide/>).

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table W30-1/2: Data Elements for Well-Child Visits in the First 30 Months of Life**

	Administrative
Measurement year	✓
Eligible population	<i>Each of the 2 rates</i>
Numerator events by administrative data	<i>Each of the 2 rates</i>
Numerator events by supplemental data	<i>Each of the 2 rates</i>
Reported rate	<i>Each of the 2 rates</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Well-Child Visits in the First 30 Months of Life

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	The age determination dates may be changed (e.g., select, "age 15 months as of June 30"). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	NA	There is no event/diagnosis for this measure.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Exclusions	NA	There are no exclusions for this measure.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
<ul style="list-style-type: none"> <li>Well Care Visits in the First 15 Months</li> <li>Well Care Visits for Age 15 Months–30 Months</li> </ul>	No	Value sets and logic may not be changed.

## Child and Adolescent Well-Care Visits (WCV)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- This measure is a combination measure that replaces the former “Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life” and “Adolescent Well-Care Visits” HEDIS measures.
- Added members age 7–11 years.
- Added age stratifications.
- Removed the Hybrid Data Collection Method.
- Removed the telehealth exclusion.
- Revised the Data Elements for Reporting table.
- Revised the Ages criteria in the *Rules for Allowable Adjustments* section to only allow ranges within the specified age range.

### Description

The percentage of members 3–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	<p>3–21 years as of December 31 of the measurement year. Report three age stratifications and total rate:</p> <ul style="list-style-type: none"><li>• 3–11 years.</li><li>• 12–17 years.</li><li>• 18–21 years.</li><li>• Total.</li></ul> <p>The total is the sum of the age stratifications for each product line.</p>
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the continuous enrollment period. To determine continuous enrollment for a Medicaid member for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

## Administrative Specification

**Denominator** The eligible population.

**Numerator** One or more well-care visits (Well-Care Value Set) during the measurement year.

The well-care visit must occur with a PCP or an OB/GYN practitioner, but the practitioner does not have to be the practitioner assigned to the member.

### Note

- Refer to Appendix 3 for the definition of PCP and OB/GYN and other prenatal care practitioners.
- This measure is based on the American Academy of Pediatrics Bright Futures: Guidelines for Health Supervision of Infants, Children and Adolescents (published by the National Center for Education in Maternal and Child Health). Visit the Bright Futures website for more information about well-child visits (<https://brightfutures.aap.org/materials-and-tools/guidelines-and-pocket-guide/>).

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table WCV-1/2: Data Elements for Child and Adolescent Well-Care Visits**

	Administrative
Measurement year	✓
Eligible population	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>For each age stratification and total</i>
Numerator events by supplemental data	<i>For each age stratification and total</i>
Reported rate	<i>For each age stratification and total</i>



## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Child and Adolescent Well-Care Visits

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	The age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age may be changed if the range is within the specified age range (3–21 years). Organizations must consult American Academy of Pediatrics guidelines when considering whether to expand the age ranges outside of the current thresholds.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	NA	There is no event/diagnosis for this measure.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Exclusions	NA	There are no exclusions for this measure.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Well-Child Visit(s)	No	Value sets and logic may not be changed.

## Prenatal and Postpartum Care (PPC)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Revised the definition of last enrollment segment.
- Clarified that visits that occur prior to the enrollment start date (during the pregnancy) meet criteria.
- Added telephone visits (Telephone Visits Value Set) e-visits and virtual check-ins (Online Assessments Value Set) to the Timeliness of Prenatal Care rate (administrative specification) and clarified in the *Notes* that services provided via telephone, e-visit or virtual check-in are eligible for use in reporting both rates.
- Updated the Hybrid specification to indicate that sample size reduction is allowed using only the current year's administrative rate for MY 2020; for MY 2021, organizations may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate.
- Added examples of "pregnancy diagnosis" in the Hybrid specification of the Timeliness of Prenatal Care indicator.

### Description

The percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. For these women, the measure assesses the following facets of prenatal and postpartum care.

- *Timeliness of Prenatal Care.* The percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the organization.
- *Postpartum Care.* The percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery.

### Definitions

<b>First trimester</b>	280–176 days prior to delivery (or EDD).
<b>Last enrollment segment</b>	The period of continuous enrollment (with no gaps in enrollment) during the pregnancy with the start date that is closest to the delivery date. Use guideline "Members Who Switch Products/Product Lines" in the <i>General Guidelines for Data Collection and Reporting</i> to determine continuous enrollment.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. If an organization reports this measure using the Hybrid method, and a member is found to be in hospice or using hospice services during medical record review, the member is removed from the sample and replaced by a member from the oversample. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Age</b>	None specified.
<b>Continuous enrollment</b>	43 days prior to delivery through 60 days after delivery.

<b>Allowable gap</b>	No allowable gap during the continuous enrollment period.
<b>Anchor date</b>	Date of delivery.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	<p><i>Delivered a live birth on or between October 8 of the year prior to the measurement year and October 7 of the measurement year.</i> Include women who delivered in any setting.</p> <p><i>Multiple births.</i> Women who had two separate deliveries (different dates of service) between October 8 of the year prior to the measurement year and October 7 of the measurement year count twice. Women who had multiple live births during one pregnancy count once.</p> <p>Follow the steps below to identify the eligible population, which is the denominator for both rates.</p> <p><b>Step 1</b> Identify deliveries. Identify all women with a delivery (<u>Deliveries Value Set</u>) on or between October 8 of the year prior to the measurement year and October 7 of the measurement year.</p> <p><b>Note:</b> <i>The intent is to identify the date of delivery (the date of the “procedure”). If the date of delivery cannot be interpreted on the claim, use the date of service or, for inpatient claims, the date of discharge.</i></p> <p><b>Step 2</b> Exclude non-live births (<u>Non-live Births Value Set</u>).</p> <p><b>Step 3</b> Identify continuous enrollment. Determine if enrollment was continuous 43 days prior to delivery through 60 days after delivery, with no gaps.</p>

### Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	
<b>Timeliness of Prenatal Care</b>	<p>A prenatal visit during the required timeframe. Follow the steps below to identify numerator compliance.</p> <p><b>Step 1</b> Identify women whose last enrollment segment started before, on or between 280 and 219 days before delivery (or EDD).</p> <p>These women must have a prenatal visit during the first trimester.</p> <p><b>Step 2</b> Identify women whose last enrollment segment started less than 219 days before delivery (or EDD).</p> <p>These women must have a prenatal visit any time during the period that begins 280 days prior to delivery and ends 42 days after enrollment start date.</p> <p>Do not count visits that occur on or after the date of delivery. Visits that occur prior to the woman’s enrollment start date during the pregnancy meet criteria.</p> <p><b>Step 3</b> Identify prenatal visits that occurred during the required timeframe (the time frame identified in step 1 or 2). Any of the following, where the practitioner type is an OB/GYN or other prenatal care practitioner or PCP, meet criteria for a prenatal visit:</p>

- A bundled service (Prenatal Bundled Services Value Set) where the organization can identify the date when prenatal care was initiated (because bundled service codes are used on the date of delivery, these codes may be used only if the claim form indicates when prenatal care was initiated).
- A visit for prenatal care (Stand Alone Prenatal Visits Value Set).
- A prenatal visit (Prenatal Visits Value Set; Telephone Visits Value Set; Online Assessments Value Set) **with** a pregnancy-related diagnosis code (Pregnancy Diagnosis Value Set).

**Postpartum Care** A postpartum visit on or between 7 and 84 days after delivery. Any of the following meet criteria:

- A postpartum visit (Postpartum Visits Value Set).
- Cervical cytology (Cervical Cytology Lab Test Value Set; Cervical Cytology Result or Finding Value Set).
- A bundled service (Postpartum Bundled Services Value Set) where the organization can identify the date when postpartum care was rendered (because bundled service codes are used on the date of delivery, not on the date of the postpartum visit, these codes may be used only if the claim form indicates when postpartum care was rendered).

Exclude services provided in an acute inpatient setting (Acute Inpatient Value Set; Acute Inpatient POS Value Set).

**Note:** The practitioner requirement only applies to the Hybrid Specification. The organization is not required to identify practitioner type in administrative data.

## Hybrid Specification

<b>Denominator</b>	<p>A systematic sample drawn from the eligible population for each product line.</p> <p>For MY 2020 reporting, the organization may reduce the sample size using the current year's administrative rate. The prior year's reported rate may not be used when reducing the sample size for MY 2020 reporting.</p> <p>For MY 2021 reporting, organizations may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate.</p> <p>Refer to the <i>Guidelines for Calculations and Sampling</i> for information on reducing the sample size.</p>
<b>Numerator</b>	
<b><i>Timeliness of Prenatal Care</i></b>	A prenatal visit during the required timeframe. Refer to the Administrative Specification to identify the required timeframe for each woman based on the date of enrollment in the organization and the gaps in enrollment during the pregnancy.
<b><u>Administrative</u></b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from the administrative data.

**Medical record**

Prenatal care visit to an OB/GYN or other prenatal care practitioner, or PCP. For visits to a PCP, a diagnosis of pregnancy must be present. Documentation in the medical record must include a note indicating the date when the prenatal care visit occurred, and evidence of *one* of the following.

- Documentation indicating the woman is pregnant or references to the pregnancy; for example:
  - Documentation in a standardized prenatal flow sheet, **or**
  - Documentation of LMP, EDD or gestational age, **or**
  - A positive pregnancy test result, **or**
  - Documentation of gravidity and parity, **or**
  - Documentation of complete obstetrical history, **or**
  - Documentation of prenatal risk assessment and counseling/education.
- A basic physical obstetrical examination that includes auscultation for fetal heart tone, **or** pelvic exam with obstetric observations, **or** measurement of fundus height (a standardized prenatal flow sheet may be used).
- Evidence that a prenatal care procedure was performed, such as:
  - Screening test in the form of an obstetric panel (must include all of the following: hematocrit, differential WBC count, platelet count, hepatitis B surface antigen, rubella antibody, syphilis test, RBC antibody screen, Rh and ABO blood typing), **or**
  - TORCH antibody panel alone, **or**
  - A rubella antibody test/titer with an Rh incompatibility (ABO/Rh) blood typing, **or**
  - Ultrasound of a pregnant uterus.

**Postpartum Care**

A postpartum visit on or between 7 and 84 days after delivery, as documented through either administrative data or medical record review.

**Administrative**

Refer to *Administrative Specification* to identify positive numerator hits from the administrative data.

**Medical record**

Postpartum visit to an OB/GYN or other prenatal care practitioner, or PCP on or between 7 and 84 days after delivery. Do not include postpartum care provided in an acute inpatient setting.

Documentation in the medical record must include a note indicating the date when a postpartum visit occurred and *one* of the following.

- Pelvic exam.
- Evaluation of weight, BP, breasts and abdomen.
  - Notation of “breastfeeding” is acceptable for the “evaluation of breasts” component.
- Notation of postpartum care, including, but not limited to:
  - Notation of “postpartum care,” “PP care,” “PP check,” “6-week check.”
  - A preprinted “Postpartum Care” form in which information was documented during the visit.
- Perineal or cesarean incision/wound check.
- Screening for depression, anxiety, tobacco use, substance use disorder, or preexisting mental health disorders.

- Glucose screening for women with gestational diabetes.
- Documentation of any of the following topics:
  - Infant care or breastfeeding.
  - Resumption of intercourse, birth spacing or family planning.
  - Sleep/fatigue.
  - Resumption of physical activity.
  - Attainment of healthy weight.

### Note

- *Criteria for identifying prenatal care for women who were not continuously enrolled during the first trimester allow more flexibility than criteria for women who were continuously enrolled.*
  - *For women whose last enrollment segment started before, on or between 280 and 219 days before delivery, the organization has sufficient opportunity to provide prenatal care by the end of the first trimester.*
  - *For women whose last enrollment segment started less than 219 days before delivery, the organization has sufficient opportunity to provide prenatal care within 42 days after enrollment.*
- *Services that occur over multiple visits count toward this measure if all services are within the time frame established in the measure. Ultrasound and lab results alone are not considered a visit; they must be combined with an office visit with an appropriate practitioner in order to count for this measure.*
- *For each member, the organization must use one date (date of delivery or EDD) to define the start and end of the first trimester. If multiple EDDs are documented, the organization must define a method to determine which EDD to use, and use that date consistently. If the organization elects to use EDD, and the EDD is not on or between October 8 of the year prior to the measurement year and October 7 of the measurement year, the member is excluded as a valid data error and replaced by the next member of the oversample. The LMP may not be used to determine the first trimester.*
- *The organization may use EDD to identify the first trimester for the Timeliness of Prenatal Care rate and use the date of delivery for the Postpartum Care rate.*
- *A Pap test does not count as a prenatal care visit for the administrative and hybrid specification of the Timeliness of Prenatal Care rate, but is acceptable for the Postpartum Care rate as evidence of a pelvic exam. A colposcopy alone is not numerator compliant for either rate.*
- *The intent is that a prenatal visit is with a PCP or OB/GYN or other prenatal care practitioner. Ancillary services (lab, ultrasound) may be delivered by an ancillary provider. Nonancillary services (e.g., fetal heart tone, prenatal risk assessment) must be delivered by the required provider type.*
- *The intent is to assess whether prenatal and preventive care was rendered on a routine, outpatient basis rather than assessing treatment for emergent events.*
- *Refer to Appendix 3 for the definition of PCP and OB/GYN and other prenatal care practitioner.*
- *For both rates, services provided during a telephone visit, e-visit or virtual check-in are eligible for use in reporting.*

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table PPC-1/2: Data Elements for Prenatal and Postpartum Care**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	<i>For each of the 2 rates</i>	<i>For each of the 2 rates</i>
Eligible population	<i>For each of the 2 rates</i>	<i>For each of the 2 rates</i>
Number of numerator events by administrative data in eligible population (before exclusions)		<i>For each of the 2 rates</i>
Current year's administrative rate (before exclusions)		<i>For each of the 2 rates</i>
Minimum required sample size (MRSS)		<i>For each of the 2 rates</i>
Oversampling rate		<i>For each of the 2 rates</i>
Number of oversample records		<i>For each of the 2 rates</i>
Number of medical records excluded because of valid data errors		<i>For each of the 2 rates</i>
Number of employee/dependent medical records excluded		<i>For each of the 2 rates</i>
Records added from the oversample list		<i>For each of the 2 rates</i>
Denominator		<i>For each of the 2 rates</i>
Numerator events by administrative data	<i>For each of the 2 rates</i>	<i>For each of the 2 rates</i>
Numerator events by medical records		<i>For each of the 2 rates</i>
Reported rate	<i>For each of the 2 rates</i>	<i>For each of the 2 rates</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Prenatal and Postpartum Care

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	NA	There are no ages specified in this measure.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	Yes, with limits	Only events that contain (or map to) codes in the value sets may be used to identify visits. The value sets and logic may not be changed. Organizations may not change the logic but may change the delivery date and account for the impact on other date-dependent events. <b>Note:</b> Organizations may assess at the member level (vs. discharge level) by applying measure logic appropriately (i.e., percentage of members with deliveries).
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Exclusions	NA	There are no exclusions for this measure.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
<ul style="list-style-type: none"> <li>Timeliness of Prenatal Care</li> <li>Postpartum Care</li> </ul>	No	Value sets and logic may not be changed. If the delivery-date range is changed, all numerator events must be measured in relation to the new range.



**Quality ID #134 (NQF 0418): Preventive Care and Screening: Screening for Depression and Follow-Up Plan**

– National Quality Strategy Domain: Community/Population Health

– Meaningful Measure Area: Prevention, Treatment, and Management of Mental Health

**2020COLLECTION TYPE:**

**MEDICARE PART B CLAIMS**

**MEASURE TYPE:**

Process

**DESCRIPTION:**

Percentage of patients aged 12 years and older screened for depression on the date of the encounter or 14 days prior to the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the eligible encounter

**INSTRUCTIONS:**

This measure is to be submitted a minimum of **once per measurement period** for patients seen during the measurement period. The most recent quality-data code submitted will be used for performance calculation. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. The follow-up plan must be related to a positive depression screening, example: "Patient referred for psychiatric evaluation due to positive depression screening".

**Measure Submission Type:**

Measure data may be submitted by individual MIPS eligible clinicians using Medicare Part B claims. The listed denominator criteria are used to identify the intended patient population. The numerator quality-data codes included in this specification are used to submit the quality actions allowed by the measure on the claim form(s). All measure-specific coding should be submitted on the claim(s) representing the denominator eligible encounter and selected numerator option.

**DENOMINATOR:**

All patients aged 12 years and older at the beginning of the measurement period with at least one eligible encounter during the measurement period

***DENOMINATOR NOTE:*** \*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services will not be counted in the denominator population for Medicare Part B claims measures.

**Denominator Criteria (Eligible Cases):**

Patients aged ≥ 12 years on date of encounter

**AND**

**Patient encounter during the performance period (CPT or HCPCS):** 59400, 59510, 59610, 59618, 90791, 90792, 90832, 90834, 90837, 92625, 96105, 96110, 96112, 96116, 96125, 96136, 96138, 96156, 96158, 97161, 97162, 97163, 97165, 97166, 97167, 99078, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99318, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99339, 99340, 99401\*, 99402\*, 99403\*, 99483, 99484, 99492, 99493, 99384\*, 99385\*, 99386\*, 99387\*, 99394\*, 99395\*, 99396\*, 99397\*, G0101, G0402, G0438, G0439, G0444

## **NUMERATOR:**

Patients screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age appropriate standardized tool AND, if positive, a follow-up plan is documented on the date of the eligible encounter

### **Definitions:**

**Screening** – Completion of a clinical or diagnostic tool used to identify people at risk of developing or having a certain disease or condition, even in the absence of symptoms.

**Standardized Depression Screening Tool** – A normalized and validated depression screening tool developed for the patient population in which it is being utilized. The name of the age appropriate standardized depression screening tool utilized must be documented in the medical record.

Examples of depression screening tools include but are not limited to:

- **Adolescent Screening Tools (12-17 years)**

Patient Health Questionnaire for Adolescents (PHQ-A), Beck Depression Inventory-Primary Care Version (BDI-PC), Mood Feeling Questionnaire (MFQ), Center for Epidemiologic Studies Depression Scale (CES-D), Patient Health Questionnaire (PHQ-9), Pediatric Symptom Checklist (PSC-17), and PRIME MD-PHQ-2

- **Adult Screening Tools (18 years and older)**

Patient Health Questionnaire (PHQ-9), Beck Depression Inventory (BDI or BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Depression Scale (DEPS), Duke Anxiety-Depression Scale (DADS), Geriatric Depression Scale (GDS), Cornell Scale for Depression in Dementia (CSDD), PRIME MD-PHQ-2, Hamilton Rating Scale for Depression (HAM-D), Quick Inventory of Depressive Symptomatology Self-Report (QID-SR), Computerized Adaptive Testing Depression Inventory (CAT-DI), and Computerized Adaptive Diagnostic Screener (CAD-MDD)

- **Perinatal Screening Tools**

Edinburgh Postnatal Depression Scale, Postpartum Depression Screening Scale, Patient Health Questionnaire 9 (PHQ-9), Beck Depression Inventory, Beck Depression Inventory-II, Center for Epidemiologic Studies Depression Scale, and Zung Self-rating Depression Scale

**Follow-Up Plan** – Documented follow-up for a positive depression screening **must** include one or more of the following:

- Additional evaluation or assessment for depression
- Suicide Risk Assessment
- Referral to a practitioner who is qualified to diagnose and treat depression
- Pharmacological interventions
- Other interventions or follow-up for the diagnosis or treatment of depression

Examples of a follow-up plan include but are not limited to:

- \* Additional evaluation or assessment for depression such as psychiatric interview, psychiatric evaluation, or assessment for bipolar disorder
- \* Completion of any Suicide Risk Assessment such as Beck Depression Inventory or Beck Hopelessness Scale
- \* Referral to a practitioner or program for further evaluation for depression, for example, referral to a psychiatrist, psychologist, social worker, mental health counselor, or other mental health service such as family or group therapy, support group, depression management program, or other service for treatment of depression
- \* Other interventions designed to treat depression such as psychotherapy, pharmacological interventions, or additional treatment options
- \* Pharmacologic treatment for depression is often indicated during pregnancy and/or lactation. Review and discussion of the risks of untreated versus treated depression is advised. Consideration of each patient's prior disease and treatment history, along with the risk profiles for individual pharmacologic agents, is important when selecting pharmacologic therapy with the greatest likelihood of treatment effect.

**Not Eligible for Depression Screening or Follow-Up Plan (Denominator Exclusion) –**

- Patient has an active diagnosis of depression prior to any encounter during the measurement period- F01.51, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.89, F32.9, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9, F34.1, F34.81, F34.89, F43.21, F43.23, F53.0, F53.1, O90.6, O99.340, O99.341, O99.342, O99.343, O99.345
- Patient has a diagnosed bipolar disorder prior to any encounter during the measurement period- F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78, F31.81, F31.89, F31.9

**Patients with a Documented Reason for not Screening for Depression (Denominator Exception) –** One or more of the following conditions are documented during the encounter during the measurement period:

- Patient refuses to participate
- Patient is in an urgent or emergent situation where time is of the essence and to delay treatment would jeopardize the patient's health status
- Situations where the patient's cognitive capacity, functional capacity or motivation to improve may impact the accuracy of results of standardized depression assessment tools. For example: certain court appointed cases or cases of delirium

**Numerator Instructions:**

A depression screen is completed on the date of the encounter or up to 14 days prior to the date of the encounter using an age appropriate standardized depression screening tool AND if positive, either additional evaluation for depression, suicide risk assessment, referral to a practitioner who is qualified to diagnose and treat depression, pharmacological interventions, or other interventions or follow-up for the diagnosis or treatment of depression is documented on the date of the eligible encounter. Depression screening is required once per measurement period, not at all encounters; this is patient based and not an encounter based measure. The name of the age appropriate standardized depression screening tool utilized must be documented in the medical record. The depression screening must be reviewed and addressed in the office of the provider filing the code on the date of the encounter. Positive pre-screening results indicating a patient is at high risk for self-harm should receive more urgent intervention as determined by the provider practice. The screening should occur during a qualified encounter or up to 14 days prior to the date of the qualifying encounter.

**Numerator Quality-Data Coding Options:**

**Depression Screening or Follow-Up Plan not Documented, Patient not Eligible**

***Denominator Exclusion:*** G9717:

Documentation stating the patient has an active diagnosis of depression or has a diagnosed bipolar disorder, therefore screening or follow-up not required

**OR**

**Screening for Depression Documented as Positive, AND Follow-Up Plan Documented**

***Performance Met:*** G8431:

Screening for depression is documented as being positive AND a follow-up plan is documented

**OR**

**Screening for Depression Documented as Negative, Follow-Up Plan not Required**

***Performance Met:*** G8510:

Screening for depression is documented as negative, a follow-up plan is not required

**OR**

**Screening for Depression not Completed, Documented Reason**

***Denominator Exception:*** G8433:

Screening for depression not completed, documented reason

**OR**

**Screening for Depression not Documented, Reason not Given**

**Performance Not Met: G8432:**

Depression screening not documented, reason not given

**OR**

**Screening for Depression Documented as Positive, Follow-Up Plan not Documented, Reason not Given**

**Performance Not Met: G8511:**

Screening for depression documented as positive, follow-up plan not documented, reason not given

**RATIONALE:**

Depression is a serious medical illness associated with higher rates of chronic disease increased health care utilization, and impaired functioning (Pratt & Brody, 2014). 2016 U.S. survey data indicate that 12.8 percent of adolescents (2.2 million adolescents) had a major depressive episode (MDE) in the past year, with nine percent of adolescents (2.2 million adolescents) having one MDE with severe impairment; 6.7 percent of adults aged 18 or older (16.2 million adults) had at least one MDE in the past year, with 4.3 percent of adults (10.3 million adults) having one MDE with severe impairment in the past year (Substance Abuse and Mental Health Services Administration, 2017). Data indicate that severity of depressive symptoms factor into having difficulty with work, home, or social activities. For example, as the severity of depressive symptoms increased, rates of having difficulty with work, home, or social activities related to depressive symptoms increased. For those twelve and older with mild depressive symptoms, 45.7% reported difficulty with activities and those with severe depressive symptoms, 88.0% reported difficulty (Pratt & Brody, 2014). Children and teens with major depressive disorder (MDD) has been found to have difficulty carrying out their daily activities, relating to others, and growing up healthy with an increased risk of suicide (Siu & the U.S. Preventive Services Task Force [USPSTF], 2016). Additionally, perinatal depression (considered here as depression arising in the period from conception to the end of the first postnatal year) affects up to 15% of women. Depression and other mood disorders, such as bipolar disorder and anxiety disorders, especially during the perinatal period, can have devastating effects on women, infants, and families (Molenaar et al., 2018). Maternal suicide rates rise over hemorrhage and hypertensive disorders as a cause of maternal mortality (American College of Obstetricians and Gynecologists, 2015).

Negative outcomes associated with depression make it crucial to screen in order to identify and treat depression in its early stages. While Primary Care Providers (PCPs) serve as the first line of defense in the detection of depression, studies show that PCPs fail to recognize up to 50% of depressed patients: "Coyle et al. (2003), suggested that the picture is more grim for adolescents, and that more than 70% of children and adolescents suffering from serious mood disorders go unrecognized or inadequately treated" (Borner et al., 2010, p. 948). "In nationally representative U.S. surveys, about eight percent of adolescents reported having major depression in the past year. Only 36% to 44% of children and adolescents with depression receive treatment, suggesting that the majority of depressed youth are undiagnosed and untreated" (Sui on behalf of USPSTF, 2016, p. 360 & p. 364) Evidence supports that screening for depression in pregnant and postpartum women is of moderate net benefit and treatment options for positive depression screening should be available for patients twelve and older including pregnant and postpartum women.

If preventing negative patient outcomes is not enough, the substantial economic burden of depression for individuals and society alike makes a case for screening for depression on a regular basis. Depression imposes economic burden through direct and indirect costs. "In the United States, an estimated \$22.8 billion was spent on depression treatment in 2009, and lost productivity cost an additional estimated \$23 billion in 2011" (Sui & USPSTF, 2016, p. 383-384).

This measure seeks to align with clinical guideline recommendations as well as the Healthy People 2020 recommendation for routine screening for mental health problems as a part of primary care for both children and adults (U.S. Department of Health and Human Services, 2014) and makes an important contribution to the quality domain of community and population health.

**CLINICAL RECOMMENDATION STATEMENTS:****Adolescent Recommendation (12-18 years):**

“The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation)” (Sui on behalf of, USPSTF, 2016, p. 360).

“Clinicians and health care systems should try to consistently screen adolescents ages 12-18 for major depressive disorder, but only when systems are in place to ensure accurate diagnosis, careful selection of treatment, and close follow-up” (Wilkinson et al., 2013, p. 16).

**Adult Recommendation (18 years and older):**

“The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation)” (Sui 2016, p. 380).

The Institute for Clinical Systems Improvement (ICSI) health care guideline, Adult Depression in Primary Care, provides the following recommendations:

1. “Clinicians should routinely screen all adults for depression using a standardized instrument.”
2. “Clinicians should establish and maintain follow-up with patients.”
3. “Clinicians should screen and monitor depression in pregnant and post-partum women.” (Trangle et al., 2016 p.p. 8–10)

**COPYRIGHT:**


These measures were developed by Quality Insights, Inc. as a special project under the Quality Insights' Medicare Quality Improvement Organization (QIO) contract HHSM-500-2005-PA001C with the Centers for Medicare & Medicaid Services. These measures are in the public domain.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Quality Insights, Inc. disclaims all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. CPT® contained in the Measure specifications is copyright 2004-2019 American Medical Association. ICD-10 is copyright 2019 World Health Organization. All Rights Reserved. These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

**THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.**

**2020 Medicare Part B Claims Flow for Quality ID #134 NQF #0418:  
Preventive Care and Screening: Screening for Depression and Follow-Up Plan**

*Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.*



SAMPLE CALCULATIONS:

Data Completeness Rate=

$$\frac{\text{Denominator Exclusion (x=10 pts)} + \text{Performance Met (a'+a''=50 pts)} + \text{Denominator Exception (b'=10 pts)} + \text{Performance Not Met (c'+c''=20 pts)}}{\text{Eligible Population / Denominator (d=100 patients)}} = \frac{90 \text{ patients}}{100 \text{ patients}} = 90.00\%$$

Performance Rate=

$$\frac{\text{Performance Met (a'+a''=50 patients)}}{\text{Data Completeness Numerator (90 patients) - Denominator Exclusion (x = 10 patients) - Denominator Exception (b'= 10 patients)}} = \frac{50 \text{ patients}}{70 \text{ patients}} = 71.43\%$$

\*See the posted measure specification for specific coding and instruction to submit this measure.

NOTE: Submission Frequency: Patient-Process

CPT only copyright 2019 American Medical Association. All rights reserved.  
The measure diagrams were developed by CMS as a supplemental resource to be used  
in conjunction with the measure specifications. They should not be used alone or as a  
substitution for the measure specification. v4

**2020 Medicare Part B Claims Flow Narrative for Quality ID #134 NQF #0418:  
Preventative Care and Screening: Screening for Depression and Follow-Up Plan**

**Disclaimer:** Refer to the measure specification for specific coding and instructions to submit this measure.

1. Start with Denominator
2. Check Patient Age:
  - a. If the Patient Age is greater than or equal to 12 Years on Date of Eligible Encounter equals No during the measurement period, do not include in Eligible Population. Stop Processing.
  - b. If the Patient Age is greater than or equal to 12 Years on Date of Eligible Encounter equals Yes during the measurement period, proceed to check Encounter Performed.
3. Check Encounter Performed:
  - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
  - b. If Encounter as Listed in the Denominator equals Yes, include in the Eligible Population.
4. Denominator Population:
  - a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 100 patients in the Sample Calculation.
5. Start Numerator
6. Check Depression Screening or Follow-Up Plan Not Documented, Patient Not Eligible:
  - a. If Screening for Depression or Follow-Up Plan Not Documented, Patient Not Eligible equals Yes, include in Data Completeness Met and Denominator Exclusion.
  - b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x<sup>1</sup> equals 10 patients in the Sample Calculation.
  - c. If Screening for Depression or Follow-Up Plan Not Documented, Patient Not Eligible equals No, proceed to check Screening for Depression Documented as Positive, And Follow-up Plan Documented.
7. Check Screening for Depression Documented as Positive, And Follow-up Plan Documented:
  - a. If Screening for Depression Documented as Positive, And Follow-up Plan Documented equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a<sup>1</sup> equals 20 patients in the Sample Calculation.
  - c. If Screening for Depression Documented as Positive, And Follow-up Plan Documented equals No, proceed to check Screening for Depression Documented as Negative, Follow-up Plan Not Required.
8. Check Screening for Depression Documented as Negative, Follow-up Plan Not Required:



- a. If Screening for Depression Documented as Negative, Follow-up Plan Not Required equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a<sup>2</sup> equals 30 patients in the Sample Calculation.
  - c. If Screening for Depression Documented as Negative, Follow-up Plan Not Required equals No, proceed to check Screening for Depression Not Completed, Documented Reason.
9. Check Screening for Depression Not Completed, Documented Reason:
  - a. If Screening for Depression Not Completed, Documented Reason equals Yes, include in the Data Completeness Met and Denominator Exception.
  - b. Data Completeness Met and Denominator Exception letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b<sup>1</sup> equals 10 patients in the Sample Calculation.
  - c. If Screening for Depression Not Completed, Documented Reason equals No, proceed to check Screening for Depression Not Documented, Reason Not Given.
10. Check Screening for Depression Not Documented, Reason Not Given:
  - a. If Screening for Depression Not Documented, Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
  - b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c<sup>1</sup> equals 10 patients in the Sample Calculation.
  - c. If Screening for Depression Not Documented, Reason Not Given equals No, proceed to check Screening for Depression Documented as Positive, Follow-Up Plan Not Documented, Reason Not Given.
11. Check Screening for Depression Documented as Positive, Follow-Up Plan Not Documented, Reason Not Given:
  - a. If Screening for Depression Documented as Positive, Follow-Up Plan Not Documented, Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
  - b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c<sup>2</sup> equals 10 patients in the Sample Calculation.
  - c. If Screening for Depression Documented as Positive, Follow-Up Plan Not Documented, Reason Not Given equals No, proceed to check Data Completeness Not Met
12. Check Data Completeness Not Met:
  - a. If Data Completeness Not Met, the Quality Data Code was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS:

Data Completeness Rate=

$$\frac{\text{Denominator Exclusion (x'=10 pts)} + \text{Performance Met (a'+a''=50 pts)} + \text{Denominator Exception (b'=10 pts)} + \text{Performance Not Met (c'+c''=20 pts)}}{\text{Eligible Population / Denominator (d=100 patients)}} = \frac{90 \text{ patients}}{100 \text{ patients}} = 90.00\%$$

Performance Rate=

$$\frac{\text{Performance Met (a'+a''=50 patients)}}{\text{Data Completeness Numerator (90 patients) - Denominator Exclusion (x'=10 patients) - Denominator Exception (b'=10 patients)}} = \frac{50 \text{ patients}}{70 \text{ patients}} = 71.43\%$$

**PCMH+ Measure List**  
**January 10, 2017**

Measure Name	Description	Steward	NQF #	PCMH+ Measure Type
Adolescent well-care visits	This measure is used to assess the percentage of enrolled members 12 through 21 years of age who had at least one comprehensive well-care visit with a primary care practitioner (PCP) or an obstetrics and gynecology (OB/GYN) practitioner during the measurement year.	NCQA		Scoring
Annual fluoride treatment ages 0<4	Annual fluoride treatment ages 0<4 (in a pediatric or dental setting)	DSS		Reporting Only
Annual monitoring for persistent medications (roll-up)	The percentage of patients 18 years of age and older who received a least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. - Angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) - Digoxin - Diuretics - <u>Total Rate will be measured</u>	NCQA	2371	Reporting Only
Appropriate treatment for children with upper respiratory infection	Percentage of children 3 months to 18 years of age with a diagnosis of URI who were not dispensed an antibiotic medication. A higher rate indicates appropriate care (i.e. the proportion for whom antibiotics were not prescribed)	NCQA	0069	Reporting Only
Asthma Medication Ratio	The percentage of members 5-64 years of age with persistent asthma and had a ratio of controller medications to total medications of 0.50 or greater during the measurement year.	NCQA	1800	Reporting Only
Avoidance of antibiotic treatment in adults with acute bronchitis	The percentage of adults 18–64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription. A higher rate indicates appropriate care (i.e. the proportion for whom antibiotics were not prescribed)	NCQA	0058	Scoring
Behavioral Health Screening 1-17	The percentage of children ages 1-17, who were screened for developmental or behavioral problems using a validated survey instrument, approved by the AAP.	DSS		Challenge
Breast cancer screening	The percentage of women 50-74 years of age who had a mammogram to screen for breast cancer in a two year period.	NCQA	2372	Reporting Only

## Asthma Medication Ratio (AMR)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Removed the restriction that only three of the four visits with an asthma diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Clarified in step 1 when the diagnosis must be on the discharge claim.
- Added Dupilumab to the “Anti-interleukin-4” description in the [Dupilumab Medications List](#).
- Clarified NDC code mapping requirements in the *Notes*.

### Description

The percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

### Definitions

**Oral medication dispensing event**

One prescription of an amount lasting 30 days or less. To calculate dispensing events for prescriptions longer than 30 days, divide the days supply by 30 and round down to convert. For example, a 100-day prescription is equal to three dispensing events ( $100/30 = 3.33$ , rounded down to 3). Allocate the dispensing events to the appropriate year based on the date on which the prescription is filled.

Multiple prescriptions for different medications dispensed on the same day are counted as separate dispensing events. If multiple prescriptions for the same medication are dispensed on the same day, sum the days supply and divide by 30.

Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs.

**Inhaler dispensing event**

When *identifying the eligible population*, use the definition below to count inhaler dispensing events.

All inhalers (i.e., canisters) of the same medication dispensed on the same day count as one dispensing event. Different inhaler medications dispensed on the same day are counted as different dispensing events. For example, if a member received three canisters of Medication A and two canisters of Medication B on the same date, it would count as two dispensing events.

Allocate the dispensing events to the appropriate year based on the date when the prescription was filled.

Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs.

<b>Injection dispensing event</b>	<p>Each injection counts as one dispensing event. Multiple dispensed injections of the same or different medications count as separate dispensing events. For example, if a member received two injections of Medication A and one injection of Medication B on the same date, it would count as three dispensing events.</p> <p>Use the medication lists to determine if drugs are the same or different. Drugs in different medication lists are considered different drugs.</p> <p>Allocate the dispensing events to the appropriate year based on the date when the prescription was filled.</p>
<b>Units of medication</b>	<p>When identifying medication units for the numerator, count each individual medication, defined as an amount lasting 30 days or less, as one medication unit. One medication unit equals one inhaler canister, one injection, one infusion or a 30-day or less supply of an oral medication. For example, two inhaler canisters of the same medication dispensed on the same day count as two medication units and only one dispensing event.</p> <p>Use the package size and units columns in the medication lists to determine the number of canisters or injections. Divide the dispensed amount by the package size to determine the number of canisters or injections dispensed. For example, if the package size for an inhaled medication is 10 g and pharmacy data indicates the dispensed amount is 30 g, three inhaler canisters were dispensed.</p>

## Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	<p>Ages 5–64 as of December 31 of the measurement year. Report the following age stratifications and total rate:</p> <ul style="list-style-type: none"> <li>• 5–11 years.</li> <li>• 12–18 years.</li> <li>• 19–50 years.</li> <li>• 51–64 years.</li> <li>• Total.</li> </ul>
<b>Continuous enrollment</b>	<p>The total is the sum of the age stratifications for each product line.</p> <p>The measurement year and the year prior to the measurement year.</p>
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage during each year of continuous enrollment.
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefits</b>	Medical. Pharmacy during the measurement year.

**Event/diagnosis** Follow the steps below to identify the eligible population.

**Step 1** Identify members as having persistent asthma who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.

- At least one ED visit (ED Value Set), with a principal diagnosis of asthma (Asthma Value Set).
- At least one acute inpatient encounter (Acute Inpatient Value Set), with a principal diagnosis of asthma (Asthma Value Set) **without** telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).
- At least one acute inpatient discharge with a principal diagnosis of asthma (Asthma Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- At least four outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set) or e-visits or virtual check-ins (Online Assessments Value Set), on different dates of service, with any diagnosis of asthma (Asthma Value Set) **and** at least two asthma medication dispensing events for any controller or reliever medication. Visit type need not be the same for the four visits. Use all the medication lists in the tables below to identify asthma controller and reliever medications.
- At least four asthma medication dispensing events for any controller or reliever medication. Use all the medication lists in the tables below to identify asthma controller and reliever medications.

**Step 2** A member identified as having persistent asthma because of at least four asthma medication dispensing events, where leukotriene modifiers or antibody inhibitors were the sole asthma medication dispensed in that year, must also have at least one diagnosis of asthma (Asthma Value Set), in any setting, in the same year as the leukotriene modifier or antibody inhibitor (the measurement year or the year prior to the measurement year).

**Step 3:  
Required  
exclusions**

Exclude members who met any of the following criteria:

- Members who had any diagnosis from any of the following value sets, any time during the member's history through December 31 of the measurement year:
  - Emphysema Value Set.
  - Other Emphysema Value Set.
  - COPD Value Set.
  - Obstructive Chronic Bronchitis Value Set.
  - Chronic Respiratory Conditions Due to Fumes or Vapors Value Set.
  - Cystic Fibrosis Value Set.
  - Acute Respiratory Failure Value Set.

- Members who had no asthma controller or reliever medications dispensed during the measurement year. Use all the medication lists in the tables below to identify asthma controller and reliever medications.

### Administrative Specification

**Denominator** The eligible population.

**Numerator** The number of members who have a medication ratio of 0.50 or greater during the measurement year. Follow the steps below to calculate the ratio.

Use all the medication lists in the Asthma Controller Medications table below to identify asthma controller medications. Use all the medication lists in the Asthma Reliever Medications table below to identify asthma reliever medications.

- Step 1** For each member, count the units of asthma controller medications dispensed during the measurement year. Refer to the definition of *Units of medications*.
- Step 2** For each member, count the units of asthma reliever medications dispensed during the measurement year. Refer to the definition of *Units of medications*.
- Step 3** For each member, sum the units calculated in step 1 and step 2 to determine units of total asthma medications.
- Step 4** For each member, calculate the ratio of controller medications to total asthma medications using the following formula. Round (using the .5 rule) to the nearest whole number.

$$\frac{\text{Units of Controller Medications (step 1)}}{\text{Units of Total Asthma Medications (step 3)}}$$

- Step 5** Sum the total number of members who have a ratio of 0.50 or greater in step 4.

### Asthma Controller Medications

Description	Prescriptions	Medication Lists	Route
Antiasthmatic combinations	• Dyphylline-guaifenesin	<a href="#">Dyphylline Guaifenesin Medications List</a>	Oral
Antibody inhibitors	• Omalizumab	<a href="#">Omalizumab Medications List</a>	Injection
Anti-interleukin-4	• Dupilumab	<a href="#">Dupilumab Medications List</a>	Injection
Anti-interleukin-5	• Benralizumab	<a href="#">Benralizumab Medications List</a>	Injection
Anti-interleukin-5	• Mepolizumab	<a href="#">Mepolizumab Medications List</a>	Injection
Anti-interleukin-5	• Reslizumab	<a href="#">Reslizumab Medications List</a>	Injection
Inhaled steroid combinations	• Budesonide-formoterol	<a href="#">Budesonide Formoterol Medications List</a>	Inhalation
Inhaled steroid combinations	• Fluticasone-salmeterol	<a href="#">Fluticasone Salmeterol Medications List</a>	Inhalation

Description	Prescriptions	Medication Lists	Route
Inhaled steroid combinations	• Fluticasone-vilanterol	<a href="#">Fluticasone Vilanterol Medications List</a>	Inhalation
Inhaled steroid combinations	• Formoterol-mometasone	<a href="#">Formoterol Mometasone Medications List</a>	Inhalation
Inhaled corticosteroids	• Beclomethasone	<a href="#">Beclomethasone Medications List</a>	Inhalation
Inhaled corticosteroids	• Budesonide	<a href="#">Budesonide Medications List</a>	Inhalation
Inhaled corticosteroids	• Ciclesonide	<a href="#">Ciclesonide Medications List</a>	Inhalation
Inhaled corticosteroids	• Flunisolide	<a href="#">Flunisolide Medications List</a>	Inhalation
Inhaled corticosteroids	• Fluticasone	<a href="#">Fluticasone Medications List</a>	Inhalation
Inhaled corticosteroids	• Mometasone	<a href="#">Mometasone Medications List</a>	Inhalation
Leukotriene modifiers	• Montelukast	<a href="#">Montelukast Medications List</a>	Oral
Leukotriene modifiers	• Zafirlukast	<a href="#">Zafirlukast Medications List</a>	Oral
Leukotriene modifiers	• Zileuton	<a href="#">Zileuton Medications List</a>	Oral
Methylxanthines	• Theophylline	<a href="#">Theophylline Medications List</a>	Oral

**Asthma Reliever Medications**

Description	Prescriptions	Medication Lists	Route
Short-acting, inhaled beta-2 agonists	Albuterol	<a href="#">Albuterol Medications List</a>	Inhalation
Short-acting, inhaled beta-2 agonists	Levalbuterol	<a href="#">Levalbuterol Medications List</a>	Inhalation

**Note**

- Do not use RxNorm codes when assessing the numerator.
- When mapping NDC codes, medications described as “injection,” “prefilled syringe,” “subcutaneous,” “intramuscular” or “auto-injector” are considered “injections” (route).
- When mapping NDC codes, medications described as “metered dose inhaler,” “dry powder inhaler” or “inhalation powder” are considered “inhalation” (route) medications.
- Do not map medications described as “nasal spray” to “inhalation” medications.



**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table AMR-1/2: Data Elements for Asthma Medication Ratio**

Data Elements	Administrative
Measurement year	✓
Eligible population	<i>For each age stratification and total</i>
Number of required exclusions	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>For each age stratification and total</i>
Numerator events by supplemental data	<i>For each age stratification and total</i>
Reported rate	<i>For each age stratification and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Asthma Medication Ratio

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Using product line criteria is not required. Including any product line, combining product lines, or not including product line criteria is allowed.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select "age as of June 30"). The denominator age may be changed within the specified age range (ages 5–64 years). The denominator age may also be expanded to 65 years of age and older.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	Yes, with limits	Only events or diagnoses that contain (or map to) codes in the medication lists and value sets may be used to identify visits. Medication lists, value sets and logic may not be changed. <i>Note: This measure uses dispensed medications; modifying the measurement period can affect other dates; however, the order and relationship of the events may not be changed.</i>
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Required Exclusions	No	Apply required exclusions according to specified value sets.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Medication ratio of 0.50 or greater	No	Medication Lists and logic may not be changed.

---

## Comprehensive Diabetes Care (CDC)

---

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

---

- Retired the “HbA1c control (<7.0%) for a selected population” indicator.
- Retired the “Medical Attention for Nephropathy” indicator for the commercial and Medicaid product lines.
- Clarified in the measure description that organizations must use the same data collection method for the HbA1c testing and control indicators (this information was previously included in the General Guidelines).
- Removed the restriction that only one of the two visits with a diabetes diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added palliative care as a required exclusion.
- Deleted the HbA1c Level 7.0–9.0 Value Set.
- Updated the Administrative Specification logic and value sets for the Eye Exam indicator.
- Added telephone visits, e-visits and virtual check-ins to the Administrative Specification as appropriate settings for BP readings.
- Added Nebivolol-valsartan to the “Antihypertensive combinations” description in the ACE inhibitor and ARB Medications List.
- Added Donepezil-memantine to the “Dementia combinations” description in the Dementia Medications List.
- Added polycystic ovarian syndrome to the optional exclusions.
- Added a *Note* to the *Denominator-Sample Size Reduction* section in the Hybrid Specification.
- Clarified that documentation of “HB1c” meets criteria for the Hybrid Specification of the HbA1c testing indicator.
- Clarified that eye exam results read by a system that provides an artificial intelligence (AI) interpretation meet criteria.
- Removed the requirements for remote monitoring devices to allow BPs taken by any digital device.
- Removed the exclusion of BP readings reported or taken by the member.
- Revised the Data Elements for Reporting tables.
- In the *Rules for Allowable Adjustments* section, clarified that the required exclusions criteria may be adjusted with limits.

### Description

The percentage of members 18–75 years of age with diabetes (type 1 and type 2) who had each of the following:

- |                                    |  |
|------------------------------------|--|
| • Hemoglobin A1c (HbA1c) testing.* | • Eye exam (retinal) performed.        |
| • HbA1c poor control (>9.0%).*     | • Medical attention for nephropathy.** |
| • HbA1c control (<8.0%).*          | • BP control (<140/90 mm Hg).          |

\*Organizations must use the same data collection method (Administrative or Hybrid) to report these indicators.

\*\*This indicator is only reported for the Medicare product line.

## Eligible Population

**Note:** Members in hospice are excluded from the eligible population. If an organization reports this measure using the Hybrid method, and a member is found to be in hospice or using hospice services during medical record review, the member is removed from the sample and replaced by a member from the oversample. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Stratification</b>	<p>For only Medicare, for only the Eye Exam (retinal) indicator, report the following SES stratifications and total:</p> <ul style="list-style-type: none"> <li>• Non-LIS/DE, Nondisability.</li> <li>• LIS/DE.</li> <li>• Disability.</li> <li>• LIS/DE and Disability.</li> <li>• Other.</li> <li>• Unknown.</li> <li>• Total Medicare.</li> </ul> <p><b>Note:</b> The stratifications are mutually exclusive and the sum of all six stratifications is the total population. The stratifications are reported in a separate table.</p>
<b>Ages</b>	18–75 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	<p>There are two ways to identify members with diabetes: by claim/encounter data and by pharmacy data. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.</p> <p><i>Claim/encounter data.</i> Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years):</p> <ul style="list-style-type: none"> <li>• At least one acute inpatient encounter (<u>Acute Inpatient Value Set</u>) with a diagnosis of diabetes (<u>Diabetes Value Set</u>) <b>without</b> telehealth (<u>Telehealth Modifier Value Set</u>; <u>Telehealth POS Value Set</u>).</li> <li>• At least one acute inpatient discharge with a diagnosis of diabetes (<u>Diabetes Value Set</u>) on the discharge claim. To identify an acute inpatient discharge:</li> </ul>

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), ED visits (ED Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim), on different dates of service, with a diagnosis of diabetes (Diabetes Value Set). Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
    3. Identify the discharge date for the stay.
 Only include nonacute inpatient encounters (Nonacute Inpatient Value Set) **without** telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).

*Pharmacy data.* Members who were dispensed insulin or hypoglycemics/ antihyperglycemics on an ambulatory basis during the measurement year or the year prior to the measurement year (Diabetes Medications List).

#### Diabetes Medications

Description	Prescription	
Alpha-glucosidase inhibitors	<ul style="list-style-type: none"> <li>• Acarbose</li> <li>• Miglitol</li> </ul>	
Amylin analogs	<ul style="list-style-type: none"> <li>• Pramlintide</li> </ul>	
Antidiabetic combinations	<ul style="list-style-type: none"> <li>• Alogliptin-metformin</li> <li>• Alogliptin-pioglitazone</li> <li>• Canagliflozin-metformin</li> <li>• Dapagliflozin-metformin</li> <li>• Empagliflozin-linagliptin</li> <li>• Empagliflozin-metformin</li> <li>• Glimepiride-pioglitazone</li> <li>• Glipizide-metformin</li> <li>• Glyburide-metformin</li> <li>• Linagliptin-metformin</li> <li>• Metformin-pioglitazone</li> <li>• Metformin-repaglinide</li> <li>• Metformin-rosiglitazone</li> <li>• Metformin-saxagliptin</li> <li>• Metformin-sitagliptin</li> </ul>	
Insulin	<ul style="list-style-type: none"> <li>• Insulin aspart</li> <li>• Insulin aspart-insulin aspart protamine</li> <li>• Insulin degludec</li> <li>• Insulin detemir</li> <li>• Insulin glargine</li> <li>• Insulin glulisine</li> <li>• Insulin isophane human</li> <li>• Insulin isophane-insulin regular</li> <li>• Insulin lispro</li> <li>• Insulin lispro-insulin lispro protamine</li> <li>• Insulin regular human</li> <li>• Insulin human inhaled</li> </ul>	
Meglitinides	<ul style="list-style-type: none"> <li>• Nateglinide</li> <li>• Repaglinide</li> </ul>	
Glucagon-like peptide-1 (GLP1) agonists	<ul style="list-style-type: none"> <li>• Dulaglutide</li> <li>• Exenatide</li> <li>• Albiglutide</li> <li>• Liraglutide (excluding Saxenda®)</li> </ul>	

Description	Prescription		
Sodium glucose cotransporter 2 (SGLT2) inhibitor	• Canagliflozin	• Dapagliflozin	• Empagliflozin
Sulfonylureas	• Chlorpropamide • Glimepiride	• Glipizide • Glyburide	• Tolazamide • Tolbutamide
Thiazolidinediones	• Pioglitazone	• Rosiglitazone	
Dipeptidyl peptidase-4 (DDP-4) inhibitors	• Alogliptin • Linagliptin	• Saxagliptin • Sitagliptin	

**Note:** *Glucophage/metformin as a solo agent is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only.*

#### Required exclusion

Exclude members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

#### Exclusions

Exclude members who meet any of the following criteria:

**Note:** *Supplemental and medical record data may not be used for these exclusions.*

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty **and** advanced illness. Members must meet **BOTH** of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
      1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).

2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the discharge date for the stay.
    - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
    - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim.
- To identify an acute inpatient discharge:
1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- A dispensed dementia medication (Dementia Medications List).

**Dementia Medications**

Description	Prescription
Cholinesterase inhibitors	• Donepezil   • Galantamine   • Rivastigmine
Miscellaneous central nervous system agents	• Memantine
Dementia combinations	• Donepezil-memantine

**Administrative Specification**

**Denominator**      The eligible population.

**Numerators**

**HbA1c Testing**      An HbA1c test (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) performed during the measurement year.

**HbA1c Poor Control >9%**      Use codes (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) to identify the *most recent* HbA1c test during the measurement year. The member is numerator compliant if the most recent HbA1c level is >9.0% or is missing a result, or if an HbA1c test was not done during the measurement year. The member is not numerator compliant if the result for the most recent HbA1c test during the measurement year is ≤9.0%.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

Value Set	Numerator Compliance
<u>HbA1c Level Less Than 7.0 Value Set</u>	Not compliant
<u>HbA1c Level Greater Than or Equal To 7.0 and Less Than 8.0 Value Set</u>	Not compliant
<u>HbA1c Level Greater Than or Equal To 8.0 and Less Than or Equal To 9.0 Value Set</u>	Not compliant
<u>HbA1c Level Greater Than 9.0 Value Set</u>	Compliant

**Note:** A lower rate indicates better performance for this indicator (i.e., low rates of poor control indicate better care).

**HbA1c Control <8%** Use codes (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) to identify the most recent HbA1c test during the measurement year. The member is numerator compliant if the most recent HbA1c level is <8.0%. The member is not numerator compliant if the result for the most recent HbA1c test is ≥8.0% or is missing a result, or if an HbA1c test was not done during the measurement year.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

Value Set	Numerator Compliance
<u>HbA1c Level Less Than 7.0 Value Set</u>	Compliant
<u>HbA1c Level Greater Than or Equal To 7.0 and Less Than 8.0 Value Set</u>	Compliant
<u>HbA1c Level Greater Than or Equal To 8.0 and Less Than or Equal To 9.0 Value Set</u>	Not compliant
<u>HbA1c Level Greater Than 9.0 Value Set</u>	Not compliant

**Eye Exam** Screening or monitoring for diabetic retinal disease as identified by administrative data. This includes diabetics who had one of the following:

- A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year.
- A *negative* retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the year prior to the measurement year.
- Bilateral eye enucleation any time during the member's history through December 31 of the measurement year.

Any of the following meet criteria:

- Any code in the Diabetic Retinal Screening Value Set billed by an eye care professional (optometrist or ophthalmologist) during the measurement year.



- Any code in the Diabetic Retinal Screening Value Set billed by an eye care professional (optometrist or ophthalmologist) during the year prior to the measurement year, with a negative result (negative for retinopathy).
- Any code in the Diabetic Retinal Screening Value Set billed by an eye care professional (optometrist or ophthalmologist) during the year prior to the measurement year, with a diagnosis of diabetes without complications (Diabetes Mellitus Without Complications Value Set).
- Any code in the Eye Exam With Evidence of Retinopathy Value Set or Eye Exam Without Evidence of Retinopathy Value Set billed by any provider type during the measurement year.
- Any code in the Eye Exam Without Evidence of Retinopathy Value Set billed by any provider type during the year prior to the measurement year.
- Any code in the Diabetic Retinal Screening Negative In Prior Year Value Set billed by any provider type during the measurement year.
- Unilateral eye enucleation (Unilateral Eye Enucleation Value Set) **with** a bilateral modifier (Bilateral Modifier Value Set).
- Two unilateral eye enucleations (Unilateral Eye Enucleation Value Set) with service dates 14 days or more apart. For example, if the service date for the first unilateral eye enucleation was February 1 of the measurement year, the service date for the second unilateral eye enucleation must be on or after February 15.
- Left unilateral eye enucleation (Unilateral Eye Enucleation Left Value Set) **and** right unilateral eye enucleation (Unilateral Eye Enucleation Right Value Set) on the same or different dates of service.
- A unilateral eye enucleation (Unilateral Eye Enucleation Value Set) and a left unilateral eye enucleation (Unilateral Eye Enucleation Left Value Set) with service dates 14 days or more apart.
- A unilateral eye enucleation (Unilateral Eye Enucleation Value Set) and a right unilateral eye enucleation (Unilateral Eye Enucleation Right Value Set) with service dates 14 days or more apart.

**Medical  
Attention for  
Nephropathy**

A nephropathy screening or monitoring test **or** evidence of nephropathy, as documented through administrative data. This includes diabetics who had one of the following during the measurement year:

- A nephropathy screening or monitoring test (Urine Protein Tests Value Set).
- Evidence of treatment for nephropathy or ACE/ARB therapy (Nephropathy Treatment Value Set).
- Evidence of stage 4 chronic kidney disease (CKD Stage 4 Value Set).
- Evidence of ESRD (ESRD Diagnosis Value Set) or dialysis (Dialysis Procedure Value Set).
- Evidence of nephrectomy (Nephrectomy Value Set) or kidney transplant (Kidney Transplant Value Set).
- A visit with a nephrologist, as identified by the organization's specialty provider codes (no restriction on the diagnosis or procedure code submitted).

- At least one ACE inhibitor or ARB dispensing event (ACE Inhibitor and ARB Medications List).

**ACE Inhibitor and ARB Medications**

Description	Prescription					
Angiotensin converting enzyme inhibitors	• Benazepril	• Enalapril	• Lisinopril	• Perindopril	• Ramipril	
	• Captopril	• Fosinopril	• Moexipril	• Quinapril	• Trandolapril	
Angiotensin II inhibitors	• Azilsartan	• Eprosartan	• Losartan	• Telmisartan		
	• Candesartan	• Irbesartan	• Olmesartan	• Valsartan		
Antihypertensive combinations	• Amlodipine-benazepril	• Azilsartan-chlorthalidone	• Hydrochlorothiazide-moexipril			
	• Amlodipine-hydrochlorothiazide-valsartan	• Benazepril-hydrochlorothiazide	• Hydrochlorothiazide-olmesartan			
	• Amlodipine-hydrochlorothiazide-olmesartan	• Candesartan-hydrochlorothiazide	• Hydrochlorothiazide-quinapril			
	• Amlodipine-olmesartan	• Captopril-hydrochlorothiazide	• Hydrochlorothiazide-telmisartan			
	• Amlodipine-perindopril	• Enalapril-hydrochlorothiazide	• Hydrochlorothiazide-valsartan			
	• Amlodipine-telmisartan	• Fosinopril-hydrochlorothiazide	• Nebivolol-valsartan			
	• Amlodipine-valsartan	• Hydrochlorothiazide-irbesartan	• Sacubitril-valsartan			
		• Hydrochlorothiazide-lisinopril	• Trandolapril-verapamil			
		• Hydrochlorothiazide-losartan				

**BP Control <140/90 mm Hg** Identify the most recent BP reading (Systolic Blood Pressure Value Set; Diastolic Blood Pressure Value Set) taken during an outpatient visit (Outpatient Value Set) telephone visit (Telephone Visits Value Set), e-visit or virtual check-in (Online Assessments Value Set), or a nonacute inpatient encounter (Nonacute Inpatient Value Set), or remote monitoring event (Remote Blood Pressure Monitoring Value Set) during the measurement year.

The member is numerator compliant if the BP is <140/90 mm Hg. The member is not compliant if the BP is ≥140/90 mm Hg, if there is no BP reading during the measurement year or if the reading is incomplete (e.g., the systolic or diastolic level is missing). If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent codes during the measurement year to determine numerator compliance for both systolic and diastolic levels.

Value Set	Numerator Compliance
<u>Systolic Less Than 140 Value Set</u>	Systolic compliant
<u>Systolic Greater Than or Equal To 140 Value Set</u>	Systolic not compliant
<u>Diastolic Less Than 80 Value Set</u>	Diastolic compliant
<u>Diastolic 80–89 Value Set</u>	Diastolic compliant
<u>Diastolic Greater Than or Equal To 90 Value Set</u>	Diastolic not compliant

## Exclusions (optional)

Members who do not have a diagnosis of diabetes (Diabetes Value Set), in any setting, during the measurement year or the year prior to the measurement year **and** who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes (Diabetes Exclusions Value Set), in any setting, during the measurement year or the year prior to the measurement year.

Organizations that apply optional exclusions must exclude members from the denominator for all indicators. The denominator for all rates must be the same. If the member was included in the measure based on claim or encounter data, as described in the event/diagnosis criteria, the optional exclusions do not apply because the member had a diagnosis of diabetes.

## Hybrid Specification

**Denominator** Organizations should use a sample size of 411.

For Medicare reporting, the denominator for the Total Medicare SES stratification is the entire systematic sample. Do not pull samples for each stratification. The individual stratifications for the denominators and all numerators must sum to the total.

**Denominator—sample size reduction** The organization may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate for the lowest rate among all the reported CDC indicators. The lowest rate for all reported indicators must be used when reducing the sample size.

**Note:** The rate for the HbA1c control (<7.0%) for a selected population indicator may not be used to reduce the MY 2020 or MY 2021 sample size because it was retired. The rate for the Medical attention for nephropathy indicator may not be used to reduce the MY 2020 or MY 2021 sample size for the commercial and Medicaid product lines because it was retired.

## Numerators

**HbA1c Testing** An HbA1c test performed during the measurement year as identified by administrative data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** At a minimum, documentation in the medical record must include a note indicating the date when the HbA1c test was performed and the result or finding. Count notation of the following in the medical record:

- A1c
- HB1c
- Glycohemoglobin
- HbA1c
- Hemoglobin A1c
- Glycated hemoglobin
- HgbA1c
- Glycohemoglobin A1c
- Glycosylated hemoglobin

**HbA1c Poor Control >9%** The *most recent* HbA1c level (performed during the measurement year) is >9.0% or is missing, or was not done during the measurement year, as documented through laboratory data or medical record review.

**Note:** A lower rate indicates better performance for this indicator (i.e., low rates of poor control indicate better care).

<b><u>Administrative</u></b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.
<b><u>Medical record</u></b>	<p>At a minimum, documentation in the medical record must include a note indicating the date when the HbA1c test was performed and the result. The member is numerator compliant if the result for the most recent HbA1c level during the measurement year is &gt;9.0% or is missing, or if an HbA1c test was not done during the measurement year. The member is not numerator compliant if the most recent HbA1c level during the measurement year is ≤9.0%.</p> <p>Ranges and thresholds do not meet criteria for this indicator. A distinct numeric result is required for numerator compliance.</p>
<b><i>HbA1c Control</i></b> <b>&lt;8%</b>	The <i>most recent</i> HbA1c level (performed during the measurement year) is <8.0% as identified by laboratory data or medical record review.
<b><u>Administrative</u></b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.
<b><u>Medical record</u></b>	<p>At a minimum, documentation in the medical record must include a note indicating the date when the HbA1c test was performed and the result. The member is numerator compliant if the most recent HbA1c level during the measurement year is &lt;8.0%. The member is not numerator compliant if the result for the most recent HbA1c level during the measurement year is ≥8.0% or is missing, or if an HbA1c test was not performed during the measurement year.</p> <p>Ranges and thresholds do not meet criteria for this indicator. A distinct numeric result is required for numerator compliance.</p>
<b><i>Eye Exam</i></b>	<p>Screening or monitoring for diabetic retinal disease as identified by administrative data or medical record review. This includes diabetics who had one of the following:</p> <ul style="list-style-type: none"> <li>• A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year.</li> <li>• A <i>negative</i> retinal or dilated exam (negative for retinopathy) by an eye care professional (optometrist or ophthalmologist) in the year prior to the measurement year.</li> <li>• Bilateral eye enucleation any time during the member's history through December 31 of the measurement year.</li> </ul>
<b><u>Administrative</u></b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.
<b><u>Medical record</u></b>	<p>At a minimum, documentation in the medical record must include one of the following:</p> <ul style="list-style-type: none"> <li>• A note or letter prepared by an ophthalmologist, optometrist, PCP or other health care professional indicating that an ophthalmoscopic exam was completed by an eye care professional (optometrist or ophthalmologist), the date when the procedure was performed and the results.</li> </ul>

- A chart or photograph indicating the date when the fundus photography was performed and one of the following:
  - Evidence that an eye care professional (optometrist or ophthalmologist) reviewed the results.
  - Evidence results were read by a qualified reading center that operates under the direction of a medical director who is a retinal specialist.
  - Evidence results were read by a system that provides an artificial intelligence (AI) interpretation.
- Evidence that the member had bilateral eye enucleation or acquired absence of both eyes. Look as far back as possible in the member's history through December 31 of the measurement year.
- Documentation of a negative retinal or dilated exam by an eye care professional (optometrist or ophthalmologist) in the year prior to the measurement year, where results indicate retinopathy was not present (e.g., documentation of normal findings).
  - Documentation does not have to state specifically “no diabetic retinopathy” to be considered negative for retinopathy; however, it must be clear that the patient had a dilated or retinal eye exam by an eye care professional (optometrist or ophthalmologist) and that retinopathy was not present. Notation limited to a statement that indicates “diabetes without complications” does not meet criteria.

**Medical  
Attention for  
Nephropathy**

A nephropathy screening or monitoring test during the measurement year **or** evidence of nephropathy during the measurement year, as documented through either administrative data or medical record review.

**Note:** A process flow diagram is included at the end of this specification to help implement this measure.

**Administrative**

Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record**

Any of the following during the measurement year meet criteria for a nephropathy screening or monitoring test or evidence of nephropathy.

- A urine test for albumin or protein. At a minimum, documentation must include a note indicating the date when a urine test was performed, and the result or finding. Any of the following meet the criteria:
  - 24-hour urine for albumin or protein.
  - Timed urine for albumin or protein.
  - Spot urine (e.g., urine dipstick or test strip) for albumin or protein.
  - Urine for albumin/creatinine ratio.
  - 24-hour urine for total protein.
  - Random urine for protein/creatinine ratio.
- Documentation of a visit to a nephrologist.
- Documentation of a renal transplant.
- Documentation of a nephrectomy.

- Documentation of medical attention for any of the following (no restriction on provider type):
  - Diabetic nephropathy.
  - ESRD.
  - Chronic renal failure (CRF).
  - Chronic kidney disease (CKD).
  - Renal insufficiency.
  - Proteinuria.
  - Albuminuria.
  - Renal dysfunction.
  - Acute renal failure (ARF).
  - Dialysis, hemodialysis or peritoneal dialysis.
- Evidence of ACE inhibitor/ARB therapy. Documentation in the medical record must include evidence that the member received ACE inhibitor/ARB therapy during the measurement year. Any of the following meet criteria:
  - Documentation that a prescription for an ACE inhibitor/ARB was written during the measurement year.
  - Documentation that a prescription for an ACE inhibitor/ARB was filled during the measurement year.
  - Documentation that the member took an ACE inhibitor/ARB during the measurement year.

***BP Control***  
***<140/90 mm Hg***

The *most recent* BP level (taken during the measurement year) is <140/90 mm Hg, as documented through administrative data or medical record review.

**Administrative**

Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record**

The organization should use the medical record from which it abstracts data for the other CDC indicators. If the organization does not abstract for other indicators, it should use the medical record of the provider that manages the member's diabetes. If that medical record does not contain a BP, the organization may use the medical record of another PCP or specialist from whom the member receives care.

Identify the most recent BP reading noted during the measurement year. Do not include BP readings that meet the following criteria:

- Taken during an acute inpatient stay or an ED visit.
- Taken on the same day as a diagnostic test or diagnostic or therapeutic procedure that requires a change in diet or change in medication on or one day before the day of the test or procedure, with the exception of fasting blood tests.
- Taken by the member using a non-digital device such as with a manual blood pressure cuff and a stethoscope.

Identify the lowest systolic and lowest diastolic BP reading from the most recent BP notation in the medical record. If multiple readings were recorded for a single date, use the lowest systolic and lowest diastolic BP on that date as the representative BP. The systolic and diastolic results do not need to be from the same reading.

The member is not numerator compliant if the BP does not meet the specified threshold or is missing, or if there is no BP reading during the measurement year or if the reading is incomplete (i.e., the systolic or diastolic level is missing).

### Exclusions (optional)

Refer to *Administrative Specification* for exclusion criteria. Identify members who did not have a diagnosis of diabetes, in any setting, during the measurement year or the year prior to the measurement year, **and** who had a diagnosis of gestational diabetes or steroid-induced diabetes, in any setting, during the measurement year or the year prior to the measurement year.

### Note

- Organizations may select a data collection method (Administrative vs. Hybrid) at the indicator level, but the method used for HbA1c testing and control rates must be consistent.
- Blindness is not an exclusion for a diabetic eye exam because it is difficult to distinguish between individuals who are legally blind but require a retinal exam and those who are completely blind and therefore do not require an exam.
- To facilitate HEDIS reporting the denominator for all rates must be the same. While an eye exam is not possible, services measured in the other indicators are important for members with bilateral eye enucleation. For these reasons bilateral eye enucleation is considered a numerator hit (rather than an optional exclusion).
- Hypertensive retinopathy is not handled differently from diabetic retinopathy when reporting the Eye Exam indicator; for example, an eye exam documented as positive for hypertensive retinopathy is counted as positive for diabetic retinopathy and an eye exam documented as negative for hypertensive retinopathy is counted as negative for diabetic retinopathy. The intent of the Eye Exam indicator is to ensure that members with evidence of any type of retinopathy have an eye exam annually, while members who remain free of retinopathy (i.e., the retinal exam was negative for retinopathy) are screened every other year.
- If a combination of administrative, supplemental or hybrid data are used, the most recent result must be used, regardless of data source, for the indicators that require use of the most recent result.
- If an organization chooses to apply the optional exclusions, members must be numerator negative for at least one indicator, with the exception of HbA1c Poor Control (>9%). Remove members from the eligible population who are numerator negative for any indicator (other than for HbA1c Poor Control [>9%]) and substitute members from the oversample. Do not exclude members who are numerator compliant for all indicators except HbA1c Poor Control (>9%), because a lower rate indicates better performance for this indicator.
- When excluding BP readings from the BP Control <140/90 mm Hg indicator, the intent is to identify diagnostic or therapeutic procedures that require a medication regimen, a change in diet or a change in medication. For example (this list is just for reference, and is not exhaustive):
  - A colonoscopy requires a change in diet (NPO on the day of procedure) and a medication change (a medication is taken to prep the colon).
  - Dialysis, infusions and chemotherapy (including oral chemotherapy) are all therapeutic procedures that require a medication regimen.

- A nebulizer treatment with albuterol is considered a therapeutic procedure that requires a medication regimen (the albuterol).
- A patient forgetting to take regular medications on the day of the procedure is not considered a required change in medication, and therefore the BP reading is eligible.
- BP readings taken on the same day that the patient receives a common low-intensity or preventive procedure are eligible for use. For example, the following procedures are considered common low-intensity or preventive procedures (this list is just for reference, and is not exhaustive):
  - Vaccinations.
  - Injections (e.g., allergy, vitamin B-12, insulin, steroid, toradol, Depo-Provera, testosterone, lidocaine).
  - TB test.
  - IUD insertion.
  - Eye exam with dilating agents.
  - Wart or mole removal.



## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CDC-1/2: Data Elements for Comprehensive Diabetes Care**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Eligible population	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Number of required exclusions	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Number of numerator events by administrative data in eligible population (before exclusions)		<i>Each of the 5 rates</i>
Current year's administrative rate (before exclusions)		<i>Each of the 5 rates</i>
Minimum required sample size (MRSS)		<i>Each of the 5 rates</i>
Oversampling rate		<i>Each of the 5 rates</i>
Number of oversample records		<i>Each of the 5 rates</i>
Number of medical records excluded because of valid data errors		<i>Each of the 5 rates</i>
Number of administrative data records excluded		<i>Each of the 5 rates</i>
Number of medical records excluded		<i>Each of the 5 rates</i>
Number of employee/dependent medical records excluded		<i>Each of the 5 rates</i>
Records added from the oversample list		<i>Each of the 5 rates</i>
Denominator		<i>Each of the 5 rates</i>
Numerator events by administrative data	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Numerator events by supplemental data	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>
Numerator events by medical records		<i>Each of the 5 rates</i>
Reported rate	<i>Each of the 5 rates</i>	<i>Each of the 5 rates</i>

**Table CDC-A-3: Data Elements for Comprehensive Diabetes Care**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	<i>Each of the 6 rates</i>	<i>Each of the 6 rates</i>
Eligible population	<i>Each of the 6 rates</i>	<i>Each of the 6 rates</i>
Number of required exclusions	<i>Each of the 6 rates</i>	<i>Each of the 6 rates</i>
Number of numerator events by administrative data in eligible population (before exclusions)		<i>Each of the 6 rates</i>
Current year's administrative rate (before exclusions)		<i>Each of the 6 rates</i>
Minimum required sample size (MRSS)		<i>Each of the 6 rates</i>
Oversampling rate		<i>Each of the 6 rates</i>
Number of oversample records		<i>Each of the 6 rates</i>
Number of medical records excluded because of valid data errors		<i>Each of the 6 rates</i>

	Administrative	Hybrid
Number of administrative data records excluded		<i>Each of the 6 rates</i>
Number of medical records excluded		<i>Each of the 6 rates</i>
Number of employee/dependent medical records excluded		<i>Each of the 6 rates</i>
Records added from the oversample list		<i>Each of the 6 rates</i>
Denominator		<i>Each of the 6 rates</i>
Numerator events by administrative data	<i>Each of the 6 rates</i>	<i>Each of the 6 rates</i>
Numerator events by supplemental data	<i>Each of the 6 rates</i>	<i>Each of the 6 rates</i>
Numerator events by medical records		<i>Each of the 6 rates</i>
Reported rate	<i>Each of the 6 rates</i>	<i>Each of the 6 rates</i>

**Table CDC-B-3: Data Elements for Comprehensive Diabetes Care: Eye Exam (Medicare SES Stratifications only. Report the Total Medicare population in Table CDC-A-3)**

	Administrative	Hybrid
Eligible population	<i>Each of the 6 stratifications</i>	<i>Each of the 6 stratifications</i>
Number of required exclusions	<i>Each of the 6 stratifications</i>	<i>Each of the 6 stratifications</i>
Denominator		<i>Each of the 6 stratifications</i>
Numerator events by administrative data	<i>Each of the 6 stratifications</i>	<i>Each of the 6 stratifications</i>
Numerator events by medical records		<i>Each of the 6 stratifications</i>
Numerator events by supplemental data	<i>Each of the 6 stratifications</i>	<i>Each of the 6 stratifications</i>
Reported rate	<i>Each of the 6 stratifications</i>	<i>Each of the 6 stratifications</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Comprehensive Diabetes Care

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select, "age as of June 30"). Changing denominator age range is allowed within specified age range (ages 18–75 years). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	No	Only events or diagnoses that contain (or map to) codes in the medication lists and value sets may be used to identify visits. Medication lists, value sets and logic may not be changed
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied; value sets and logic may not be changed.
Required Exclusions	Yes	The palliative care exclusion is not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i>
Exclusions: I-SNP, LTI, Frailty or Advanced Illness	Yes	These exclusions are not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .

Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
<ul style="list-style-type: none"> <li>• Hemoglobin A1c (HbA1c) testing</li> <li>• HbA1c poor control (&gt;9.0%)</li> <li>• HbA1c control (&lt;8.0%)</li> <li>• Eye exam (retinal) performed</li> <li>• Medical attention for nephropathy</li> <li>• BP control (&lt;140/90 mm HG)</li> </ul>	No	Medication lists, value sets and logic may not be changed.

## Kidney Health Evaluation for Patients With Diabetes (KED)\*

\*This measure was developed by NCQA with input from the National Kidney Foundation.

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- First-year measure (MY 2020).

#### Description

The percentage of members 18–85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) **and** a urine albumin-creatinine ratio (uACR), during the measurement year.

#### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18–85 years as of December 31 of the measurement year. Report three age stratifications and a total rate: <ul style="list-style-type: none"><li>• 18–64.</li><li>• 65–74.</li><li>• 75–85.</li><li>• Total.</li></ul> The total is the sum of the age stratifications.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	Follow the steps below to identify the eligible population.  <b>Step 1</b> There are two ways to identify members with diabetes: by claim/encounter data and by pharmacy data. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.  <i>Claim/encounter data.</i> Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years): <ul style="list-style-type: none"><li>• At least one acute inpatient encounter (<u>Acute Inpatient Value Set</u>) with a diagnosis of diabetes (<u>Diabetes Value Set</u>) <b>without</b> telehealth (<u>Telehealth Modifier Value Set</u>; <u>Telehealth POS Value Set</u>).</li></ul>

- At least one acute inpatient discharge with a diagnosis of diabetes (Diabetes Value Set) on the discharge claim. To identify an acute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  3. Identify the discharge date for the stay.
- At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), ED visits (ED Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim), on different dates of service, with a diagnosis of diabetes (Diabetes Value Set). Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge:
  1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the discharge date for the stay.

Only include nonacute inpatient encounters (Nonacute Inpatient Value Set) **without** telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).

*Pharmacy data.* Members who were dispensed insulin or hypoglycemics/ antihyperglycemics on an ambulatory basis during the measurement year or the year prior to the measurement year (Diabetes Medications List).

#### Diabetes Medications

Description	Prescription	
Alpha-glucosidase inhibitors	• Acarbose	• Miglitol
Amylin analogs	• Pramlintide	
Antidiabetic combinations	• Alogliptin-metformin • Alogliptin-pioglitazone • Canagliflozin-metformin • Dapagliflozin-metformin • Empagliflozin-linagliptin	• Empagliflozin-metformin • Glimepiride-pioglitazone • Glipizide-metformin • Glyburide-metformin • Linagliptin-metformin • Metformin-pioglitazone • Metformin-repaglinide • Metformin-rosiglitazone • Metformin-saxagliptin • Metformin-sitagliptin
Insulin	• Insulin aspart • Insulin aspart-insulin aspart protamine • Insulin degludec • Insulin detemir • Insulin glargine • Insulin glulisine	• Insulin isophane human • Insulin isophane-insulin regular • Insulin lispro • Insulin lispro-insulin lispro protamine • Insulin regular human • Insulin human inhaled
Meglitinides	• Nateglinide	• Repaglinide

Description	Prescription		
Glucagon-like peptide-1 (GLP1) agonists	<ul style="list-style-type: none"> <li>• Dulaglutide</li> <li>• Exenatide</li> </ul>	<ul style="list-style-type: none"> <li>• Albiglutide</li> <li>• Liraglutide (excluding Saxenda®)</li> </ul>	
Sodium glucose cotransporter 2 (SGLT2) inhibitor	<ul style="list-style-type: none"> <li>• Canagliflozin</li> </ul>	<ul style="list-style-type: none"> <li>• Dapagliflozin</li> </ul>	<ul style="list-style-type: none"> <li>• Empagliflozin</li> </ul>
Sulfonylureas	<ul style="list-style-type: none"> <li>• Chlorpropamide</li> <li>• Glimepiride</li> </ul>	<ul style="list-style-type: none"> <li>• Glipizide</li> <li>• Glyburide</li> </ul>	<ul style="list-style-type: none"> <li>• Tolazamide</li> <li>• Tolbutamide</li> </ul>
Thiazolidinediones	<ul style="list-style-type: none"> <li>• Pioglitazone</li> </ul>	<ul style="list-style-type: none"> <li>• Rosiglitazone</li> </ul>	
Dipeptidyl peptidase-4 (DDP-4) inhibitors	<ul style="list-style-type: none"> <li>• Alogliptin</li> <li>• Linagliptin</li> </ul>	<ul style="list-style-type: none"> <li>• Saxagliptin</li> <li>• Sitagliptin</li> </ul>	

**Note:** Glucophage/metformin as a solo agent is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only.

**Step 2:** Exclude members who meet any of the following criteria:  
**Required exclusions**

- Members with evidence of ESRD (ESRD Diagnosis Value Set) or dialysis (Dialysis Procedure Value Set) any time during the member's history on or prior to December 31 of the measurement year.
- Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set) during the measurement year.

**Step 3:** Exclude members who meet any of the following criteria:

**Note:** Supplemental and medical record data may not be used for these exclusions.

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.
- Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty **and** advanced illness. Members must meet **BOTH** of the following frailty and advanced illness criteria to be excluded:
  1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
  2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
    - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis

(Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  3. Identify the discharge date for the stay.
- At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
  - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
    3. Identify the discharge date for the stay.
  - A dispensed dementia medication (Dementia Medications List).
- Members 81 years of age and older as of December 31 of the measurement year (all product lines) with frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.

#### ***Dementia Medications***

Description	Prescription
Cholinesterase inhibitors	• Donepezil    • Galantamine    • Rivastigmine
Miscellaneous central nervous system agents	• Memantine
Dementia combinations	• Donepezil-memantine



## Administrative Specification

**Denominator**      The eligible population.

**Numerator**

- Kidney Health Evaluation**      Members who received **both** of the following during the measurement year on the same or different dates of service:
- At least one eGFR (Estimated Glomerular Filtration Rate Lab Test Value Set).
  - At least one uACR identified by **both** a quantitative urine albumin test (Quantitative Urine Albumin Lab Test Value Set) **and** a urine creatinine test (Urine Creatinine Lab Test Value Set) **with** service dates four or less days apart. For example, if the service date for the quantitative urine albumin test was December 1 of the measurement year, then the urine creatinine test must have a service date on or between November 27 and December 5 of the measurement year.

### Exclusions (optional)

Members who do not have a diagnosis of diabetes (Diabetes Value Set), in any setting, during the measurement year or the year prior to the measurement year **and** who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes (Diabetes Exclusions Value Set), in any setting, during the measurement year or the year prior to the measurement year.

If the member was included in the measure based on claim or encounter data, as described in the event/diagnosis criteria, the optional exclusions do not apply because the member had a diagnosis of diabetes.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table KED-1/2/3: Data Elements for Kidney Health Evaluation for Patients With Diabetes**

Administrative	
Measurement year	✓
Eligible population	<i>For each age stratification and total</i>
Number of required exclusions	<i>For each age stratification and total</i>
Number of optional exclusions	<i>For each age stratification and total</i>
Number of numerator events by administrative data	<i>For each age stratification and total</i>
Number of numerator events by supplemental data	<i>For each age stratification and total</i>
Reported rate	<i>For each age stratification and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

**Note:** These allowable adjustments are for use for the MY 2021.

### Rules for Allowable Adjustments for Kidney Health Evaluation for Patients With Diabetes

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age may be changed if the range is within the specified age range (18–85 years).
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefit	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	No	Only events or diagnoses that contain (or map to) codes in the medication lists and value sets may be used to identify visits. Medication lists, value sets and logic may not be changed
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Required Exclusions	Yes, with limits	Apply required exclusions according to specified value sets. The palliative care exclusion is not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Exclusions: I-SNP, LTI, Frailty or Advanced Illness	Yes	These exclusions are not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Value sets may not be changed.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Kidney Health Evaluation	No	Value sets and logic may not be changed.

## Controlling High Blood Pressure (CBP)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Revised the time frame in the event/diagnosis criteria to look for two outpatient visits with a diagnosis of hypertension in the first six months of the measurement year and the year prior to the measurement year.
- Removed the restriction that only one of the two visits with a hypertension diagnosis be an outpatient telehealth, telephone visit, e-visit or virtual check-in when identifying the event/diagnosis.
- Added palliative care as a required exclusion.
- Added telephone visits, e-visits and virtual check-ins to the advanced illness exclusion.
- Added Donepezil-memantine to the “Dementia combinations” description in the [Dementia Medications List](#).
- In the Administrative Specification, added telephone visits, e-visits and virtual check-ins as appropriate settings for BP readings.
- Updated the Hybrid Specification to indicate that sample size reduction is not allowed for MY 2020; sample size reduction is allowed for MY 2021.
- Removed the requirements for remote monitoring devices to allow BPs taken by any digital device.
- Removed the exclusion of BP readings reported or taken by the member.
- Added the “Number of required exclusions” data element to the Data Elements for Reporting table.
- Added guidance for adjusting required exclusions in the *Rules for Allowable Adjustments* section.

### Description

The percentage of members 18–85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm Hg) during the measurement year.

### Definitions

<b>Adequate control</b>	Both a representative systolic BP <140 mm Hg and a representative diastolic BP of <90 mm Hg.
<b>Representative BP</b>	The most recent BP reading during the measurement year on or after the second diagnosis of hypertension. If multiple BP measurements occur on the same date, or are noted in the chart on the same date, use the lowest systolic and lowest diastolic BP reading. If no BP is recorded during the measurement year, assume that the member is “not controlled.”

## Eligible Population

**Note:** Members in hospice are excluded from the eligible population. If a member is found to be in hospice or using hospice services during medical record review, the member is removed from the sample and replaced by a member from the oversample. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18–85 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in continuous enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (e.g., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	<p>Members who had at least two visits on different dates of service with a diagnosis of hypertension on or between January 1 of the year prior to the measurement year and June 30 of the measurement year. Visit type need not be the same for the two visits. Any of the following code combinations meet criteria:</p> <ul style="list-style-type: none"> <li>• Outpatient visit (<u>Outpatient Without UBREV Value Set</u>) with any diagnosis of hypertension (<u>Essential Hypertension Value Set</u>).</li> <li>• A telephone visit (<u>Telephone Visits Value Set</u>) with any diagnosis of hypertension (<u>Essential Hypertension Value Set</u>).</li> <li>• An e-visit or virtual check-in (<u>Online Assessments Value Set</u>) with any diagnosis of hypertension (<u>Essential Hypertension Value Set</u>).</li> </ul>
<b>Required exclusion</b>	Members receiving palliative care ( <u>Palliative Care Assessment Value Set</u> ; <u>Palliative Care Encounter Value Set</u> ; <u>Palliative Care Intervention Value Set</u> ) during the measurement year.
<b>Exclusions</b>	<p>Exclude members who meet any of the following criteria:</p> <p><b>Note:</b> Supplemental and medical record data may not be used for these exclusions.</p> <ul style="list-style-type: none"> <li>• Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following: <ul style="list-style-type: none"> <li>– Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.</li> <li>– Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year.</li> </ul> </li> <li>• Members 66–80 years of age as of December 31 of the measurement year (all product lines) with frailty <b>and</b> advanced illness. Members must meet <i>both</i> of the following frailty and advanced illness criteria to be excluded:</li> </ul>

1. At least one claim/encounter for frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.
2. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
  - At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
    3. Identify the discharge date for the stay.
  - At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
  - At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
    3. Identify the discharge date for the stay.
  - A dispensed dementia medication (Dementia Medications List).
- Members 81 years of age and older as of December 31 of the measurement year (all product lines) with frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) during the measurement year.

**Dementia Medications**

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"> <li>• Donepezil</li> <li>• Galantamine</li> <li>• Rivastigmine</li> </ul>
Miscellaneous central nervous system agents	<ul style="list-style-type: none"> <li>• Memantine</li> </ul>
Dementia combinations	<ul style="list-style-type: none"> <li>• Donepezil-memantine</li> </ul>

## Administrative Specification

**Denominator** The eligible population.

**Numerator** Identify the most recent BP reading (Systolic Blood Pressure Value Set; Diastolic Blood Pressure Value Set) taken during an outpatient visit (Outpatient Without UBREV Value Set), telephone visit (Telephone Visits Value Set), e-visit or virtual check-in (Online Assessments Value Set), a nonacute inpatient encounter (Nonacute Inpatient Value Set), or remote monitoring event (Remote Blood Pressure Monitoring Value Set) during the measurement year.

The BP reading must occur *on or after* the date of the second diagnosis of hypertension (identified using the event/diagnosis criteria).

The member is numerator compliant if the BP is <140/90 mm Hg. The member is not compliant if the BP is ≥140/90 mm Hg, if there is no BP reading during the measurement year or if the reading is incomplete (e.g., the systolic or diastolic level is missing). If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

Organizations that use CPT Category II codes to identify numerator compliance for this indicator must search for all codes in the following value sets and use the most recent codes during the measurement year to determine numerator compliance for both systolic and diastolic levels.

Value Set	Numerator Compliance
<u>Systolic Less Than 140 Value Set</u>	Systolic compliant
<u>Systolic Greater Than or Equal To 140 Value Set</u>	Systolic not compliant
<u>Diastolic Less Than 80 Value Set</u>	Diastolic compliant
<u>Diastolic 80–89 Value Set</u>	Diastolic compliant
<u>Diastolic Greater Than or Equal To 90 Value Set</u>	Diastolic not compliant

## Exclusions (optional)

- Exclude from the eligible population all members with evidence of end-stage renal disease (ESRD) (ESRD Diagnosis Value Set), dialysis (Dialysis Procedure Value Set), nephrectomy (Nephrectomy Value Set) or kidney transplant (Kidney Transplant Value Set; History of Kidney Transplant Value Set) on or prior to December 31 of the measurement year.
- Exclude from the eligible population female members with a diagnosis of pregnancy (Pregnancy Value Set) during the measurement year.
- Exclude from the eligible population all members who had a nonacute inpatient admission during the measurement year. To identify nonacute inpatient admissions:
  - Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  - Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
  - Identify the admission date for the stay.

## Hybrid Specification

<b>Denominator</b>	<p>A systematic sample drawn from the eligible population.</p> <p>For MY 2020 reporting, because Controlling High Blood Pressure has been significantly revised, sample size reduction is not allowed.</p> <p>For MY 2021 reporting, the organization may reduce the sample size using the current year's administrative rate or the prior year's audited, product line specific rate.</p> <p>Refer to the Guidelines for Calculations and Sampling for information on reducing the sample size.</p>
<b>Identifying the medical record</b>	<p>All eligible BP measurements recorded in the record must be considered. If an organization cannot find the medical record, the member remains in the measure denominator and is considered noncompliant for the numerator.</p> <p>Use the following guidance to find the appropriate medical record to review.</p> <ul style="list-style-type: none"> <li>• Identify the member's PCP.</li> <li>• If the member had more than one PCP for the time-period, identify the PCP who most recently provided care to the member.</li> <li>• If the member did not visit a PCP for the time-period or does not have a PCP, identify the practitioner who most recently provided care to the member.</li> <li>• If a practitioner other than the member's PCP manages the hypertension, the organization may use the medical record of that practitioner.</li> </ul>
<b>Numerator</b>	<p>The number of members in the denominator whose most recent BP (both systolic and diastolic) is adequately controlled during the measurement year. For a member's BP to be controlled the systolic and diastolic BP must be &lt;140/90 mm Hg (adequate control). To determine if a member's BP is adequately controlled, the representative BP must be identified.</p>
<b>Administrative</b>	<p>Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.</p>
<b>Medical record</b>	<p>Identify the most recent BP reading noted during the measurement year.</p> <p>The BP reading must occur on or after the date when the second diagnosis of hypertension (identified using the event/diagnosis criteria) occurred.</p> <p>Do not include BP readings:</p> <ul style="list-style-type: none"> <li>• Taken during an acute inpatient stay or an ED visit.</li> <li>• Taken on the same day as a diagnostic test or diagnostic or therapeutic procedure that requires a change in diet or change in medication on or one day before the day of the test or procedure, with the exception of fasting blood tests.</li> <li>• Taken by the member using a non-digital device such as with a manual blood pressure cuff and a stethoscope.</li> </ul>

Identify the lowest systolic and lowest diastolic BP reading from the most recent BP notation in the medical record. If multiple readings were recorded for a single date, use the lowest systolic and lowest diastolic BP on that date as the representative BP. The systolic and diastolic results do not need to be from the same reading.

The member is not compliant if the BP reading is  $\geq 140/90$  mm Hg or is missing, or if there is no BP reading during the measurement year or if the reading is incomplete (e.g., the systolic or diastolic level is missing).

### Exclusions (optional)

Refer to the *Administrative Specification* for exclusion criteria. Exclusionary evidence in the medical record must include a note indicating diagnosis of pregnancy or evidence of a nonacute inpatient admission during the measurement year, **or** evidence of ESRD, dialysis, nephrectomy or kidney transplant any time during the member's history through December 31 of the measurement year.

### Note

- *When identifying the most recent BP reading, all eligible BP readings in the appropriate medical record should be considered, regardless of practitioner type and setting (excluding acute inpatient and ED visit settings).*
- *An EMR can be used to identify the most recent BP reading if it meets the criteria for appropriate medical record.*
- *When excluding BP readings from the numerator, the intent is to identify diagnostic or therapeutic procedures that require a medication regimen, a change in diet or a change in medication. For example (this list is just for reference, and is not exhaustive):*
  - *A colonoscopy requires a change in diet (NPO on the day of procedure) and a medication change (a medication is taken to prep the colon).*
  - *Dialysis, infusions and chemotherapy (including oral chemotherapy) are all therapeutic procedures that require a medication regimen.*
  - *A nebulizer treatment with albuterol is considered a therapeutic procedure that requires a medication regimen (the albuterol).*
  - *A patient forgetting to take regular medications on the day of the procedure is not considered a required change in medication, and therefore the BP reading is eligible.*
- *BP readings taken on the same day that the member receives a common low-intensity or preventive procedure are eligible for use. For example, the following procedures are considered common low-intensity or preventive (this list is just for reference, and is not exhaustive):*
  - *Vaccinations.*
  - *Injections (e.g., allergy, vitamin B-12, insulin, steroid, toradol, Depo-Provera, testosterone, lidocaine).*
  - *TB test.*
  - *IUD insertion.*
  - *Eye exam with dilating agents.*
  - *Wart or mole removal.*



## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CBP-1/2/3: Data Elements for Controlling High Blood Pressure**

	Admin	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of required exclusions	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year's administrative rate (before exclusions)		✓
Minimum required sample size (MRSS)		✓
Oversampling rate		✓
Number of oversample records		✓
Number of medical records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	✓	✓
Numerator events by medical records		✓
Numerator events by supplemental data	✓	✓
Reported rate	✓	✓

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Controlling High Blood Pressure

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Using product line criteria is not required. Including any product line, combining product lines, or not including product line criteria is allowed.
Ages	Yes, with limits	Age determination dates may be changed (e.g., select, "age as of June 30"). The denominator age may be changed if the range is within the specified age range (ages 18–85 years). The denominator age may not be expanded.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefit	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	No	Only events that contain (or map to) codes in the value sets may be used to identify visits. Value sets and logic may not be changed.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Required Exclusions	Yes	The palliative care exclusion is not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Optional Exclusions	No, if applied	Optional exclusions are not required, but if they are used, only specified exclusions may be applied. Value sets may not be changed.
Exclusions: I-SNP, LTI, Frailty or Advanced Illness	Yes	These exclusions are not required. Refer to <i>Exclusions</i> in the <i>Guidelines for the Rules for Allowable Adjustments</i> .
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Adequate control of blood pressure	No	Value sets and logic may not be changed.

## Follow-Up Care for Children Prescribed ADHD Medication (ADD)

### SUMMARY OF CHANGES TO HEDIS 2020

- Updated the exclusions (step 4) for both rates.
- Clarified in the continuous enrollment criteria of Rate 2 how to handle members who switch between products.
- Added the *Rules for Allowable Adjustments of HEDIS* section.

### Description

The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported.

1. *Initiation Phase*. The percentage of members 6–12 years of age as of the IPSP with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase.
2. *Continuation and Maintenance (C&M) Phase*. The percentage of members 6–12 years of age as of the IPSP with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

### Definitions

<b>Intake Period</b>	The 12-month window starting March 1 of the year prior to the measurement year and ending the last calendar day of February of the measurement year.
<b>Negative Medication History</b>	A period of 120 days (4 months) prior to the IPSP when the member had no ADHD medications dispensed for either new or refill prescriptions.
<b>IPSP</b>	Index Prescription Start Date. The earliest prescription dispensing date for an ADHD medication where the date is in the Intake Period and there is a Negative Medication History.
<b>Initiation Phase</b>	The 30 days following the IPSP.
<b>C&amp;M Phase</b>	The 300 days following the IPSP (10 months).
<b>New Episode</b>	The member must have a 120-day (4-month) Negative Medication History on or before the IPSP.
<b>Continuous Medication Treatment</b>	The number of medication treatment days during the 10-month follow-up period must be $\geq 210$ days (i.e., 300 treatment days – 90 gap days).
<b>Treatment days (covered days)</b>	The actual number of calendar days covered with prescriptions within the specified 300-day measurement interval (e.g., a prescription of a 90 days supply dispensed on the 220th day will have 80 days counted in the 300-day interval).

## Eligible Population: Rate 1—Initiation Phase

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	Six years as of March 1 of the year prior to the measurement year to 12 years as of the last calendar day of February of the measurement year.
<b>Continuous enrollment</b>	120 days (4 months) prior to the IPSD through 30 days after the IPSD.
<b>Allowable gap</b>	None.
<b>Anchor date</b>	None.
<b>Benefits</b>	Medical and pharmacy.
<b>Event/diagnoses</b>	Follow the steps below to identify the eligible population for the Initiation Phase.
<b>Step 1</b>	Identify all children in the specified age range who were dispensed an ADHD medication ( <a href="#">ADHD Medications List</a> ) during the 12-month Intake Period.

### ADHD Medications

Description	Prescription
CNS stimulants	<ul style="list-style-type: none"> <li>• Amphetamine-dextroamphetamine</li> <li>• Dextroamphetamine</li> <li>• Lisdexamfetamine</li> <li>• Methylphenidate</li> <li>• Dexmethylphenidate</li> <li>• Methamphetamine</li> </ul>
Alpha-2 receptor agonists	<ul style="list-style-type: none"> <li>• Clonidine</li> <li>• Guanfacine</li> </ul>
Miscellaneous ADHD medications	<ul style="list-style-type: none"> <li>• Atomoxetine</li> </ul>

**Step 2** Test for Negative Medication History. For each member identified in step 1, test each ADHD prescription for a Negative Medication History. The IPSD is the dispensing date of the earliest ADHD prescription in the Intake Period with a Negative Medication History.

**Step 3** Calculate continuous enrollment. Members must be continuously enrolled for 120 days (4 months) prior to the IPSD through 30 days after the IPSD.

**Step 4** Exclude members who had an acute inpatient encounter for a mental, behavioral or neurodevelopmental disorder during the 30 days after the IPSD. Either of the following meet criteria:

- An acute inpatient encounter ([Acute Inpatient Value Set](#)) with a principal diagnosis of mental, behavioral or neurodevelopmental disorder ([Mental, Behavioral and Neurodevelopmental Disorders Value Set](#)).
- An acute inpatient discharge with a principal diagnosis of mental, behavioral or neurodevelopmental disorder ([Mental, Behavioral and Neurodevelopmental Disorders Value Set](#)). To identify an acute inpatient discharge:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

### Administrative Specification: *Rate 1—Initiation Phase*

<b>Denominator</b>	The Rate 1 eligible population.
<b>Numerator</b>	<p>An outpatient, intensive outpatient or partial hospitalization follow-up visit with a practitioner with prescribing authority, within 30 days after the IPSP. Any of the following code combinations billed by a practitioner with prescribing authority meet criteria:</p> <ul style="list-style-type: none"> <li>• An outpatient visit (<u>Visit Setting Unspecified Value Set <i>with</i> Outpatient POS Value Set</u>).</li> <li>• An outpatient visit (<u>BH Outpatient Value Set</u>).</li> <li>• An observation visit (<u>Observation Value Set</u>).</li> <li>• A health and behavior assessment or intervention (<u>Health and Behavior Assessment or Intervention Value Set</u>).</li> <li>• An intensive outpatient encounter or partial hospitalization (<u>Visit Setting Unspecified Value Set <i>with</i> Partial Hospitalization POS Value Set</u>).</li> <li>• An intensive outpatient encounter or partial hospitalization (<u>Partial Hospitalization or Intensive Outpatient Value Set</u>).</li> <li>• A community mental health center visit (<u>Visit Setting Unspecified Value Set <i>with</i> Community Mental Health Center POS Value Set</u>).</li> </ul> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• Do not count a visit on the IPSP as the Initiation Phase visit.</li> <li>• Do not count visits billed with a telehealth modifier (<u>Telehealth Modifier Value Set</u>) or billed with a telehealth POS code (<u>Telehealth POS Value Set</u>).</li> </ul>

### Eligible Population: *Rate 2—C&M Phase*

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	Six years as of March 1 of the year prior to the measurement year to 12 years as of the last calendar day of February of the measurement year.
<b>Continuous enrollment</b>	<p>Members must be continuously enrolled in the organization for 120 days (4 months) prior to the IPSP and 300 days (10 months) after the IPSP.</p> <p>Members who switch product lines or products between the Rate 1 and Rate 2 continuous enrollment periods are only included in Rate 1. However, if an organization reports products combined, then a member who switches between those products (e.g., the products included in the HEDIS reporting entity) is included in both rates. For example, if an organization reports HMO and POS products combined and a member switches from HMO to POS between the</p>

Rate 1 and Rate 2 continuous enrollment period, the member is included in both Rate 1 and Rate 2.

**Allowable gap** One 45-day gap in enrollment between 31 days and 300 days (10 months) after the IPSP. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

**Anchor date** None.

**Benefits** Medical and pharmacy.

**Event/diagnosis** Follow the steps below to identify the eligible population for the C&M Phase.

- Step 1** Identify all members who meet the eligible population criteria for Rate 1—Initiation Phase.
- Step 2** Calculate continuous enrollment. Members must be continuously enrolled in the organization for 120 days (4 months) prior to the IPSP and 300 days (10 months) after the IPSP.
- Step 3** Calculate the continuous medication treatment. Using the members in step 2, determine if the member filled a sufficient number of prescriptions to provide continuous treatment for at least 210 days out of the 300-day period after the IPSP. The definition of “continuous medication treatment” allows gaps in medication treatment, up to a total of 90 days during the 300-day (10-month) period. (This period spans the Initiation Phase [1 month] and the C&M Phase [9 months].)

Gaps can include either washout period gaps to change medication or treatment gaps to refill the same medication.

Regardless of the number of gaps, the total gap days may be no more than 90. Count any combination of gaps (e.g., one washout gap of 14 days and numerous weekend drug holidays).

- Step 4** Exclude members who had an acute inpatient encounter for a mental, behavioral or neurodevelopmental disorder during the 300 days (10 months) after the IPSP. Either of the following meet criteria:
- An acute inpatient encounter (Acute Inpatient Value Set) with a principal diagnosis of mental, behavioral or neurodevelopmental disorder (Mental, Behavioral and Neurodevelopmental Disorders Value Set).
  - An acute inpatient discharge with a principal diagnosis of mental, behavioral or neurodevelopmental disorder (Mental, Behavioral and Neurodevelopmental Disorders Value Set). To identify an acute inpatient discharge:
    1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
    2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
    3. Identify the discharge date for the stay.

**Administrative Specification: Rate 2—C&M Phase**

**Denominator** The Rate 2 eligible population.

**Numerator** Identify all members who meet the following criteria:

- Numerator compliant for *Rate 1—Initiation Phase*, **and**
- At least two follow-up visits on different dates of service with any practitioner, from 31–300 days (9 months) after the IPSPD.

Only one of the two visits (during days 31–300) may be a telephone visit (Telephone Visits Value Set) or a telehealth visit.

Identify follow-up visits using the code combinations below, then identify telehealth visits by the presence of a telehealth modifier (Telehealth Modifier Value Set) or the presence of a telehealth POS code (Telehealth POS Value Set) on the claim.

Any of the following code combinations identify follow-up visits:

- An outpatient visit (Visit Setting Unspecified Value Set **with** Outpatient POS Value Set).
- An outpatient visit (BH Outpatient Value Set).
- An observation visit (Observation Visit Value Set).
- A health and behavior assessment or intervention (Health and Behavior Assessment or Intervention Value Set).
- An intensive outpatient encounter or partial hospitalization (Visit Setting Unspecified Value Set **with** Partial Hospitalization POS Value Set).
- An intensive outpatient encounter or partial hospitalization (Partial Hospitalization or Intensive Outpatient Value Set).
- A community mental health center visit (Visit Setting Unspecified Value Set **with** Community Mental Health Center POS Value Set).
- A telehealth visit (Visit Setting Unspecified Value Set **with** Telehealth POS Value Set).
- A telephone visit (Telephone Visits Value Set).

**Exclusions (optional)**

Exclude from the denominator for both rates, members with a diagnosis of narcolepsy (Narcolepsy Value Set) any time during their history through December 31 of the measurement year.

**Note**

- For members who have multiple overlapping prescriptions, count the overlap days once toward the days supply (whether the overlap is for the same drug or for a different drug).
- Refer to Appendix 3 for the definition of prescribing practitioner.
- Organizations may have different methods for billing intensive outpatient encounters and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Organizations whose billing methods are comparable to inpatient billing may count each unit of service as an individual visit. The unit of service must have occurred during the period required for the rate (e.g., within 30 days after or from 31–300 days after the IPSPD).

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table ADD-1/2: Data Elements for Follow-Up Care for Children Prescribed ADHD Medication**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	<i>Each of the 2 rates</i>
Number of optional exclusions	<i>Each of the 2 rates</i>
Numerator events by administrative data	<i>Each of the 2 rates</i>
Numerator events by supplemental data	<i>Each of the 2 rates</i>
Reported rate	<i>Each of the 2 rates</i>



## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS. HEDIS measures may not be adjusted for any NCQA program.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Follow-Up Care for Children Prescribed ADHD Medication

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes	The age determination dates may be changed (e.g., select, "age as of June 30"). Changing the denominator age range is allowed.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Using a benefit is not required; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	Yes, with limits	Only events or diagnoses that contain (or map to) codes in the medication lists and value sets may be used to identify visits. Medication lists, value sets and logic may not be changed. <b>Note:</b> This measure uses newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication; modifying the measurement period can affect other dates; however, the order and relationship of the events may not be changed.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	No, if applied	The optional exclusions are not required, but if they are used, only the specified exclusions may be applied and the value sets may not be changed.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Initiation Phase	No	Value sets and logic may not be changed.
Continuation and Management Phase	Yes, with limits	Value sets and logic may not be changed. Timing of visit determination may be changed.

# ***Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)\****

**\*Developed with financial support from the Agency for Healthcare Research and Quality (AHRQ) and Centers for Medicare & Medicaid Services (CMS) under the CHIPRA Pediatric Quality Measures Program Centers of Excellence grant number U18 HS020503.**

---

## **SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021**

---

- Clarified in the *Rules for Allowable Adjustments of HEDIS* that when adjusting ages, the upper age range may be expanded or there may be no upper age limit.

## **Description**

The percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported:

1. The percentage of children and adolescents on antipsychotics who received blood glucose testing.
2. The percentage of children and adolescents on antipsychotics who received cholesterol testing.
3. The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.

## **Eligible Population**

**Note:** *Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.*

<b>Product lines</b>	Commercial, Medicaid (report each product line separately).
<b>Ages</b>	1–17 years as of December 31 of the measurement year. Report two age stratifications and a total rate for each of the three indicators: <ul style="list-style-type: none"><li>• 1–11 years.</li><li>• 12–17 years.</li><li>• Total.</li></ul> <p>The total is the sum of the age stratifications.</p>
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the measurement year.
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical and pharmacy.
<b>Event/diagnosis</b>	At least two antipsychotic medication dispensing events ( <u><a href="#">Antipsychotic Medications List</a></u> ; <u><a href="#">Antipsychotic Combination Medications List</a></u> ; <u><a href="#">Prochlorperazine</a></u>

Medications List) of the same or different medications, on different dates of service during the measurement year.

#### **Antipsychotic Medications**

Description	Prescription		
Miscellaneous antipsychotic agents	<ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Asenapine</li> <li>• Brexpiprazole</li> <li>• Cariprazine</li> <li>• Clozapine</li> <li>• Haloperidol</li> </ul>	<ul style="list-style-type: none"> <li>• Iloperidone</li> <li>• Loxapine</li> <li>• Lurasidone</li> <li>• Molindone</li> <li>• Olanzapine</li> <li>• Paliperidone</li> </ul>	<ul style="list-style-type: none"> <li>• Pimozide</li> <li>• Quetiapine</li> <li>• Risperidone</li> <li>• Ziprasidone</li> </ul>
Phenothiazine antipsychotics	<ul style="list-style-type: none"> <li>• Chlorpromazine</li> <li>• Fluphenazine</li> <li>• Perphenazine</li> </ul>	<ul style="list-style-type: none"> <li>• Thioridazine</li> <li>• Trifluoperazine</li> </ul>	
Thioxanthenes	<ul style="list-style-type: none"> <li>• Thiothixene</li> </ul>		
Long-acting injections	<ul style="list-style-type: none"> <li>• Aripiprazole</li> <li>• Fluphenazine decanoate</li> <li>• Haloperidol decanoate</li> </ul>	<ul style="list-style-type: none"> <li>• Olanzapine</li> <li>• Paliperidone palmitate</li> <li>• Risperidone</li> </ul>	

#### **Antipsychotic Combination Medications**

Description	Prescription	
Psychotherapeutic combinations	<ul style="list-style-type: none"> <li>• Fluoxetine-olanzapine</li> </ul>	<ul style="list-style-type: none"> <li>• Perphenazine-amitriptyline</li> </ul>

#### **Prochlorperazine Medications**

Description	Prescription
Phenothiazine antipsychotics	<ul style="list-style-type: none"> <li>• Prochlorperazine</li> </ul>

### **Administrative Specification**

**Denominator** The eligible population.

#### **Numerator**

**Blood Glucose** Members who received at least one test for blood glucose (Glucose Lab Test Value Set; Glucose Test Result or Finding Value Set) or HbA1c (HbA1c Lab Test Value Set; HbA1c Test Result or Finding Value Set) during the measurement year.

**Cholesterol** Members who received at least one test for LDL-C (LDL-C Lab Test Value Set; LDL-C Test Result or Finding Value Set) or cholesterol (Cholesterol Lab Test Value Set; Cholesterol Test Result or Finding Value Set) during the measurement year.

**Blood Glucose and Cholesterol** Members who received both of the following during the measurement year on the same or different dates of service.

- At least one test for blood glucose (Glucose Lab Test Value Set, Glucose Test Result or Finding Value Set) or HbA1c (HbA1c Lab Test Value Set, HbA1c Test Result or Finding Value Set).
- At least one test for LDL-C (LDL-C Lab Test Value Set; LDL-C Test Result or Finding Value Set) or cholesterol (Cholesterol Lab Test Value Set; Cholesterol Test Result or Finding Value Set).

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table APM-1/2: Data Elements for Metabolic Monitoring for Children and Adolescents on Antipsychotics**

	Administrative
Measurement year	✓
Eligible population	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>Each indicator, for each age stratification and total</i>
Numerator events by supplemental data	<i>Each indicator, for each age stratification and total</i>
Reported rate	<i>Each indicator, for each age stratification and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### **Guidance for Allowable Adjustments for Metabolic Monitoring for Children and Adolescents on Antipsychotics**

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes	The age determination dates may be changed (e.g., select, "age as of June 30"). Changing the denominator age range is allowed within a specified age range (ages 1–17+ years). Additionally, the upper age range may be expanded, or no upper age limit may be used.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	No	Only dispensing events that contain (or map to) codes in the medication lists and value sets may be used to identify antipsychotic medication events. Medication lists, value sets and logic may not be changed.
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Exclusions	NA	There are no exclusions for this measure.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
Metabolic monitoring	No	Value sets and logic may not be changed.

## Follow-Up After Hospitalization for Mental Illness (FUH)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Replaced “mental health practitioner” with “mental health provider.”
- Removed the mental health provider requirement for follow-up visits for intensive outpatient encounters, partial hospitalizations, community mental health centers and electroconvulsive therapy settings.
- Added visits in a behavioral healthcare setting to the numerator.
- Added telephone visits to the numerator.
- Deleted the Mental Health Practitioner Value Set.
- Revised the instructions in the *Notes* for identifying mental health providers.

### Description

The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider. Two rates are reported:

1. The percentage of discharges for which the member received follow-up within 30 days after discharge.
2. The percentage of discharges for which the member received follow-up within 7 days after discharge.

### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	6 years and older as of the date of discharge. Report three age stratifications and total rate: <ul style="list-style-type: none"><li>• 6–17 years.</li><li>• 18–64 years.</li><li>• 65 years and older.</li><li>• Total.</li></ul>
<b>Continuous enrollment</b>	The total is the sum of the age stratifications. Date of discharge through 30 days after discharge.
<b>Allowable gap</b>	No gaps in enrollment.
<b>Anchor date</b>	None.
<b>Benefits</b>	Medical and mental health (inpatient and outpatient).
<b>Event/diagnosis</b>	An acute inpatient discharge with a principal diagnosis of mental illness or intentional self-harm ( <u>Mental Illness Value Set</u> ; <u>Intentional Self-Harm Value Set</u> ) on the discharge claim on or between January 1 and December 1 of the measurement year. To identify acute inpatient discharges:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the discharge date for the stay.

The denominator for this measure is based on discharges, not on members. If members have more than one discharge, include all discharges on or between January 1 and December 1 of the measurement year.

**Acute  
readmission or  
direct transfer**

Identify readmissions and direct transfers to an acute inpatient care setting during the 30-day follow-up period:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
3. Identify the admission date for the stay.

Exclude both the initial discharge and the readmission/direct transfer discharge if the last discharge occurs after December 1 of the measurement year.

If the readmission/direct transfer to the acute inpatient care setting was for a principal diagnosis (use only the principal diagnosis on the discharge claim) of mental health disorder or intentional self-harm (Mental Health Diagnosis Value Set; Intentional Self-Harm Value Set), count only the last discharge.

If the readmission/direct transfer to the acute inpatient care setting was for any other principal diagnosis (use only the principal diagnosis on the discharge claim) exclude both the original and the readmission/direct transfer discharge.

**Nonacute  
readmission or  
direct transfer**

Exclude discharges followed by readmission or direct transfer to a nonacute inpatient care setting within the 30-day follow-up period, regardless of principal diagnosis for the readmission. To identify readmissions and direct transfers to a nonacute inpatient care setting:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
3. Identify the admission date for the stay.

These discharges are excluded from the measure because rehospitalization or direct transfer may prevent an outpatient follow-up visit from taking place.

## Administrative Specification

**Denominator** The eligible population.

**Numerators**

**30-Day Follow-Up** A follow-up visit with a mental health provider within 30 days after discharge. Do not include visits that occur on the date of discharge.

**7-Day Follow-Up** A follow-up visit with a mental health provider within 7 days after discharge. Do not include visits that occur on the date of discharge.

For both indicators, any of the following meet criteria for a follow-up visit.

- An outpatient visit (Visit Setting Unspecified Value Set) **with** (Outpatient POS Value Set) **with** a mental health provider.

- An outpatient visit (BH Outpatient Value Set) **with** a mental health provider.
- An intensive outpatient encounter or partial hospitalization (Visit Setting Unspecified Value Set) **with** (Partial Hospitalization POS Value Set).
- An intensive outpatient encounter or partial hospitalization (Partial Hospitalization or Intensive Outpatient Value Set).
- A community mental health center visit (Visit Setting Unspecified Value Set; BH Outpatient Value Set; Observation Value Set; Transitional Care Management Services Value Set) **with** (Community Mental Health Center POS Value Set).
- Electroconvulsive therapy (Electroconvulsive Therapy Value Set) **with** (Ambulatory Surgical Center POS Value Set; Community Mental Health Center POS Value Set; Outpatient POS Value Set; Partial Hospitalization POS Value Set).
- A telehealth visit: (Visit Setting Unspecified Value Set) **with** (Telehealth POS Value Set) **with** a mental health provider.
- An observation visit (Observation Value Set) **with** a mental health provider.
- Transitional care management services (Transitional Care Management Services Value Set), **with** a mental health provider.
- A visit in a behavioral healthcare setting (Behavioral Healthcare Setting Value Set).
- A telephone visit (Telephone Visits Value Set) **with** a mental health provider.

### Note

---

- Organizations may have different methods for billing intensive outpatient visits and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Organizations whose billing methods are comparable to inpatient billing may count each unit of service as an individual visit. The unit of service must have occurred during the required period for the rate (e.g., within 30 days after discharge or within 7 days after discharge).
- Refer to Appendix 3 for the definition of “mental health provider.” Organizations must develop their own methods to identify mental health providers. Methods are subject to review by the HEDIS auditor.



## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table FUH-1/2/3: Data Elements for Follow-Up After Hospitalization  
for Mental Illness**

	Administrative
Measurement year	✓
Eligible population	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>Each of the 2 rates for each age stratification and total</i>
Numerator events by supplemental data	<i>Each of the 2 rates for each age stratification and total</i>
Reported rate	<i>Each of the 2 rates for each age stratification and total</i>

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Follow-Up After Hospitalization for Mental Illness

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes	The age determination dates may be changed (e.g., select, "age as of June 30"). Changing the denominator age range is allowed.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	Yes, with limits	Only events or diagnoses that contain (or map to) codes in the value sets may be used to identify inpatient stays and diagnoses. Value sets and logic may not be changed. <b>Note:</b> Organizations may assess at the member level (vs. discharge level) by applying measure logic appropriately (i.e., percentage of members who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses who had a follow-up visit with a mental health practitioner).
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	NA	There are no exclusions for this measure.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
<ul style="list-style-type: none"> <li>30-Day Follow-Up</li> <li>7-Day Follow-Up</li> </ul>	No	Value sets and logic may not be changed.

## Follow-Up After Emergency Department Visit for Mental Illness (FUM)

### SUMMARY OF CHANGES TO HEDIS MY 2020 & MY 2021

- Added telephone visits, e-visits and virtual check-ins to the numerator.

#### Description

The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness. Two rates are reported:

1. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
2. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

#### Eligible Population

**Note:** Members in hospice are excluded from the eligible population. Refer to General Guideline 17: Members in Hospice.

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Ages** 6 years and older as of the date of the ED visit. Report three age stratifications and total rate:

- 6–17 years.
- 18–64 years.
- 65 years and older.
- Total.

The total is the sum of the age stratifications.

**Continuous enrollment** Date of the ED visit through 30 days after the ED visit (31 total days).

**Allowable gap** No gaps in enrollment.

**Anchor date** None.

**Benefit** Medical and mental health.

**Event/diagnosis** An ED visit (ED Value Set) with a principal diagnosis of mental illness or intentional self-harm (Mental Illness Value Set; Intentional Self-Harm Value Set) on or between January 1 and December 1 of the measurement year where the member was 6 years or older on the date of the visit.

The denominator for this measure is based on ED visits, not on members. If a member has more than one ED visit, identify all eligible ED visits between January 1 and December 1 of the measurement year and do not include more than one visit per 31-day period as described below.

**Multiple visits in a 31-day period** If a member has more than one ED visit in a 31-day period, include only the first eligible ED visit. For example, if a member has an ED visit on January 1, include the January 1 visit and do not include ED visits that occur on or between January 2 and January 31; then, if applicable, include the next ED visit that occurs on or after February 1. Identify visits chronologically, including only one per 31-day period.

**Note:** Removal of multiple visits in a 31-day period is based on **eligible** visits. Assess each ED visit for exclusions before removing multiple visits in a 31-day period.

**ED visits followed by inpatient admission** Exclude ED visits that result in an inpatient stay and ED visits followed by an admission to an acute or nonacute inpatient care setting on the date of the ED visit or within the 30 days after the ED visit (31 total days), regardless of the principal diagnosis for the admission. To identify admissions to an acute or nonacute inpatient care setting:

1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
2. Identify the admission date for the stay.

These events are excluded from the measure because admission to an acute or nonacute inpatient setting may prevent an outpatient follow-up visit from taking place.

## Administrative Specification

**Denominator** The eligible population.

### Numerators

**30-Day Follow-Up** A follow-up visit with any practitioner, with a principal diagnosis of a mental health disorder or with a principal diagnosis of intentional self-harm and any diagnosis of a mental health disorder within 30 days after the ED visit (31 total days). Include visits that occur on the date of the ED visit.

**7-Day Follow-Up** A follow-up visit with any practitioner, with a principal diagnosis of a mental health disorder or with a principal diagnosis of intentional self-harm and any diagnosis of a mental health disorder within 7 days after the ED visit (8 total days). Include visits that occur on the date of the ED visit.

For both indicators, any of the following meet criteria for a follow-up visit.

- An outpatient visit (Visit Setting Unspecified Value Set **with** Outpatient POS Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An outpatient visit (BH Outpatient Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An intensive outpatient encounter or partial hospitalization (Visit Setting Unspecified Value Set **with** Partial Hospitalization POS Value Set), **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An intensive outpatient encounter or partial hospitalization (Partial Hospitalization or Intensive Outpatient Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).

- A community mental health center visit (Visit Setting Unspecified Value Set **with** Community Mental Health Center POS Value Set), **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- Electroconvulsive therapy (Electroconvulsive Therapy Value Set) **with** (Ambulatory Surgical Center POS Value Set; Community Mental Health Center POS Value Set; Outpatient POS Value Set; Partial Hospitalization POS Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- A telehealth visit (Visit Setting Unspecified Value Set **with** Telehealth POS Value Set), **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An observation visit (Observation Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- A telephone visit (Telephone Visits Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An e-visit or virtual check-in (Online Assessments Value Set) **with** a principal diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An outpatient visit (Visit Setting Unspecified Value Set **with** Outpatient POS Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An outpatient visit (BH Outpatient Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An intensive outpatient encounter or partial hospitalization (Visit Setting Unspecified Value Set **with** Partial Hospitalization POS Value Set), **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An intensive outpatient encounter or partial hospitalization (Partial Hospitalization or Intensive Outpatient Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- A community mental health center visit (Visit Setting Unspecified Value Set **with** Community Mental Health Center POS Value Set), **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- Electroconvulsive therapy (Electroconvulsive Therapy Value Set) **with** (Ambulatory Surgical Center POS Value Set; Community Mental Health Center POS Value Set; Outpatient POS Value Set; Partial Hospitalization POS Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).

- A telehealth visit (Visit Setting Unspecified Value Set **with** Telehealth POS Value Set), **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An observation visit (Observation Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- A telephone visit (Telephone Visits Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).
- An e-visit or virtual check-in (Online Assessments Value Set) **with** a principal diagnosis of intentional self-harm (Intentional Self-Harm Value Set), **with** any diagnosis of a mental health disorder (Mental Health Diagnosis Value Set).

### Note

- Organizations may have different methods for billing intensive outpatient visits and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Organizations whose billing methods are comparable to inpatient billing may count each unit of service as an individual visit. The unit of service must have occurred during the required period for the rate (within 30 days after the ED visit or within 7 days after the ED visit).

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table FUM-1/2/3: Data Elements for Follow-Up After Emergency Department Visit for Mental Illness**

	Administrative
Measurement year	✓
Eligible population	For each age stratification and total
Numerator events by administrative data	Each of the 2 rates for each age stratification and total
Numerator events by supplemental data	Each of the 2 rates for each age stratification and total
Reported rate	Each of the 2 rates for each age stratification and total

## Rules for Allowable Adjustments of HEDIS

This section *may not* be used for reporting health plan HEDIS.

NCQA's Rules for Allowable Adjustments of HEDIS describe how NCQA's HEDIS measure specifications can be adjusted for non-health plan reporting. Refer to the *Guidelines for the Rules of Allowable Adjustments of HEDIS* for additional information.

### Rules for Allowable Adjustments for Follow-Up After Emergency Department Visit for Mental Illness

NONCLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Product Lines	Yes	Organizations are not required to use product line criteria; product lines may be combined and all (or no) product line criteria may be used.
Ages	Yes	Age determination dates may be changed (i.e., age 6 as of the date of the ED visit). Changing the denominator age range is allowed.
Continuous enrollment, Allowable gap, Anchor Date	Yes	Organizations are not required to use enrollment criteria; adjustments are allowed.
Benefits	Yes	Organizations are not required to use a benefit; adjustments are allowed.
Other	Yes	Organizations may use additional eligible population criteria to focus on a population of interest such as gender, sociodemographic characteristic or geographic region.
CLINICAL COMPONENTS		
Eligible Population	Adjustments Allowed (Yes/No)	Notes
Event/Diagnosis	Yes, with limits	Only events or diagnoses that contain (or map to) codes in the value sets may be used to identify visits with a diagnosis. Value sets and logic may not be changed. <b>Note:</b> Organizations may assess at the member level by applying measure logic appropriately (i.e., percentage of members with documentation of an emergency department visit with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness).
Denominator Exclusions	Adjustments Allowed (Yes/No)	Notes
Optional Exclusions	NA	There are no exclusions for this measure.
Numerator Criteria	Adjustments Allowed (Yes/No)	Notes
<ul style="list-style-type: none"> <li>30-Day Follow-Up</li> <li>7-Day Follow-Up</li> </ul>	No	Value sets and logic may not be changed.

## Definitions:

**Screening** – Completion of a clinical or diagnostic tool used to identify people at risk of developing or having a certain disease or condition, even in the absence of symptoms.

**Standardized Depression Screening Tool** – A normalized and validated depression screening tool developed for the Member population in which it is being utilized. The name of the age appropriate standardized depression screening tool utilized must be documented in the medical record.

Examples of depression screening tools include but are not limited to:

- **Adolescent Screening Tools (12-17 years):** Patient Health Questionnaire for Adolescents (PHQ-A), Beck Depression Inventory-Primary Care Version (BDI-PC), Mood Feeling Questionnaire (MFQ), Center for Epidemiologic Studies Depression Scale (CES-D), and PRIME MD-PHQ2
- **Adult Screening Tools (18 years and older):** Patient Health Questionnaire (PHQ-9 or PHQ-2), Beck Depression Inventory (BDI or BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Depression Scale (DEPS), Duke Anxiety-Depression Scale (DADS), Geriatric Depression Scale (GDS), Cornell Scale Screening, and PRIME MD-PHQ2

## Substance Use Assessment in Primary Care

**Methodology:** IEHP-Defined Quality Measure

**Measure Description:** The percentage of members 18 years and older who were screened for substance use during the measurement year (2020).

CODES TO IDENTIFY SUBSTANCE USE ASSESSMENT IN PRIMARY CARE:			
Service	Code Type	Code	Code Description
Substance Use Assessment in Primary Care	CPT	99408	Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention (SBI) Services 15 to 30 Minutes
Substance Use Assessment in Primary Care	CPT	99409	Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention (SBI) Services Greater than 30 Minutes
Substance Use Assessment in Primary Care	HCPCS	G0396	Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention 15 to 30 Minutes



## CODES TO IDENTIFY SUBSTANCE USE ASSESSMENT IN PRIMARY CARE:

Service	Code Type	Code	Code Description
Substance Use Assessment in Primary Care	HCPCS	G0397	Alcohol and/or Substance (other than tobacco) Abuse Structured Screening (e.g. Audit DAST) and Brief Intervention Greater than 30 Minutes
Substance Use Assessment in Primary Care	HCPCS	G0442	Annual Alcohol Misuse Screening 15 Minutes
Substance Use Assessment in Primary Care	HCPCS	G0443	Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes
Substance Use Assessment in Primary Care	HCPCS	H0049	Alcohol and/or Drug Assessment
Substance Use Assessment in Primary Care	HCPCS	H0050	Alcohol and/or Drug Service Brief Intervention Per 15 Minutes

**Denominator:** All Members aged 18 years and older during the measurement year (2020). Member counted only once in the denominator.

**Numerator:** Members who were screened for substance use at least once during the measurement year (2020).

## Population: Women

### Breast Cancer Screening (BCS)

**Methodology:** HEDIS®

**Measure Description:** The percentage of women 50–74 years of age who had a mammogram to screen for breast cancer any time on or between October 1 two years prior to the measurement year (2018) and December 31 of the measurement year (2020).

- The eligible population in the measure meets all of the following criteria:
  1. Women 52-74 years as of December 31 of the measurement year (2020).
  2. Continuous enrollment from October 1 two years prior to the measurement year (2018) through December 31 of the measurement year (2020) with no more than one gap in enrollment of up to 45 days for each calendar year of continuous enrollment. No gaps in enrollment are allowed from October 1 two years prior to the measurement year (2018) through December 31 two years prior to the measurement year (2018).

## Concurrent Use of Opioids and Benzodiazepines (COB-

NQF Endorsement Status	Endorsed
NQF ID	3389
Measure Type	Process
Measure Content Last Updated	2021-02-01
Info As Of	Not Available

### Properties

Description	Percentage of Medicaid beneficiaries age 18 and older with concurrent use of prescription opioids and benzodiazepines.
Numerator	<p>The number of individuals from the denominator with:</p> <p>Two or more prescription claims for any benzodiazepine (Table COB-B) with unique dates of service, AND</p> <p>Concurrent use of opioids and benzodiazepines for 30 or more cumulative days.</p> <p>Table COB-B. Benzodiazepinesa</p> <p>Benzodiazepine Medications</p> <p>Alprazolam</p> <p>Chlordiazepoxide</p> <p>Clobazam</p> <p>Clonazepam Clorazepate</p> <p>Diazepam</p> <p>Estazolam</p> <p>Flurazepam Lorazepam</p> <p>Midazolam</p> <p>Oxazepam</p> <p>Quazepam Temazepam</p> <p>Triazolam</p>
Denominator	<p>Age 18 and older as of January 1 of the measurement year. Identify individuals with 2 or more prescriptions for opioids (Table COB-A) with unique dates of service, for which the sum of the days supply is 15 or more during the measurement year.</p> <p>Exclude individuals who met at least one of the following during the</p>

## Concurrent Use of Opioids and Benzodiazepines (COB-

measurement year:

Hospice

Cancer Diagnosis Table COB-A. Opioid Medications

Opioid Medications

Buprenorphine

Butorphanol

Codeine

Dihydrocodeine

Fentanyl Hydrocodone

Hydromorphone

Levorphanol

Meperidine

Methadone Morphine

Opium

Oxycodone Oxymorphone

Pentazocine

Tapentadol

Tramadol

### Denominator Exclusions

Beneficiaries with cancer are excluded from this measure and may be identified using the ICD-10 codes in Table COB-C, available at <https://www.medicaid.gov/license-agreement.html> file=%2Fmedicaid%2Fquality-of-care%2Fdownloads%2F2018-adult-non-hedis-value-set-directory.zip.

The cancer exclusion criterion is for beneficiaries with a diagnosis code for cancer during the measurement year. Their initial diagnosis may have occurred previously; however, the diagnosis code for cancer must be present

### Rationale

Not Available

### Evidence

Not Available

## Developer/Steward

### Steward

Pharmacy Quality Alliance

### Contact

Not Available

### Measure Developer

Not Available

## Concurrent Use of Opioids and Benzodiazepines (COB-

Development Stage	Fully Developed
-------------------	-----------------

### Characteristics

Measure Type	Process
Meaningful Measure Area	Not Available
Healthcare Priority	Making Care Safer by Reducing Harm Caused in the Delivery of Care
eCQM Spec Available	No
NQF Endorsement Status	Endorsed
NQF ID	3389
Last NQF Update	2020-10-19
Target Population Age	18+
Target Population Age (High)	Not Available
Target Population Age (Low)	18
Reporting Level	Not Available
Conditions	Substance Abuse
Subconditions	Opioid Dependency
Care Settings	Hospital Outpatient; Other; Outpatient

### Groups

Core Measure Set	Medicaid Adult Core Set
------------------	-------------------------

Measure Group	Group Identifier
---------------	------------------

Adult Core Set
----------------

## Concurrent Use of Opioids and Benzodiazepines (COB-

### Measure Links

#### Measure Program: Medicaid

Info As Of	Not Available
------------	---------------

Program / Model Notes
-----------------------

Data Sources	Claims Data
--------------	-------------

Purposes	Not Available
----------	---------------

Quality Domain	Not Available
----------------	---------------

Reporting Frequency	Not Available
---------------------	---------------

Impacts Payment	No
-----------------	----

Reporting Status	Active
------------------	--------

Data Reporting Begin Date	2018-10-01
---------------------------	------------

Data Reporting End Date	Not Available
-------------------------	---------------

### Measure Program Links

<a href="https://www.medicaid.gov/">https://www.medicaid.gov/</a>
---

## Use of Pharmacotherapy for Opioid Use Disorder (OUD-HH)

<b>NQF Endorsement Status</b>	Endorsed
<b>NQF ID</b>	3400
<b>Measure Type</b>	Process
<b>Measure Content Last Updated</b>	2021-02-01
<b>Info As Of</b>	Not Available

### Properties

<b>Description</b>	The percentage of Medicaid beneficiaries ages 18 to 64 with an OUD who filled a prescription for or were administered or ordered an FDA-approved medication for the disorder during the measure year. The measure will report any medications used in medication-assisted treatment of opioid dependence and addiction and four separate rates representing the following types of FDA-approved drug products: buprenorphine; oral naltrexone; long-acting, injectable naltrexone; and methadone.
<b>Numerator</b>	Medicaid beneficiaries ages 18 to 64 with an OUD who filled a prescription for or were administered or ordered an FDA-approved medication for the disorder during the measure year.
<b>Denominator</b>	Number of Medicaid beneficiaries with at least one encounter with a diagnosis of opioid abuse, dependence, or remission (primary or other) at any time during the measurement year.
<b>Denominator Exclusions</b>	Not Available
<b>Rationale</b>	Not Available
<b>Evidence</b>	Not Available

### Developer/Steward

<b>Steward</b>	CMS
----------------	-----

## Use of Pharmacotherapy for Opioid Use Disorder (OUD-HH)

Contact	Not Available
Measure Developer	Not Available
Development Stage	Fully Developed

### Characteristics

Measure Type	Process
Meaningful Measure Area	Prevention, Treatment, and Management of Mental Health
Healthcare Priority	Promote Effective Prevention & Treatment of Chronic Disease
eCQM Spec Available	No
NQF Endorsement Status	Endorsed
NQF ID	3400
Last NQF Update	2020-08-12
Target Population Age	18-64
Target Population Age (High)	64
Target Population Age (Low)	18
Reporting Level	State
Conditions	Substance Abuse
Subconditions	Opioid Dependency
Care Settings	Ambulatory Care- Clinician Office/Clinic; Ambulatory Care: Outpatient Rehabilitation; Behavioral Health/Psychiatric: Inpatient; Behavioral Health/Psychiatric: Outpatient ; Hospital/Acute Care Facility

### Groups

## Use of Pharmacotherapy for Opioid Use Disorder (OUD-HH)

Core Measure Set	Not Available
------------------	---------------

Measure Group	Group Identifier
---------------	------------------

Innovation Accelerator Program
--------------------------------

### Measure Links

#### Measure Program: Medicaid

Info As Of	Not Available
------------	---------------

Program / Model Notes
-----------------------

Data Sources	Administrative Data (non-claims); Claims Data
--------------	---

Purposes	Not Available
----------	---------------

Quality Domain	Behavioral Health Care
----------------	------------------------

Reporting Frequency	Not Available
---------------------	---------------

Impacts Payment	Not Available
-----------------	---------------

Reporting Status	Active
------------------	--------

Data Reporting Begin Date	2020-01-01
---------------------------	------------

Data Reporting End Date	Not Available
-------------------------	---------------

### Measure Program Links

<https://www.medicaid.gov/>